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Abstract 
Vitamin £ supplementation and atherosclerosis. Epidemiological studies in 
smokers and elderly. 
PhD.- thesis byFrouwk/e de Waart, Division of Human Nutrition & Epidemiology, 
Wageningen University, The Netherlands, January 17, 2000 
The antioxidant vitamin E may have beneficial effects on several indicators of human health. 
We studied the impact on atherosclerosis, immune response and total mortality in smokers and 
elderly people, who are at risk for increased oxidative stress. Vitamin E may exert its effect on 
atherosclerosis by protecting low density lipoprotein (LDL) against lipid peroxidation. 
Moreover, lipid peroxidation may also negatively influence the immune response. In addition 
to its antioxidant function, vitamin E may be beneficial through effects on cellular function, 
e.g., by preserving endothelium-dependent vaso-relaxation or decreasing cytokine production. 
Observational studies. In a cross-sectional study among 158 male lifelong smokers aged 50 to 
75 years, adjusted vitamin E intake and plasma levels were not associated with intima media 
wall thickness (IMT) of the common carotid artery. IMT ,which is a marker for atherosclerosis, 
was measured non-invasively by using the B-mode ultrasound technique. In a prospective study 
among 638 independently living elderly aged 65 to 85, no significant association was observed 
between cholesterol adjusted serum levels of vitamin E and 7.2 years total mortality. (Hazard 
ratio for lowest tertile vs. highest of 1.11, 95% confidence interval 0.74 to 1.65). 
Intervention trials. In a randomized placebo-controlled double-blind trial among 218 lifelong 
male smokers, 400 IU (364 mg) vitamin E was administered daily for two years. A non 
significant (p=0.34) reduced progression of carotid IMT by 47% was observed compared to a 
significant spontaneous progression in the placebo group of 0.030 mm (p=0.006). Results were 
adjusted for initial IMT values and traditional CVD risk factors. Vitamin E significantly 
reduced the in vitro susceptibility of LDL to oxidation, which was not related to progression. 
In this trial results were stratified by genetic predisposition. Smokers lacking the detoxifying 
enzyme activity of glutathion S-transferase u (genotype GSTM1-0) were compared with those 
with the positive genotype (GSTM1-7). In the GSTM1-0 group vitamin E reduced the 
proportion of smokers with increased carotid IMT by 62% (p=0.06) for the left posterior and by 
73% (p=0.01) for the left anterior wall. No effects were observed for the IMT at the right side. 
In a 3-month randomized double-blind placebo-controlled trial among 83 apparently healthy 
elderly, aged 67-87 years, 100 mg vitamin E supplementation significantly decreased the 
percentage of oxidized linoleic acid in LDL (10.4%) compared to the placebo group (4.6%). In 
this trial vitamin E supplementation did not affect the cellular and humoral immune response. 
In conclusion, no supportive evidence is provided that vitamin E supplementation has 
beneficial effects on atherosclerosis and immune response among smokers and elderly. The 
observations for GSTM1-0 genotype needs further confirmation. The protective effect of 
vitamin E on LDL oxidation in vitro lacks validation in vivo. Research on biomarkers of lipid 
oxidation and arterial damage needs priority to more adequately assess the clinical relevance 
and optimal intake of vitamin E. 
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1 
Introduction 
Will the 'goodfairies' please prove to us that vitamin E lessens human 
degenerative disease? 
For almost eight decades now, potential health benefits of vitamin E have been 
studied. Vitamin E deficiency signs including neuropathic and myopathic symptoms, 
and disorders of the reproductive system have been well documented in studies among 
animals . In humans vitamin E deficiency rarely occurs except in starvation, 
premature infants and conditions where fat absorption is limited3. Other than these 
categories with deficiencies, studies on health benefits of vitamin E in humans 
primarily focus on doses that go beyond correcting deficiency. 
Renewed insights in the etiology of atherosclerosis4'5 have suggested a 
potential key role for harmful effects of the oxidative modified low density lipoprotein 
(LDL)-cholesterol6'7. This has opened new research dimensions for vitamin E6. The 
potent antioxidant and membrane stabilizing effects of vitamin E, its presence as 
major antioxidant in LDL-cholesterol, and its relative non-toxicity made it an ideal 
candidate to study beneficial effects on the atherosclerotic process and cardiovascular 
disease (CVD). 
The mechanism behind the potential immuno-stimulating effect of vitamin E is 
largely unknown but its antioxidant property8 is likely to be involved. However, non-
antioxidant functions of vitamin E have also been postulated9'10. The fact that 
functioning of specific immune defense mechanisms decreases with age11"13 renders 
elderly people a specifically appropriate human target group for the confirmation of 
potential beneficial effects of vitamin E on immune response. 
In this thesis, studies on the effect of vitamin E on atherosclerosis, immune 
response and total mortality are presented. Studies among smokers and elderly people 
are described. These groups may especially benefit from vitamin E supplementation as 
they are suspected to experience increased oxidative stress, which is defined as an 
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imbalance between reactive oxygen species (ROS) or free radicals and antioxidant 
defense14. 
Vitamin E 
Vitamin E was discovered in 1922 by Bishop and Evans as an essential substance for 
normal reproduction in the rat. Vitamin E comprises of eight compounds known as 
tocopherols and tocotrienols differing from each other in the number and position of 
the methyl groups round the ring of the molecule. Tocopherols are yellow, oily 
liquids, freely soluble in fat solvents and remarkably stable to heat3. 
a-Tocopherol has the highest antioxidant and biological activity. It is an 
extremely effective chain-breaking antioxidant that protects polyunsaturated fatty 
acids from free radical damage. Furthermore, a-tocopherol appears to be essential for 
the correct functioning of cell membranes. In plasma, vitamin E is mainly transported 
in the lipid component of plasma lipoproteins. Vitamin E is broken down in the liver 
and excreted by bile. Normal plasma levels of a-tocopherol range from 11 to 37 
umol/115. 
Vitamin E is present in small quantities in a large number of foods. The richest 
natural sources of vitamin E are wheat germ oil, vegetable oils, egg yolk, nuts, green 
plants, milk fat, and liver. The Recommended Daily Allowance (RDA) for vitamin E 
is 15 IU (10 mg a-tocopherol equivalents (aTE)) for men and 12 IU (8 mg aTE) for 
women16. 
No carcinogenic or teratogenic effects of vitamin E have been found in animal 
studies. Even at very high levels of intake vitamin E toxicity in animals is low. High 
intake of vitamin E from supplements in humans is generally considered safe9'17"19. 
Studies in individual cases showed that up to 3200 IU vitamin E per day have been 
taken by human subjects without significant adverse clinical effects. Interventions 
with megavitamin E doses ranging from 60 to 800 mg showed no negative effects on 
hepatic or renal function, thyroid gland, neuromuscular system and hematologic 
parameters in healthy subjects in periods from 4 weeks to 6 months20"22. One may 
question if this is only short-term safety and long-term accumulating effects cannot be 
ruled out. Moreover, specific subgroups may be vulnerable. Vitamin E may increase 
blood-clotting time in individuals with disease- or drug-induced vitamin K deficiency 
and is therefore not advised during anticoagulant therapy. 
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The oxidation hypothesis of atherosclerosis 
An increased concentration of plasma LDL cholesterol is an established risk factor for 
atherosclerosis, the primary disease process underlying cardiovascular disease (CVD) 
cases. 
The oxidation theory of atherosclerosis7 states that oxidative modification of 
LDL (oxLDL) renders it more atherogenic than native LDL6. The oxidation of LDL 
by free radicals in the arterial intima is mediated by smooth muscle cells, 
macrophages and endothelial cells. OxLDL, but not native LDL, is recognized by 
scavenger receptors leading to uncontrolled uptake by macrophages in the intima and 
the formation of foam cells. These lipid loaden foam cells are found in early 
atherosclerotic lesions and at the leading edges of more advanced lesions. oxLDL 
inhibits the motility of tissue macrophages, it is chemotactic for circulating 
monocytes, and it is cytotoxic. Its cytotoxicity may be extremely important in lesion 
progression, specifically in the development of the extra-cellular lipid core as foam 
cells undergo necrosis. Furthermore, oxLDL has immunologic properties and thus 
induces the formation of auto-antibodies23'24. OxLDL has also been postulated to 
negatively influence endothelium functioning25'26 such as impairment of endothelium 
dependent relaxation25. 
Several lines of evidence support the existence of oxLDL in vivo. OxLDL (or 
closely related epitopes) has been identified in animal and human lesions23 and has 
been successfully extracted from these lesions23'27. Furthermore, auto-antibodies 
against epitopes of oxLDL23'24 have been demonstrated in human plasma. The indirect 
measure of in vitro oxidation of LDL, which quantifies the lag phase of copper-
induced oxidation of isolated LDL by monitoring conjugated dienes formation28, has 
been extensively used as a marker of enhanced LDL oxidation. However, its 
biological relevance in vivo is debated29,30. Plasma auto-antibody levels against 
oxLDL are increasingly used as an in vivo marker for oxLDL. Several case-control 
studies and one cross-sectional study support a role for oxidation of LDL in 
atherosclerotic disease showing correlations between the above mentioned in vitro31'32 
and in vivo30'33'35 measurements of oxLDL and atherosclerotic disease. However, 
studies failing to show significantly increased oxLDL in CVD patients compared to 
control subjects are as manifold36"42. 
The protective effect of vitamin E on CVD is believed to originate from its 
capacity to prevent lipid peroxidation in LDL28'43. Several human intervention trials 
confirm this, although the minimum dose required to significantly decrease the in 
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vitro susceptibility of LDL to oxidation is still not agreed upon and doses of 25 IU44 as 
well as 400 IU45 have been suggested as minimum requirements for effect. 
Epidemiological evidence for benefits of vitamin £ on cardiovascular 
disease 
Epidemiological studies in humans including cross cultural, case-control studies and 
large prospective studies suggest a beneficial effect of high dietary or serum levels of 
vitamin E, although not conclusively (see for reviews Manson et al.46, Stampfer and 
Rimm47 and Tribble48). Two large prospective studies49,50 among 87,245 nurses and 
39,910 health professionals showed a risk reduction of CHD by 20 to 40% for high 
vitamin E intake. The reductions were most pronounced in men and women who had 
taken vitamin E supplements of 100 IU or more for at least two years. Another 
observational study51 among 11,178 elderly showed reduced risks of 25% and 40% on 
respectively total- and CHD mortality for those elderly using vitamin E supplements. 
Non-supplementary dietary intake and plasma or adipose tissue levels of vitamin E are 
usually not strongly associated with CVD events. An exception is the Iowa Women's 
Health Study52 among 34,486 postmenopausal women where dietary vitamin E intake 
(excluding supplement users) but not vitamin E supplement use was associated with a 
risk reduction in CHD mortality. To substantiate the apparent benefits of vitamin E in 
the prevention or reduction of CVD morbidity and mortality, large-scale primary and 
secondary intervention trials were warranted53'53. 
At this moment the available trials on vitamin E and CVD have revealed 
conflicting results. The Alpha-Tocopherol, Beta-Carotene (ATBC-trial) Cancer 
Prevention Study54, a randomized trial among 29,133 male smokers aged 50-69, 
reported no reduction in cardiovascular risk after 6 years of 50 IU vitamin E 
treatment. There was even an increase in deaths caused by cerebral hemorrhage. 
Further analyses among a sub-population of smokers with a previous myocardial 
infarction (MI) showed that vitamin E reduced non-fatal MI but not fatal coronary 
heart disease55. A secondary randomized prevention trial56 (CHAOS-trial) of 400 and 
800 IU vitamin E among 2002 patients with angiographically proven coronary 
atherosclerosis showed also a reduction in nonfatal but not in fatal MI after a median 
follow-up of 1.4 years. However, there was a non-significant increased risk of 
cardiovascular death in the vitamin E group. Another large-scale secondary prevention 
trial57 (GISSI-Prevenzione trial) among 11,324 MI survivors showed no reduction of 
300 mg vitamin E on the combined endpoint of death, non-fatal MI, and non-fatal 
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stroke compared to the placebo group. However in secondary analyses a significant 
reduction in relative risk of 20% for all cardiovascular deaths and 35% for sudden 
death was found. Recently, at the European Society of Cardiology congress in 
Barcelona (Aug 28- Sept 1, 1999) results were presented from the HOPE trial58. The 
HOPE trial studied in a two by two factorial designed randomized trial the effect of 
ACE-inhibitor ramipril and vitamin E on a composite of MI, primary stroke or death 
from CVD among 9,541 patients with any evidence of coronary artery disease, stroke, 
peripheral vascular disease or diabetes. After a follow-up of 4.5 years, 
supplementation with 400 IU vitamin E showed no reduction in incidence of MI 
(16%) or stroke (7.1 %) or cardiovascular deaths (4.4%) compared to the placebo 
group (15.4%, 6.8% and 3.8%, respectively). The vitamin E arm of this study will be 
continued to assess the impact of prolonged vitamin E treatment on prevention of as 
well cancers as cardiovascular disease. 
Several other large primary and secondary prevention trials are still ongoing 
which will hopefully provide a more consistent answer concerning the role of vitamin 
E in the prevention and treatment of CVD59'60. 
The role of vitamin E supplementation in immune response 
The underlying mechanism for the immune-enhancing effect of vitamin E 
supplementation as found in many animal experiments is largely unknown8. Cells 
from the immune system are extra sensitive to lipid peroxidation which may 
negatively influence immune response by structurally changing the membranes of 
cells involved in immune response9. Furthermore, oxidative stress is increased in 
normal immune response as activated phagocytic cells generate hydrogen peroxides. 
By its antioxidant capacity vitamin E may improve immune response by counteracting 
these effects. Furthermore, vitamin E may exert its immune-enhancing effect by 
decreasing the production of immunosuppressive eicosanoids such as prostaglandin 
E2, which contribute to the age-associated dysregulation of immune responsiveness61" 
64
. In addition to its antioxidant function, modulation of signal transduction pathways by 
vitamin E may contribute to its immuno-stimulatory effect9'10. 
Epidemiological evidence for benefits of vitamin E on the immune response 
Observational studies in healthy elderly human subjects found no positive associations 
between vitamin E intake or status and indicators of cell-mediated immune response65"67. 
Intervention trials on the effect of vitamin E on immune response are scarce61'68,6 and 
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show inconsistent results. Two trials by Meydani et al.61'68 among free-living healthy 
human elderly subjects reported an overall improvement in cell-mediated immune 
response with a daily dose of 800 mg vitamin E for 30 d, and with 60, 200 or 800 mg 
vitamin E after 4.5 months. In the latter study68 beneficial effects significantly different 
from that of the placebo group were only found in the subjects receiving 200 mg/day. In 
a trial among non-institutionalized elderly people69 testing 50 and 100 mg vitamin E for 
6 months only elderly with a low baseline cellular immune response or physically less 
active benefited from 100 mg vitamin E supplementation by increased cellular immune 
response compared to the placebo group. 
Rationale of this thesis 
The guiding hypothesis for the studies in this thesis is that: 
Vitamin E supplementation is beneficial for health in groups with a high 
oxidative stress. 
The studies focus on smokers and elderly as two at risk groups with a potential 
oxidant-antioxidant imbalance (oxidative stress). Risk groups with high oxidant-
antioxidant imbalance are most likely to benefit from a potential effect of vitamin E 
on disease processes involving oxidative or free radical induced damage. Moreover, 
studies among these risk groups may be more efficient in terms of sample size and 
length of required study time. 
By the constituents of the smoke they inhale, smokers put themselves at 
increased free radical and oxidant burden. Higher levels of plasma lipid peroxidation 
products in smokers than in non-smokers have been found in several studies70"72. 
Because of a more rapid metabolism of antioxidant vitamins and a generally lower 
intake73'75, their antioxidant defense mechanism is lowered. Possibly as a result of this, 
atherosclerotic progression is more pronounced in smokers than in non-smokers76'77. 
Elderly people are the second population under study. Increased oxidative 
stress may accompany aging78. Age-associated increase in blood lipid peroxides has 
been reported79,80. The antioxidant defense may be decreased in elderly. First, the 
mean lower energy intake observed in elderly makes them more vulnerable for a sub-
optimal vitamin status81. Moreover, less is known about specific needs of elderly for 
vitamins and they may be increased for certain vitamins82. Second, there are studies 
fin ci HA 
showing a decrease in antioxidant enzyme activity with human aging ' ' , although 
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not conclusively78'85 and even slight increases in antioxidant enzyme activity have 
been reported79'86. 
Figure 1.1. Simplified hypothesized mechanisms and outline of studies in this thesis 
(chapter number and study population; E=elderly, S=smokers) 
LDL-choIesteroI • ox-LDL • atherosclerosis • CVD 
genetic environmental 
(3S.6E) predisposition factors 
(3S) 
(7E). * 
oxidative stress vitamin £ 
immune response 
(5E) 
impaired immune response 
total mortality 
infection 
Both the scientific and public health importance of vitamin E's protective role on 
health status warrants further empirical studies on the process and its (health) 
outcomes. The studies described in this thesis were designed as a contribution to the 
accumulating research evidence. From the beneficial health claims for vitamin E on 
degenerative disease, the described studies are restricted to the areas outlined in 
Figure 1.1: atherosclerosis and immune response. 
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Objectives and outline of the thesis 
This thesis has two main objectives: 
1. Among smokers, to study the effect of two-year vitamin E supplementation on 
atherosclerosis as operationalized by progression of common carotid intima media 
thickness (CCA-IMT). Moreover, the effect of vitamin E on in vitro susceptibility 
of LDL to oxidation was studied. A double blind placebo controlled intervention 
trial was conducted for this purpose. 
2. Among elderly, to study the effect of vitamin E on several health characteristics. 
This objective was pursued through a prospective study on the association 
between serum vitamin E and total mortality and a 3-month intervention trial 
testing the effect of vitamin E on immune response and susceptibility of LDL to 
oxidation. 
The objectives are substantiated through 3 studies, of which the key 
characteristics are summarized in Table 1.1 
Chapters 2, 3 and 4 report studies on the effects of vitamin E on 
atherosclerosis among life-long smokers. In chapter 2 we studied important 
environmental determinants of CCA-IMT with emphasis on smoking characteristics 
and plasma antioxidant vitamins. Baseline data of the intervention trial presented in 
chapter 3 were used. Chapter 3 reports a placebo-controlled randomized intervention 
study in which we investigated the effect of two year supplementation with 400 IU 
vitamin E on two indicators for atherosclerosis: reduction of the progression of CCA-
IMT and the in vitro susceptibility of LDL to oxidation. In chapter 4 we investigated 
whether the effect of vitamin E on progression of CCA-IMT is more pronounced 
among smokers with the null genotype for glutathione S- transferase u 1 (GSTM1) 
thus lacking the detoxification enzyme activity of GSTM1. 
Chapters 5, 6 and 7 deal with vitamin E effects among elderly. Chapters 5 and 
6 report the effects of 3 months vitamin E supplementation on oxidation rate of 
linoleic acid in LDL (chapter 5) and indices of cellular and humoral immune 
response (chapter 6). In chapter 7, vitamin E status and health effects are put into 
wider perspective. Specifically, in a prospective study we investigated the association 
of serum carotenoids and a-tocopherol on total mortality risk. 
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Table 1.1 Key characteristics of the studies in this thesis. 
Ch 
2 
3 
4 
5 
6 
7 
Study type 
cross-sectional 
(baseline data ch. 3) 
double-blind placebo 
controlled 
randomized trial 
see ch. 3 
double-blind placebo 
controlled 
randomized trial 
see ch. 5 
Prospective cohort 
study 
Population 
158 
CVD-free male smokers 
218 
male life-long smokers 
see ch 3 
84 
independently living 
elderly, 
65-85 yrs. 
see ch. 5 
638 
independently living elderly 
above 65 yrs. 
Study characteristics 
* plasma and dietary intake levels 
of antioxidant vitamins 
* smoking characteristics 
* CCA-IMT 
* 400IU vitamin E 
* 2 yrs. supplementation 
* progression of CCA-IMT 
* in vitro susceptibility of LDL to 
oxidation (lag time) 
* gstml polymorphism 
* progression of CCA-IMT 
* 100 IU vitamin E 
* 3 months supplementation 
* oxidation LDL-linoleic acid 
* in vitro susceptibility of LDL to 
oxidation (lag time) 
* immune response: 
antibodies (humoral) 
proliferation (cellular) 
* serum carotenoids and vitamin E 
* 7.2 yrs. follow-up 
* total mortality 
Ch=chapter, yrs.=years, CCA-IMT=common carotid artery 
gstml =glutathion S-transferase n 1 
intima media thickness (mm), 
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Smoking characteristics, antioxidant vitamins 
and carotid artery wall thickness among life-
long smokers* 
Frouwkje G. de Waart, Tineke J. Smilde,Hub Wollersheim, Anton F.H. Stalenhoef, 
Frans J. Kok 
Abstract 
We studied the associations between the common carotid-intima-media thickness 
(IMT), as a marker of atherosclerosis, and smoking characteristics and antioxidant 
vitamins among 158 male life-long CVD-free smokers. An 'increased' carotid IMT 
was defined as the upper 25th percentile of the carotid IMT distribution. The 
prevalence odds of 'increased' IMT was 2.5 times (odds ratio (OR)=2.5; 95% CI: 1.1, 
5.6) higher among smokers inhaling smoke deeply into the lungs than among 'moderate 
and non-inhalers'. This association decreased (OR=1.6, 95% CI: 0.7, 3.8) when 
adjusted for other CVD risk factors. Smokers with an 'increased' carotid IMT did not 
differ significantly in mean antioxidant vitamin intake and status with the remaining 
group. However, classical CVD risk factors contributed importantly to 'increased' 
carotid IMT. In our study depth of inhalation was the only smoking characteristic 
associated with carotid IMT although attenuated after adjustment for traditional risk 
factors for CVD. Furthermore, in these life-long smokers, not using any vitamin 
supplements, no associations were found for antioxidant vitamins. 
'Accepted Journal of Clinical Epidemiology 
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Introduction 
Smokers are extra vulnerable for free radical induced damage of the cardiovascular 
system. They are exposed to free radicals from cigarette smoke and in general they 
have lower antioxidant vitamin intake and plasma levels73"75. The risk of 
cardiovascular disease (CVD) among smokers may vary because of differences in 
smoking characteristics87'88 such as number of years smoked, number of cigarettes per 
day, use of filters, inhalation pattern, and type of tobacco, or because of differences in 
antioxidant vitamin intake or status. These variations in CVD risk factors can be 
studied in asymptomatic smokers because they have not altered their smoking or diet 
habits as a consequence of CVD. 
The risk of CVD in asymptomatic smokers can be estimated by intima-media 
wall thickness (IMT) of the common carotid artery, as measured by B-mode 
ultrasound. This technique is non-invasive, highly reproducible89'90 and positively 
associated with generalized atherosclerosis91, and with peripheral-92, cerebro- and 
cardiovascular disease93"95. Moreover, several epidemiological studies show 
associations between CVD risk factors and carotid IMT96"98. These include studies 
reporting positive associations between smoking and IMT76'99"101 and inverse 
associations between specific antioxidant vitamins and IMT39'102"105. 
To our knowledge, no previous studies have specifically addressed 
asymptomatic smokers' risk of increased carotid intima-media wall thickness by 
focusing on smoking characteristics and antioxidant vitamin intake and plasma levels. 
Here we report associations between carotid IMT and different smoking 
characteristics and antioxidant vitamin intake and status among 158 male life-long 
CVD-free smokers. Furthermore, the associations between carotid IMT and other 
CVD risk factors are presented. 
Methods 
Study population. This study uses baseline data from an ongoing two year double-
blind intervention trial on the effects of vitamin E on progression of common carotid 
artery intima-media wall thickness (IMT) among lifelong male smokers. Male 
inhabitants from Nijmegen, a city of approximately 150,000 persons in the 
Netherlands, were approached using the addresses of 7,000 male inhabitants born 
between 1919 and 1946. The addresses were obtained from the Municipal Registration 
Office. An invitation letter containing a brief explanation of the study design, a 
participation form and a questionnaire on smoking behavior, medical history and 
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demographic characteristics were sent out. The recruitment period was from October 
1995 to July 1996. Eligible cigarette smokers were invited to an information evening 
and selected based on returned questionnaires and on a medical examination. Three 
hundred and forty five smokers entered the selection procedure. Excluded were 
diabetes (n=10), users of (multi)vitamin-, vitamin E, vitamin C, 6-carotene, garlic, or 
fish oil supplements (n=29), users of vitamin K antagonists (marcoumar, 
acenocoumarol) (n=8), individuals with current illness interfering with participation 
(n=17), and subjects not compliant with the protocol or with second thoughts on 
participating or for other reasons (n=63). All together, 218 subjects ranging in age 
from 50 to 75 years were randomized for the trial of which 216 successfully 
completed the baseline measurements in three consecutive visits. 
A non-response questionnaire sent to the first 1,000 participants and returned 
by 534 revealed that the main reasons for not participating in the study were non-
smoking (n=443; 83%), current health status (n=37;7%), lack of time (n=17;3%), and 
several other reasons (n=37;7%). Participants and non-participants did not differ 
significantly in age, perceived health scores, supplement use, marital status, history 
and medication for CVD, or activity pattern. 
Written informed consent was obtained from all participants. Their general 
practitioners were informed by letter about the aim and design of the study and the 
subject's participation. The study was approved by both the medical ethical committee 
of Wageningen Agricultural University and the ethics committee of Nijmegen 
University Hospital. 
Ultrasound measurement of the common carotid artery intima-media thickness. 
Ultrasound examinations on both the left and right side of the intima-media thickness 
(IMT) of the distal 1.0 cm straight part of the common carotid artery were performed, 
using a high resolution B-mode ultrasound (Biosound Phase-2) with a transducer 
frequency of 10 MHz. Images were stored on an optical disk and analyzed with a 
semiautomatic software program (Eurequa; TSA company, Meudon France106) by one 
reader blinded for any information. Significant changes in density on a section 
perpendicular to the vessel wall from the lumen towards subadventitial structures were 
measured automatically: three measurements were made in a 1.0 cm long segment of 
both the far- and near wall. Details of the scanning and reading procedure and of the 
reproducibility have been described elsewhere90. The mean of far- and near wall at the 
left and right side was used in the analyses. 
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Smoking characteristics. The questionnaire on smoking characteristics included 
questions on the average number of cigarettes, cigars and/or pipes smoked per day, 
brand of cigarettes, type of tobacco, use of filter, depth of inhalation, age at which 
participants started smoking and number of times and duration of attempts to quit-
smoking. Nicotine and tar content of manufactured cigarettes was noted from the 
package brought to one of the visits. Duration of smoking was calculated as the age at 
the start of this study minus the age at which participants started smoking minus 
number of non-smoking years in between this period. Pack-years were calculated by 
multiplying duration of smoking by the number of cigarettes smoked per day divided 
by 20. Depth of inhalation107 was elicited by asking "When you smoke cigarettes, how 
deeply do you usually inhale the smoke?" The 5 answer categories ranged from 'into 
the mouth/just puff to 'deeply into the lungs'. In the analyses 'inhaling deeply into 
the lungs' will be compared with the other 4 categories combined. For three subjects 
no information was available on depth of inhalation. Plasma cotinine was measured by 
packed column gas-liquid chromatography108 as biomarker of short-term exposure to 
cigarette smoke. 
Antioxidant vitamins. Food frequency questionnaires109 were checked by a 
nutritionist and any inconsistencies or incomplete answers were solved by telephone. 
Coding of nutrients was done by use of an adapted version of the 1993 computerized 
Dutch nutrient base110. Vitamin E intake was calculated as mg a-tocopherol 
equivalents. 
Fasting blood samples were obtained for vitamin and lipid profile analyses. All 
samples were stored at -80° C until analyzed. For the vitamin C analyses 0.5 ml 
heparinized plasma was stabilized with 4.5 ml 5% metaphosphoric acid within one 
hour after blood collection. Vitamin C was measured fluoremetrically111. Vitamin C 
levels under the detection limit were assigned two-thirds of the value of the limit of 
detection. The plasma concentrations of a-tocopherol and B-carotene were analyzed 
by reverse phase high-performance liquid chromatography (HPLC)112. 
CVD risk factors and other measurements. Medical history, current medication, 
questions on claudication113, and family history of CVD was obtained by a research 
nurse. 
Total plasma cholesterol and triglycerides were analyzed by enzymatic 
methods using commercially available reagents (CHOD-PAP, no 237574, Boehringer 
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Mannheim GmbH, FRG and Sera-PAK, Tournai, Belgium cat. no. 6639 
respectively). HDL cholesterol was determined with the polyethylene glycol 
method114. LDL cholesterol was calculated by the Friedewald equation115. Blood 
pressure was measured in duplicate on the right arm with a sphygmomanometer with 
subjects in supine position after a 10-minute rest. Height and weight were measured. 
Body mass index was calculated as weight divided by squared height (kg/m2). 
Data analyses. An additional 58 subjects were excluded from this cross-section 
analyses, namely, those reporting CVD history (previous myocardial infarction, stroke 
or bypass operation); using CVD medication including lipid lowering drugs, aspirin, 
B-blockers, Ca-antagonists, ACE-inhibitors, nitrates, and antihypertensive drugs; or 
having positive scores on a standard angina and intermittent claudication 
questionnaire113. This left 158 individuals for the analysis. 
The smokers in the upper 25th percentile of carotid IMT were defined as the 
"increased" carotid IMT group. Age-adjusted mean values of smoking characteristics, 
antioxidant vitamins and CVD risk factors were compared between the "increased" 
carotid IMT group and the remaining group by ANCOVA (table 2.1 and 2.2). Means 
were compared by the Mann-Whitney [/-test when not-normally distributed. 
Age-adjusted correlation coefficients were calculated by age-adjusted 
standardized regression coefficients (13). Unadjusted correlations are given by 
Spearman correlation coefficients (r). 
The dietary intakes of vitamin E and B-carotene were correlated with energy 
intake. These vitamins were adjusted for energy intake by calculating their residuals 
from linear regression models with energy intake as the dependent variable116. Plasma 
a-tocopherol and B-carotene levels were highly correlated with plasma cholesterol. 
These plasma vitamins were adjusted for plasma cholesterol by calculating their 
residuals from linear regression models with plasma cholesterol as the dependent 
variable116. For ease of interpretation, descriptives are expressed as unadjusted data. 
The contribution of independent variables to carotid IMT was assessed through 
three increasingly comprehensive models (table 2.3). The first model included age and 
those smoking characteristics that in exploratory stepwise regression analysis 
significantly (p<0.05) contributed to carotid IMT (only depth of inhalation met that 
criterion). The second model also included plasma antioxidants vitamins. The third 
model extended the first model with a selection of relevant risk indicators for CVD 
including body mass index, systolic- and diastolic blood pressure, plasma 
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concentrations of LDL, HDL, triglycerides and glucose and alcohol consumption. 
Again, these CVD risk factors were selected through exploratory stepwise regression 
analysis, revealing plasma LDL and HDL and systolic blood pressure as significant 
contributors to carotid IMT. 
The strengths of associations of independent variables with carotid IMT in the 
above-mentioned three models were expressed both as regression coefficients (b) from 
multiple regression analysis and as prevalence odds ratios (OR) from multiple logistic 
regression analysis. The prevalence odds ratios of having an "increased" carotid IMT 
(dependent) were estimated for dichotomized independent variables using their 
median as the cut-off point. 
The statistical package SAS (version 6.09, 1989) was used for all the analyses. 
Table 2.1 Unadjusted mean (SD) of general characteristics and cardiovascular disease 
risk factors between lifelong male smokers in the upper quartile" of common carotid 
intima-media thickness (CCA-IMT) with the remaining group 
CCA-IMT (mm) 
age (yr.) 
height (m) 
weight (kg) 
body mass index (kg/m2) 
Blood pressure (mmHg) 
systolic 
diastolic 
Total 
n=158 
mean 
0.93 
59 
1.76 
79.6 
25.8 
138 
83 
Plasma lipid & glucose mmol/l 
total cholesterol 
LDL-cholesterol 
HDL-cholesterol 
triglycerides 
glucose 
Intake 
energy (MJ/d) 
alcohol (g/dc) 
6.0 
4.1 
1.17 
1.68 
5.6 
10.4 
14.9 
group 
SD 
0.15 
6 
6.3 
11.2 
3.4 
15 
7 
1.0 
1.0 
0.36 
0.98 
1.0 
2.5 
0-65 
lower 75%a 
n=118 
mean 
0.86 
58 
1.76 
78.7 
25.4 
135 
82 
5.9 
4.0 
1.20 
1.67 
5.6 
10.6 
16.2 
SD 
0.09 
6 
0.06 
11.2 
3.5 
16 
8 
1.0 
0.9 
0.37 
1.06 
1.0 
2.5 
0-64 
upper 
n=40 
mean 
1.13 
63 
1.75 
82.0 
26.9 
144 
84 
6.3 
4.5 
1.09 
1.69 
5.8 
9.8 
10.5 
25%a 
SD 
0.09 
6 
0.06 
10.9 
3.0 
13 
7 
1.1 
1.0 
0.30 
0.71 
0.9 
2.3 
0-82 
95% CIb 
0.2- 0.3 
2.4- 6.7 
-0.03- 0.01 
0.2- 8.7 
0.4- 3.0 
1.1-12.4 
-1.1-4.6 
0.05- 0.8 
0.2- 0.9 
-0.3- -0.03 
-0.2- 0.6 
-0.2- 0.5 
-1.6-0.3 
"Smokers in the lower 75% of CCA-IMT (ranging from 0.62 mm to 1.02 mm), and in the upper 25% of 
CCA-IMT (ranging from 1.03 mm to 1.43 mm). b95% confidence intervals for differences in age-
adjusted means between subjects in the upper 25% and lower 75% of CCA-IMT. "For alcohol intake the 
median and 90% range is given. 
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Results 
The lifelong male smokers in this study had a mean (SD) common carotid artery 
intima-media thickness (IMT) of 0.93 (0.15) mm. Carotid IMT and age were highly 
correlated, as shown by a Spearman correlation coefficient of r=0.48 (p=0.0001). 
Furthermore, age was significantly associated with most of the other cardiovascular 
risk factors. Consequently, all associations between carotid IMT and CVD risk 
indicators were adjusted for age. The CVD risk indicators plasma total- and LDL 
cholesterol, body mass index, and systolic- and diastolic blood pressure were 
significantly (p<0.01) associated with carotid IMT. These age-adjusted correlations 
were all between 0.18 and 0.27. Plasma HDL-cholesterol levels were inversely 
(p=0.006) associated with carotid IMT. 
Smokers in the upper 25% of carotid IMT (range from 1.03 to 1.43 mm) were 
defined as the 'increased' carotid IMT-group. Compared with the remaining smokers, 
they had significantly higher age-adjusted mean plasma levels of total- and LDL-
cholesterol, lower plasma HDL-cholesterol levels, higher systolic blood pressure and 
higher mean body mass index (table 2.1). 
The mean (SD) number of smoking years was around 42 (8) years, ranging from 16 to 
62 years. Inhaling smoke deeply into the lungs was reported by 51% in the 'increased' 
carotid IMT group and by 35% in the remaining group (p<0.05). None of the other 
age-adjusted smoking characteristics were significantly different between the 
'increased' carotid IMT group and the rest (table 2.2). 
A closer examination of the inhalation pattern showed a positive trend (p=0.01) 
in carotid IMT with 3 categories of inhalation after adjustment for age (figure 2.1a). 
Deep inhalers smoked more cigarettes per day (p=0.02) but still a positive trend 
(p=0.04) was found for plasma cotinine with inhalation (three categories) after 
adjustment for cigarette consumption and age. 
Figure 2.1b shows that depth of inhalation was inversely associated with 
plasma vitamin C levels (p value for trend is 0.03). 
Intake of vitamin E and 6-carotene were slightly lower in the 'increased' 
carotid IMT group. However, comparison of mean vitamin intake values, adjusted for 
age and energy intake, between the 'increased' IMT group and the remaining group 
were not statistically significant. Moreover, plasma vitamin levels were not associated 
with carotid IMT. Because fruit and vegetables are an important source of vitamin C 
and B-carotene and vegetable oils an important source of vitamin E, their associations 
with carotid IMT were also studied. Similar to vitamins, no associations were found 
27 
Table 2.2 Unadjusted mean (SD) or prevalence (%) of smoking characteristics and 
antioxidant vitamins between lifelong male smokers in the upper quartile" of common 
carotid intima-media thickness (CCA-IMT) with the remaining group 
cigarettes/d 
plasma cotinine g/ml 
Depth of inhalation % 
deeply into the lungs (yes) 
Type of tobacco % 
manufactured cigarettes 
hand-rolled cigarettes only 
mix 
Total group 
n=158 
mean 
or% 
18.4 
256.6 
39 
33 
51 
16 
SD 
9.8 
113.1 
lower 75%a 
n=118 
mean 
or% 
18.7 
256.0 
35 
35 
49 
16 
SD 
10.5 
118.1 
upper 
n=40 
mean 
or% 
17.4 
258.3 
51 
28 
55 
18 
25%a 
SD 
7.2 
98.1 
95 % CIb 
-3.9- 3.6 
-25.7- 60.0 
* 
Manufactured cigarettes only (n 71) 
light cigarettes (%) 
filter cigarettes (%) 
tar (mg) 
nicotine (mg) 
History 
age started smoking (yr.) 
pack-years 
Vitamin intake mg/dc 
vitamin Ed 
B-carotene 
vitamin C 
vegetables g/d 
fruit g/d 
vegetable oils g/d 
plasma vitamins jumol/l 
a-tocopherol 
B-carotene 
ascorbic acid 
23 
65 
12.5 
0.98 
17 
38.2 
15.2 
1.66 
85.7 
163.0 
78.4 
3.1 
29.7 
0.29 
33.4 
3.8 
0.26 
4 
21.7 
5.2 
0.70 
36-197 
62-310 
4-251 
0-15 
7.1 
0.17 
19.2 
22 
67 
12.4 
0.97 
17 
37.7 
15.3 
1.70 
85.7 
159.9 
78.4 
3.0 
29.6 
0.28 
34.0 
3.9 
0.28 
4 
23.3 
5.2 
0.73 
32-197 
61-315 
4-251 
0-15 
7.2 
0.17 
19.4 
24 
59 
12.9 
1.00 
16 
39.8 
14.7 
1.54 
87.6 
166.8 
78.6 
4.2 
30.0 
0.30 
31.7 
3.5 
0.22 
3 
16.6 
5.1 
0.61 
42-189 
67-303 
3-269 
0-21 
6.6 
0.18 
18.9 
-1.4-3.0 
-0.1-0.2 
-1.7-1.0 
-8.4- 8.2 
-1.3-1.7 
-0.2- 0.2 
-3.2- 0.8 
-0.05- 0.08 
-9.2- 5.7 
* p < 0.05 (age-adjusted) "Smokers in the lower 75% of CCA-IMT (ranging from 0.62 mm to 1.02 
mm), and in the upper 25% of CCA-IMT (ranging from 1.03 mm to 1.43 mm). b95% confidence 
intervals for differences in age-adjusted means between subjects in the upper 25% and lower 75 % of 
CCA-IMT. Plasma a-tocopherol and B-carotene are also adjusted for plasma cholesterol and vitamin E 
and B-carotene intake for energy intake as described in the method section. cFor intake of vitamin C, 
vegetables, fruit, and vegetable oils the median and 90% range is given dVitamin E is mg of a-
tocopherol equivalent 
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Chapter 2 
for these foods either. The intake of vegetables and fruit was inversely related to 
plasma cotinine levels (r=-0.17 and r=-0.23 respectively, both p<0.05). Fruit intake 
was also inversely associated with cigarettes smoked (r=-0.36, p<0.001). The 
recommended vegetable intake of 200 gram per day was met only by 28% of the 
subjects. 
Figure 2.1 Age-adjusted mean and SE of common carotid artery intima media 
thickness (CCA-IMT) and plasma vitamin C levels over categories of inhalation of 
cigarette smoke. 
Fig. 2.1a 
1.1
 n 
1 
E 0.9 
0.8 
0.7 
0.6 
Fig. 2.1b 
1 
n=23 
1 
T 
n=71 
1 
T 
n=61 
1 
mouth to back of throat lungs moderate lungs deep 
- . 50 
E 40 
3. 
^ 35 
S 30 
.a 25 
I 20 
s 15 
I lo-
iS 5 
£ 0 
T 
1 
T 
1 
T 
1 
mouth to back of throat lungs moderate lungs deep 
Table 2.3 shows three multivariate regression models. Of the smoking 
characteristics, only depth of inhalation was included in the models as it proved to be 
the only significant predictor of carotid IMT in exploratory stepwise regression. 
Model I shows that smokers inhaling deeply into the lungs had an age-adjusted carotid 
IMT that was 0.053 mm (0.022), p< 0.01, thicker than non-or moderate inhalers. 
Furthermore, the prevalence odds of 'increased' IMT was 2.5 times higher among 
deep inhalers, after adjustment for age, than in the remaining group (odds ratio (OR); 
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95% confidence interval (CI) OR=2.5 (1.1-5.6)). Including plasma antioxidant 
vitamins in model II does not significantly change any of the regression coefficients or 
prevalence odds ratios from model I. Including other CVD risk factors (model III), 
also selected by exploratory stepwise regression, explained 34% of the variance in 
carotid IMT. The regression coefficient for deep inhalation decreased from 0.053 mm 
to 0.036 mm, still borderline significant (p=0.08). Age, systolic blood pressure, LDL-
and HDL-cholesterol levels were independent predictors of carotid IMT. Prevalence 
odds ratios revealed a similar pattern with age (OR=3.3; CI=1.3-8.3), systolic blood 
pressure (OR=2.9;CI=l. 1-7.3) and LDL-cholesterol levels (OR=3.3;CI=l.4-8.0) as 
independent predictors of increased carotid IMT. Smokers with combined high levels 
of LDL and low antioxidant status with the median taken as cut-off point revealed 
age-adjusted prevalence odd ratios of having an increased IMT for a-tocopherol 
(OR=2.44; CI=1.1-5.5), B-carotene (OR=1.66, CI=0.7-3.7) and vitamin C (OR=2.41; 
0=1.1-5.5) not exceeding the age-adjusted risk for only high LDL levels (OR=3.57; 
CI=1.6-8.1). Therefore, in this group of smokers the combination of high LDL levels 
and low antioxidant status did not subsequently increases the risk of increased IMT. 
Discussion 
Depth of inhalation was the only smoking characteristic significantly associated with 
carotid intima-media thickness (IMT) within our study population of male lifelong 
smokers. 'Deep inhalers' had a mean (standard error) age-adjusted carotid IMT that 
was 0.053 mm (0.022) thicker (6%) than that of 'moderate and non-inhalers' (p<0.05). 
This association decreased and became borderline significant when adjusted for other 
CVD risk factors. Mean plasma levels and intake of antioxidant vitamins were not 
associated with carotid IMT. However, plasma vitamin C levels were significantly 
lower in smokers inhaling deeply. The CVD risk factors age, plasma LDL- and HDL 
cholesterol, and systolic blood pressure significantly contributed to carotid IMT. 
A problem in studying associations between smoking characteristics, diet and 
CVD is that people may adjust these habits in light of emerging health problems. 
Moreover, recall bias caused by smokers being deceptive about their smoking habits 
when smoking-related disease is present may lead to misclassification. Therefore, we 
studied a pre-clinical population of 158 smokers selected from available data on 216 
smokers. Because we selected an asymptomatic population, our results cannot be 
generalized to lifelong smokers. Also, self-selection may have occurred because the 
smokers under study were participants in a long-term intervention trial. They may differ 
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from individuals not willing to commit themselves to such a trial. In our study this 
effect is likely to be small. The results of a non-response study comparing 534 non-
responders with 73 responders revealed no significant differences in age, history or 
presence of CVD, physical activity, demographic characteristics and subjective health 
score. Although the non-responders differed in being mainly non-smokers. 
A reliable pre-clinical indicator of atherosclerosis is required to assess the 
association between smoking characteristics and antioxidant vitamins in an 
asymptomatic population such as ours. The use of carotid IMT measurements by B-
mode ultrasound as such an indicator is justified by reported associations between 
carotid IMT and generalized atherosclerosis91 and cardio- and cerebrovascular events at 
various sites92"95. Furthermore, the carotid IMT measurement is highly reproducible89'90 
and it is a preferable method for studying asymptomatic populations as it is non-
invasive, harmless, and has a low burden for the individual measured. The clinical 
relevance of our results of 0.053 mm (0.036 mm after adjustment for CVD risk 
factors) difference in IMT for smokers inhaling deeply may be judged by comparison 
with these other studies. This is complicated by differences in study design. In a 8.8 
years follow-up of the cholesterol lowering atherosclerosis study117 for every 0.03 
mm/year progression in IMT a relative risk of 3.1 (95% CI [2.1-4.5]) on any coronary 
event was reported. In a cross sectional study, Bots et al.95 reported a relative risk of 
1.34 for stroke and 1.25 for MI for every additional difference of 0.16 mm of CCA-
IMT after adjustment for major cardiovascular risk factors. 
The usefulness of smokers' self-reported inhalation pattern as measure of 
smoke exposure was supported in our study by the significant trend (p<0.05) between 
inhalation pattern and plasma cotinine after allowing for the effects of cigarette 
consumption. Stepney118 did not find an association of self-reported inhalation and 
long-term smoke exposure as measured by carbonmonoxide in exhaled air. However, 
only moderate and deep inhalers were compared as the group of non-inhalers and 
slightly inhalers were too small to include in the analyses. Higenbottam et. al88 found 
that the ten-year mortality rates for coronary heart disease in male cigarette smoking 
British civil servants were higher among self-reported inhalers than non-inhalers. 
Studies76'100'101 relating smoking to carotid IMT in the general population 
showed that pack-years of smoking was dose-dependently associated with carotid 
IMT. It is not clear why we did not find a significant association between pack-years 
(number of cigarettes times years smoked divided by 20) and carotid IMT. However, in 
our study, the age-adjusted mean number of pack-years was slightly higher in the group 
with 'increased' carotid IMT. Recent consumption of cigarettes, used to calculate the 
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number of pack-years, may not be a good indicator of lifelong consumption. Non-
differential misclassification of pack-years of smoking, therefore, may have attenuated 
the association with carotid IMT towards the null value. 
We did not find any significant associations between antioxidant vitamins and 
carotid IMT within our population of smokers. Antioxidant vitamins may be important 
in smokers in counteracting the effects of lipid peroxidation119. Smokers have high 
oxidative stress and usually both a lower intake and plasma level of antioxidant 
vitamins, which may render their LDL cholesterol more susceptible to lipid 
peroxidation120. Oxidation of LDL cholesterol is thought to play an important role in 
early atherosclerosis by depositing cholesterol in macrophages, leading to the 
formation of fatty streaks121. Increased oxidation of LDL-cholesterol in smokers is 
supported by reported higher levels of lipid peroxides in the plasma of smokers ' ' . 
Moreover, the susceptibility of LDL to oxidation decreased in smokers after they had 
quit123. 
Several reasons may account for the fact that we did not find an association, if 
any, between carotid IMT and unsupplemented antioxidant vitamin plasma levels 
within the group of smokers in our study. First, our measure of antioxidant vitamin 
intake and plasma levels may not accurately represent lifetime intake, and thereby 
have decreased possible associations. Erythrocyte vitamin E was significantly inversely 
associated with carotid IMT in the EVA study102 and the authors stated that erythrocyte 
vitamin E may reflect longer-term dietary intake and bioavailability than do plasma 
concentrations. Second, our study only included smokers not using any antioxidant 
supplements. Physiological concentrations of antioxidant vitamins may be insufficient 
to decrease carotid IMT. Azen et al.103 showed less annual progression of carotid IMT 
in high vitamin E supplement users (>= 100 IU) as compared with low vitamin E 
supplement users (<100 IU). However, no such differences were found between highl-
and low vitamin C supplement users. Kritchevsky et al.105 reported that the inverse 
associations between carotid IMT and vitamin C and vitamin E intake were lower 
when supplement users were omitted from the analyses in the group of older women in 
the Atherosclerosis Risk in Community (ARIC) study. Further, in the ARIC study no 
differences were found for plasma values of a-tocopherol and B-carotene and increased 
carotid IMT39. 
The associations we found between carotid IMT and classical CVD risk factors 
such as increased total plasma cholesterol, increased plasma LDL cholesterol, decreased 
HDL cholesterol, higher age, and increased blood pressure support the overall validity 
of our cross-sectional analyses. Furthermore, those associations are consistent with 
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findings of other epidemiological studies96"98. Several studies have shown a higher 
progression rate of atherosclerosis in smokers than in nonsmokers76,77. From a public 
health point of view decreasing CVD risk of smokers would best be served by quitting 
smoking. But among smokers some will be at higher CVD risk than other smokers. 
In conclusion, our results seem to indicate that (self-reported) depth of smoke 
inhalation contributes to atherosclerosis as measured by carotid IMT. However, 
traditional risk factors for CVD are more important contributors. In future 
epidemiological studies among smokers the addition of a short questionnaire on 
smoking characteristics, including depth of smoke inhalation, may be beneficial for a 
closer identification of smokers who are more sensitive than others to the atherogenic 
effect of smoking. 
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Effect of vitamin E supplementation on 2-
year progression of carotid intima media 
thickness in lifelong male smokers* 
Frouwkje G. de Waart, Tineke J. Smilde, Hub Wollersheim, Pierre N.M. Demacker, 
Anton F.H. Stalenhoef, Frans J. Kok 
Abstract 
The beneficial role of a high dose of vitamin E in cardiovascular disease prevention as 
supported by observational data awaits confirmation from intervention trials. Therefore, we 
studied the effect of a daily dose of 400 IU vitamin E on the 2-year change of the common 
carotid intima media thickness (CCA-IMT). The study was designed as a randomized 
placebo-controlled double-blind intervention trial among 218 male lifelong smokers from the 
general population, 50-75 yr. with a mean (SD) number of 43 (8) smoking years. CCA-IMT 
was measured as a marker for generalized atherosclerosis by B-mode ultrasound. The 
combination of posterior and anterior wall measurements at the right and left side was used in 
the data analyses. The baseline mean CCA-IMT was 0.95 mm (0.16) for the group (n=189) 
including persons with both baseline and 2-year CCA-IMT measurements. In the placebo 
group (n=93) the mean 2-year change ('progression') in CCA-IMT was 0.026,95% 0:0.005; 
0.047, p=0.02 after adjustment for baseline CCA-IMT and intervention period. A non-
significant reduced progression of 35% was seen in the vitamin E group (n=96) compared to 
placebo. After adjustment for traditional CVD risk factors vitamin E reduced CCA-IMT 
progression by 47% (p=0.34) compared to the progression in the placebo group ( 0.030 mm, 
95% CI 0.009; 0.050, p=0.006). Although a tendency of reduced progression was observed in 
the vitamin E supplemented group of smokers our data do not support a clear beneficial effect 
of vitamin E on atherosclerosis. 
Submitted 
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Introduction 
The accumulation of oxidized LDL-cholesterol in foam cells in the intima of the 
vessel wall and migration and proliferation of smooth muscle cells are important 
factors in the onset and progression of atherosclerosis6.Vitamin E may have a 
protective effect against atherosclerosis by preventing low density lipoprotein (LDL) 
from oxidative modification. 
Progression or regression of atherosclerosis in a general population can suitably 
be studied by following the change of the intima media thickness of the common 
carotid artery over time by B-mode ultrasound. This technique is non-invasive, highly 
reproducible89 and associated with generalized atherosclerosis91 and cardiovascular 
disease (CVD)95'117. 
Evidence for a beneficial effect of vitamin E on CVD is limited to two large 
trials. A randomized trial reported no reduction in coronary risk for male smokers54 
for 50 IU vitamin E. However, in a secondary analysis a reduction in non-fatal 
myocardial infarction (MI) but not on fatal coronary heart disease among smokers 
with previous MI was observed55. A secondary prevention trial of 400 and 800 IU/day 
showed also a reduction in nonfatal but not in fatal MI56. 
Several studies have shown a higher progression rate of atherosclerosis in 
smokers than in nonsmokers76,77. Smokers have a high exposure to free radicals and 
usually a lower intake and/or status of antioxidant vitamins71'73. 
Therefore, we studied the effect of a dose of 400 IU of vitamin E on two-year 
progression of common carotid artery intima media thickness (CCA-IMT), as a 
marker for atherosclerosis among a group of 218 male lifelong cigarette smokers from 
the general population. 
Methods 
Population and design. The study was designed as a two-year randomized double-
blind placebo-controlled trial. Male inhabitants born between 1919 and 1946 from 
Nijmegen, a city of approximately 150,000 persons in the Netherlands, were 
approached using 7,000 addresses obtained from the Municipal Registration Office. 
The recruitment period was from October 1995 to July 1996. Eligible cigarette 
smokers were invited to an information evening and selected from returned 
questionnaires and on a medical examination. Three hundred and forty five smokers 
entered the selection procedure. Excluded were diabetes patients (n=T0), users of 
(multi)vitamin-, vitamin E, vitamin C, 6-carotene, garlic, or fish oil supplements 
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(n=29), users of vitamin K antagonists (phenprocoumon, acenocoumarol) (n=8), 
individuals with current illness interfering with participation (n=17), and subjects not 
compliant to the protocol or unwillingness to participate (n=63). All together, 218 
subjects ranging in age from 50 to 75 years were randomly assigned to intervention 
(n=109) and placebo group (n=109). The subjects received either capsules containing 
a daily dose of 400 IU (268 mg) vitamin E as dl-a-tocopherol or placebo capsules 
(provided by F Hoffman La Roche Ltd, Basel). 
In 191 subjects, CCA-IMT measurements were obtained both at baseline and 
after a mean follow-up time of 1.8 years. Main reasons for the 27 subjects lost to 
follow-up regarding CCA-IMT measurements were either health related (n=4 vitamin 
E group, n=5 placebo group) of which 2 related to CVD (one person in the placebo 
group died of aneurysm of the aorta abdominalis), or unwilling to comply to the study 
protocol, not motivated to continue the study or having adverse feelings related to the 
intake of the capsules (n=7 vitamin E and n=ll placebo group). An additional 2 
subjects were excluded from the analyses both from the vitamin E group as in the 
presence of plaques, IMT could not be properly measured at baseline or at 2-year. 
This resulted in 189 subjects included in the data analysis. 
Written informed consent was obtained from all participants. The study was 
approved by the ethics committees of Wageningen University and Nijmegen 
University Hospital. 
Ultrasound measurements. Ultrasound examinations were performed at baseline and 
after 2 years on both the left and right side of the distal 1.0 cm straight part of the 
common carotid artery (CCA), using a high resolution B-mode ultrasound (Biosound 
Phase-2) with a transducer frequency of 10 MHz. Images were stored on an optical 
disk and analyzed with a semiautomatic software program (Eurequa; TSA company, 
Meudon France106) by one reader blinded to treatment assignment or any other study 
information. Three measurements were made in a 1.0 cm long segment of both the 
posterior- and anterior wall. When a plaque was present a smaller segment was taken 
with a minimum of 0.2 cm. For the scanning at 2-year a worksheet with data of the 
baseline measurement on head position and scanning angle and an on line video image 
of the baseline measurement was used by the ultrasonographer to assure high 
reproducibility. Details of the scanning and reading procedure and of the 
reproducibility have been described elsewhere90. The mean of left and right posterior 
wall and left and right anterior wall and the mean of the combination of posterior and 
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anterior wall at right and left side were used in the data analyses. Progression is 
defined as the difference of common carotid artery intima media thickness (CCA-
IMT) measurements at baseline and after two-years. 
Low density lipoprotein oxidation and antioxidant vitamins. Fasting EDTA blood 
samples for oxidation of LDL were collected and directly supplemented with 
saccharose. Fasting heparinized samples were obtained for vitamin and lipid analyses. 
All samples were stored at -80°C until analysis. 
LDL was isolated by density gradient ultracentrifugation (40,000 rpm for 18 h 
at 4°C) using a SW40 rotor (Beckman, Palo Alto, California, USA). The oxidation 
experiments were performed as described by Esterbauer et al.28 and as modified by 
Princen et al.124. Briefly, the oxidation of LDL (60 ug apolipoprotein/ml) was initiated 
by the addition of 18 uM CuSCv The change of the 234-diene absorption was 
followed spectrophotometrically(Lambda 12, Perkin Elmer, GmBH, FRG). The lag 
time (min) was determined as the intercept of the tangents drawn to the segments of 
the absorbance curves of the lag and propagation phases of conjugated dienes. All 
samples of the same person were analyzed in the same run. 
For the vitamin C analyses 0.5 ml plasma was stabilized with 4.5 ml 5% 
metaphosphoric acid within one hour after blood collection. Vitamin C was measured 
fluoremetrically. The plasma concentrations of ct-tocopherol and 6-carotene and 
vitamin levels in LDL were analyzed by reverse phase high-performance liquid 
chromatography (HPLC). 
Smoking and other CVD risk factors. Pack-years of smoking were calculated by 
multiplying duration of smoking (smoking years) by the number of cigarettes smoked 
per day divided by 20. Plasma cotinine was measured at baseline by packed column 
gas-liquid chromatography108. 
Medical history, current medication, and family history of CVD was obtained 
at baseline by a research nurse. Baseline medication for CVD included lipid lowering 
drugs, digitalis, daily aspirin use, B-blockers, Ca-antagonists, ACE-inhibitors, and 
nitrates. Blood pressure measurements, changes in smoking habits and other lifestyle 
factors and medical consumption or current illness were checked every half year. 
Body mass index (BMI) was calculated as weight divided by squared height (kg/m ). 
Total plasma cholesterol and triglycerides were analyzed enzymatically 
(Boehringer Mannheim GmbH, FRG and Sera-PAK, Tournai, Belgium). HDL 
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cholesterol was determined with the polyethylene glycol method114. LDL cholesterol 
was calculated by the Friedewald equation115. 
Data analyses. Differences within the study groups and between vitamin E and 
placebo group were tested by student t-test. Means and mean individual changes were 
compared by the Mann-Whitney U-test and Wilcoxon-signed rank test, respectively, 
when not normally distributed. Correlations are given by Spearman or Pearson 
correlation coefficients (r) where appropriate. ANCOVA was used to compare 
adjusted mean changes in CCA-IMT within and between vitamin E and placebo 
group. Multiple regression was used to study the treatment effect adjusted for classical 
risk indicators for CVD. The intervention effect is given as the regression coefficient 
for treatment group with 95% confidence intervals (CI). The statistical package SAS 
(version 6.09,1989) was used for all the analyses. A p-value of 0.05 or a 95% 
confidence interval not including 0 when testing mean differences between and within 
groups was considered statistically significant. 
Results 
The lifelong male smokers in this study had a mean (SD) age of 60 (6) years and 
smoked an average of 43 (8) years ranging from 16 to 62 years. Table 3.1 gives the 
baseline characteristics by study group. No significant differences were observed in 
smoking characteristics, body mass index, blood pressure and health characteristics 
between the vitamin E and placebo group. In the placebo group 14% of the subjects 
had experienced CVD and in the vitamin E group 9%. 
Baseline plasma lipid values did not differ between vitamin E and placebo 
group (table 3.2). Except for a small but significant difference in change in plasma 
total cholesterol, caused by changes in LDL cholesterol, no differences in changes in 
plasma lipid values, blood pressure or weight were observed between both study 
groups during the intervention period. As expected plasma and LDL-vitamin E 
increased significantly (p < 0.05) in the vitamin E supplemented group. More than 
80% of the capsules was taken by 83% of the subjects according to pill counts. 
The lagtime during the in vitro oxidation of LDL was 18.1 minutes (95% 
CL15.5 to 20.7) longer in the vitamin E than in the placebo group. This increase in 
lagtime correlated highly with increase in LDL-vitamin E in the intervention group as 
assessed by Spearman correlation r=0.7 (p=0.0001). 
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Table 3.1. Baseline characteristics by study group for male lifelong smokers. 
Placebo group Vitamin E group 
n=93 n=96 
age (y) 
body mass index (kg/m2) 
systolic blood pressure 
diastolic blood pressure 
ankle brachial pressure index 
CCA-IMT (mm) 
posterior wall 
anterior wall 
combination 4 sites 
cigarettes (number/d) 
smoking years 
pack years 
plasma cotinine ug/ml 
cardiovascular disease (CVD) history* 
hypertension (%)f 
medication for CVD (%)J 
mean or % 
59.9 
26.1 
141 
84 
1.08 
0.97 
0.95 
0.96 
18 
43 
38 
248 
14 
22 
12 
SD 
6.0 
3.3 
17 
8 
0.07 
0.22 
0.19 
0.18 
9 
7 
19 
125 
mean or % 
60.2 
25.9 
141 
84 
1.08 
0.93 
0.96 
0.94 
17 
43 
37 
252 
9 
19 
11 
SD 
6.1 
3.2 
16 
8 
0.06 
0.15 
0.18 
0.14 
9 
8 
21 
122 
* Self-reported CVD history included MI, stroke or bypass surgery. 
t Hypertension: subjects using antihypertensive medication or having systolic and/or diastolic blood 
pressure > 160 mmHg and > 95 mmHg, respectively. 
% See method section. 
The smokers in this study had a mean unadjusted CCA-IMT (4 sites) of 0.95 
(0.16), and 0.95 (0.19) and 0.96 (0.18) for the posterior and anterior wall, respectively 
(table 1). Correlations for baseline CCA-IMT with CVD risk indicators, i.e., age, 
systolic and diastolic blood pressure, BMI, plasma total- and LDL cholesterol were all 
between 0.17 and 0.48 (all p<0.05). 
In the placebo group the 2-year unadjusted change of CCA-IMT (4 sites) was 
0.022 (0.12) mm (95% CI:-0.002; 0.05,p=0.07). The baseline values for posterior wall 
and for CCA-IMT (4 sites) were somewhat lower in the vitamin E group compared to 
the placebo group while 2-year change was highly dependent on baseline values. 
Pearson correlations of change with baseline values were r=-0.37, -0.33, -0.46 (all 
p=0.0001) for posterior and anterior wall and CCA-IMT (4 sites), respectively. In 
table 3.3 changes in CCA-IMT adjusted for baseline values and difference in 
intervention period (model I) are presented. A significant progression of CCA-IMT of 
0.026 mm, 95% CI:0.005;0.047 was seen in the placebo group compared to 0.017, 
95% CI:-0.004;0.038 in the vitamin E group. Reduction in progression in the vitamin 
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.Intervention trial: Vitamin E and carotid IMTprogression in smokers 
E group was -0.009 mm 95% CI:-0.039;0.020 (35%) as compared to the placebo 
group. Further adjustments (model II) for classical risk indicators for CVD revealed a 
non significant difference of-0.014 mm 95% CI:-0.043;0.015 (47%) in CCA-IMT (4 
sites) between vitamin E and placebo group. For the posterior wall this was 62% and 
for the anterior wall 24%. 
At baseline the Spearman correlations between lagtime and CCA-IMT (4 sites), 
posterior wall and anterior wall were -0.13 (p=0.09), -0.13 (0.09) and -0.08 (p=0.31), 
respectively. There were no significant associations between changes of CCA-IMT (4 
sites), posterior and anterior wall and changes in lagtime in the vitamin E group. 
Discussion 
Our vitamin E intervention trial among lifelong smokers showed a non-significant 
47% reduction of 0.014 mm in progression of CCA-IMT for the vitamin E compared 
to the placebo group. 
Lifelong smokers are showing faster progression rates of CCA-IMT than 
nonsmokers76'77. The high baseline CCA-IMT values of 0.95 mm we observed are 
comparable to those of other high CVD risk groups, e.g. patients with familial 
hypercholesterolemia125. Furthermore, the high free radical exposure and lower 
antioxidant status73 make lifelong smokers particularly suitable to study effects of 
antioxidant supplementation. The associations we found between baseline CCA-IMT 
and CVD risk factors are consistent with findings from other epidemiological 
studies96. 
Our study design was based on the a priori expectation that a daily dosis of 400 
IU vitamin E would generate a relevant and statistically significant reduction in 
progression of CCA-IMT. Despite a 47% reduction in 2-year progression no statistical 
significance was reached, probably because of limited power. It turned out that, the 
spontaneous 2-year progression in the placebo group and the absolute difference in 
progression between vitamin E and placebo group were smaller than was expected 
based on the limited information available at the start of our trial77'126. In a 2-year 
population-based study77 faster progression (0.21 mm progression in maximum CCA-
IMT) for male smokers than non smokers was reported. Ongoing lipid lowering trials 
at that moment suggested progression rates of 0.008 to 0.10 mm/year126. Based on this 
information, we anticipated a spontaneous 2-year progression of CCA-IMT of at least 
0.10 mm in our high risk population of older, lifelong smoking males. After 
adjustment for CVD risk factors we found in the placebo group a spontaneous 
progression of only 0.030 mm, seriously reducing the power of our statistical test. 
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This smaller than expected progression is not specific to our methodology as it is in 
line with reports from recent lipid lowering trials and the ARIC study76'127. Also, the 
fact that high baseline values, like ours, have higher levels of measurement error128 
has further contributed to the lower than expected power of our study. 
Poor compliance will not have attenuated our study results since mean plasma 
vitamin E levels increased more than twofold and an individual twofold increase was 
seen in 75% of the subjects, in line with dose response studies45. Moreover, the dose 
of 400 IU vitamin E is justified, according to the CVD endpoint trial56 on vitamin E 
(400 IU) that showed reduction in nonfatal MI (but not fatal MI nor total mortality) in 
coronary patients. 
Increased oxidation of LDL in smokers is supported by higher levels of plasma 
lipid peroxides71,73 and a decrease in susceptibility to oxidation of LDL after 
quitting . Our observation of an increase in lagtime after vitamin E supplementation 
is in line with other studies45'124'129. 
The increasing number of studies reporting positive associations between 
carotid IMT and generalized atherosclerosis91 and cardio- and cerebrovascular events 
at various sites95'117 justified the use of carotid IMT measurements by B-mode 
ultrasound as intermediate endpoint for atherosclerosis in our study. Also, this allows 
for direct comparison to other studies to qualitatively assess the clinical relevance of 
our intervention effect of 0.014 mm reduction in progression of CCA-IMT. The 8.8 
years follow-up of the cholesterol lowering atherosclerosis study117 reported for every 
0.03 mm/year progression in IMT a relative risk of 3.1 (95% CI [2.1-4.5]) on any 
coronary event. Also, in a cross sectional study, Bots et al.95 reported a relative risk of 
1.34 for stroke and 1.25 for MI for every additional difference of 0.16 mm of CCA-
IMT after adjustment for major cardiovascular risk factors. Together, these findings 
suggest that our results may be of clinical relevance, but the lack of statistical 
significance of our intervention effect clearly implies that such conclusion would 
require further substantiation from additional intervention studies. 
Thus, as one of the first intervention trials, our study has not clearly shown a 
protective effect of vitamin E supplementation on atherosclerosis for the high risk 
population of older male lifelong smokers. Studies with more statistical power are 
needed to provide clear evidence for the potential beneficial action of vitamin E on the 
progression of atherosclerosis. Several large-scale vitamin E intervention trials are 
underway5 '60 and will allow for generalization across different populations. So far, 
recommendations regarding vitamin E supplementation for the prevention of 
atherosclerosis are premature in light of the available evidence. 
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Glutathione S-transferase Ml genotype \r\ 
smokers mediates effect of vitamin E on 
atherosclerosis* 
Frouwkje G. de Waart, Frans J. Kok, Tineke J. Smilde, Anneke Hijmans, Hub 
Wollersheim, Anton F.H. Stalenhoef 
Abstract 
We hypothesize that smokers with the null genotype for GSTM1 (GSTM1-0), who thus lack 
the detoxification enzyme glutathione S-transferase ul, a) show increased progression of 
atherosclerosis and b) may benefit more from vitamin E supplementation in respect of 
reduced progression of atherosclerosis than smokers with the positive genotype (GSTM1-7). 
In a randomized placebo-controlled trial we studied the effect of vitamin E (400 IU) on 
atherosclerosis, as measured by 2-year change of left and right posterior and anterior common 
carotid intima media thickness (CCA-IMT) by B-mode ultrasound, among 189 male lifelong 
smokers. The frequency of GSTM1-0 was 0.50. In the placebo group, smokers with GSTM1-
0 genotype had a higher mean 2-year progression of CCA-IMT of 0.045 mm (95% CI 0.016; 
0.074, p=0.002) compared to 0.012 mm (95% CI -0.020;0.043, p=0.47) for those with 
GSTM1-7 genotype after adjustment for baseline IMT, intervention time and major CVD risk 
factors. This was more pronounced for the posterior wall of CCA-IMT shown by a difference 
of 0.052 mm (95% CI 0.001;0.103, p=0.046) between GSTM1-0 and GSTM1-7 groups. For 
the smokers with GSTM1-0 genotype, vitamin E supplementation reduced the proportion of 
smokers with increased CCA-IMT progression at respectively the left posterior and anterior 
wall by 73% (95% CI 26%; 90% p=0.01) and 62% (95% CI -4%; 86%, p=0.06), as compared 
to placebo. In conclusion, our data suggest that smokers lacking the detoxifying enzyme GST 
|al show stronger progression of atherosclerosis and may benefit more from vitamin E 
supplementation. 
Submitted 
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Introduction 
Differences in genotype for enzyme systems involved in the biotransformation from 
cigarette smoke metabolites may differentiate the risk for cardiovascular disease 
among smokers130. The glutathione S-transferase u 1 (GSTM1) polymorphism is 
particularly relevant as fifty percent of the general Caucasian population lacks 
GSTM1 enzyme activity due to two deficient GSTM1 null alleles (GSTM1-0)131. The 
enzyme GSTM1 is involved in detoxification of potential atherogenic substances such 
as lipid peroxides, reactive oxygen species and polycyclic aromatic hydrocarbons 
from cigarette tar. 
By preventing lipid oxidation of LDL, the antioxidant vitamin E is believed to 
protect against the development of atherosclerosis129. As smokers are particularly 
exposed to free radicals and generally have a lower antioxidant vitamin status73 they 
may especially benefit from vitamin E supplementation. 
We hypothesize that smokers with the GSTM1-0 genotype have increased 
progression of atherosclerosis and benefit more from vitamin E supplementation. This 
was studied among male lifelong smokers in a double-blind placebo-controlled 
intervention trial on the effect of 400 IU vitamin E supplementation on the 2-year 
change in the common carotid intima media thickness (CCA-IMT) measured by B-
mode ultrasound as a valid and highly reproducible marker for atherosclerosis89'90'132. 
Methods 
For a double-blind placebo controlled 2-year intervention trial male inhabitants born 
between 1919 and 1946 from Nijmegen, a city in the Netherlands, were approached 
using addresses obtained from the Municipal Registration Office. The recruitment 
period was from October 1995 to July 1996. Eligible cigarette smokers were selected 
from returned questionnaires and on a medical examination. Three hundred and forty 
five smokers entered the selection procedure. Excluded were diabetes patients (n=10), 
users of (multi)vitamin-, vitamin E, vitamin C, 6-carotene, garlic, or fish oil 
supplements (n=29), users of vitamin K antagonists (phenprocoumon, acenocoumarol) 
(n=8), individuals with current illness interfering with participation (n=17), and 
subjects not compliant to the protocol or unwillingness to participate (n=63). All 
together, 218 subjects were randomized and received either 400 IU (364 mg) vitamin 
E as dl-a-tocopherol or placebo capsules (provided by F Hoffman La Roche Ltd, 
Basel). In 189 subjects, CCA-IMT measurements were obtained both at baseline and 
after a mean follow-up time of 1.8 years. Main reasons for the 29 subjects lost to 
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follow-up regarding CCA-IMT measurements were either health related (n=4 vitamin 
E group, n=5 placebo group) of which 2 related to CVD (one person in the placebo 
group died of aneurysm of the aorta abdominalis), or unwilling to comply to the study 
protocol, not motivated to continue the study or having adverse feelings related to the 
intake of the capsules (n=7 vitamin E and n=ll placebo group), or for two subjects 
(vitamin E group) in the presence of plaques IMT could not be properly measured at 
baseline or at 2-year. 
Written informed consent was obtained from all participants. The study was 
approved by the ethics committees of Wageningen University and Nijmegen 
University Hospital. 
At baseline and at two year ultrasound examination were performed on both the 
left and right side of the distal 1.0 cm straight part of the common carotid artery, using 
a high resolution B-mode ultrasound (Biosound phase-2) with a transducer frequency 
of 10 MHz90. Images were stored on an optical disk and analyzed with a 
semiautomatic software program (Eurequa; TSA company, Meudon France106) by one 
reader blinded to treatment assignment or any other study information. For the 
scanning at 2-year a worksheet with data of the baseline measurement on head 
position and scanning angle and an on line video image of the baseline measurement 
was used by the ultrasonographer to assure high reproducibility. Details of the 
scanning and reading procedure and of the reproducibility have been described 
elsewhere90. 
GSTM1 genotypes were detected from buffycoat by PCR-based assays as 
originally described by Brockmoller et al.133. Written informed consent for isolation of 
DNA was given separately by all participants prior to GSTM1 genotype detection. 
All statistical analyses were performed by SAS-PC. Mean differences and 95% 
confidence intervals in 2-year change in CCA-IMT were calculated by ANCOVA by 
computing least square means for the interaction effects of intervention and of 
GSTM1 polymorphism (PROC GLM). Adjustments were made for differences in 
baseline IMT and intervention time. In a second model further adjustments were made 
for major CVD risk factors. Increased progression of CCA-IMT was defined as CCA-
IMT values above the median in the placebo group. Logistic regression with increased 
proportion of IMT was used as an additional measure to calculate the vitamin E 
intervention effect by genotype for the left and right posterior and anterior wall 
separately. 
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Table 4.1 Mean (SD) baseline characteristics by GSTM1 genotype for 189 male 
smokers 
Characteristics 
Vitamin E intervention group (%) 
Posterior wall (PW) CCA-IMT* (mm) 
Anterior wall (AW) CCA-IMT (mm) 
Combination PW, AW CCA-IMT (mm) 
Age (y) 
Body mass index (kg/m2) 
Cigarettes (number/day) 
Pack years of cigarette smoking 
Cardiovascular disease(CVD) history (%f 
Hypertension (%)* 
Medication for CVD (%) 
GSTM1-7 
(n=94) 
54(n=51) 
0.92(0.17) 
0.95 (0.18) 
0.94(0.15) 
60(6) 
25.8(3.1) 
18(9) 
38.7(21.4) 
9 
20 
6 
GSTM1-0 
(n=95) 
47 (n=45) 
0.97(0.21) 
0.96(0.19) 
0.97(0.17) 
60(6) 
26.1 (3.4) 
17(9) 
35.4(18.4) 
15 
20 
20 
P-value 
0.34 
0.09 
0.78 
0.19 
0.75 
0.59 
0.33 
0.44 
0.18 
0.97 
0.006 
CCA-IMT=common carotid artery intima media thickness. 
^elf-reported CVD history included myocardial infarction, stroke or bypass surgery 
'Hypertension: using antihypertensive medication or having systolic and/or diastolic blood pressure 
>= 160 mmHg and >= 95 mmHg, respectively. 
Results 
Baseline values for CCA-IMT (combination of right and left posterior (PW) and 
anterior (AW) common carotid intima media thickness) and for PW and AW 
separately were non-significantly higher in the group with the GSTM1 null- compared 
to the positive genotype (table 1). In the placebo group, the increase in CCA-IMT was 
0.036 (p=0.01) in individuals with the GSTM1-0 genotype and 0.014 mm (p=0.38) in 
those with the GSTM1-7 genotype (Table 2). After adjustment for major CVD risk 
factors (model 2) the GSTM1-0 typed smokers in the placebo group showed 0.033 
mm (95% CI -0.010; 0.076, p=0.13) more increase in CCA-IMT than the GSTM1-/ 
genotype group. This difference was most pronounced in the PW (difference of 0.052 
mm, 95% CI 0.001; 0.103, p=0.046). No significant intervention effect (difference 
between vitamin E and placebo group) was found for progression CCA-IMT and 
progression of PW and AW by GSTM1 genotype. Although a larger change in CCA-
IMT was seen in the GSTM1-0 group (CCA-IMT change= -0.022 mm) than in the 
GSTM1-7 group (CCA-IMT change= -0.003 mm)(model 2). 
For the PW and AW at the left and right site separately a variable less sensitive 
towards distribution of individual values was created by defining subjects with values 
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Table 4.2. Two year change in common carotid intima media thickness (mm) by 
GSTM1 polymorphism for the placebo and vitamin E group and intervention effects 
(vitamin E - placebo) for 189 male lifelong smokers. 
GSTM1-/ GSTM1-0 
mean (95% CI) mean (95% CI) P-value* 
Model 1 2-yr change posterior and anterior wall combined (mm) 
Placebo 0.014 (-0.017; 0.045) 0.036 (0.008; 0.065) 0.29 
Vitamin E 0.015 (-0.014; 0.044) 0.019 (-0.011; 0.049) 0.85 
Intervention effect 0.001 (-0.042; 0.044) -0.017 (-0.059; 0.024) 0.54 
Model 2 2-yr change posterior and anterior wall combined (mm) 
Placebo 0.012 (-0.020; 0.043) 0.045 (0.016; 0.074) 0.13 
Vitamin E 0.008 (-0.020; 0.037) 0.023 (-0.007; 0.054) 0.49 
Intervention effect -0.003 (-0.045; 0.039) -0.022 (-0.063; 0.020) 0.54 
2-yr change posterior wall (mm) 
Placebo -0.002 (-0.038; 0.035) 0.050 (0.016; 0.084) 0.046 
Vitamin E -0.005 (-0.039; 0.028) 0.027 (-0.008; 0.063) 0.20 
Intervention effect -0.004 (-0.053; 0.046) -0.023 (-0.072; 0.026) 0.58 
2-yr change anterior wall (mm) 
Placebo 0.024 (-0.017; 0.065) 0.034 (-0.003; 0.071) 0.73 
Vitamin E 0.021 (-0.016; 0.057) 0.025 (-0.014; 0.064) 0.88 
Intervention effect -0.003 (-0.058; 0.052) -0.009 (-0.063; 0.045) 0.89 
* P-value for testing differences between genotype groups 
Model 1: adjusted for baseline CCA-IMT and intervention period; 
Model 2: model 1 + adjusted for age and baseline values of plasma LDL-, HDL-cholesterol, 
systolic blood pressure, BMI, presence of CVD, baseline antihypertensive or CVD 
medication and pack years of smoking 
above the median of 2-year IMT change (calculated from the placebo group) as 
having increased progression of IMT (Table 3). In the GSTM1-0 genotype group for 
the left PW and left AW the proportion of smokers with increased progression was 
reduced by 60% (95% CI 3%; 83%,p= 0.04) and 52% (95% CI -19%; 80%,p=0.11), 
respectively, by supplementation with vitamin E as compared to placebo. This 
reduction was more pronounced after adjustment for major CVD risk factors 
(reduction in left PW of 73%,p=0.01 and 62%, p=0.06 in left AW). An unexpected 
non significant higher proportion of men with increased progression in the right PW 
and AW by vitamin E supplementation was observed in the GSTM1-0 subjects. 
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Table 4.3 Prevalence odds ratios (OR) for the intervention effect (vitamin E minus 
placebo) of having an increased 2-yr CCA-IMT by GSTM1 polymorphism for 189 
male lifelong smokers. 
Model 1 
Posterior wall right 
Posterior wall left 
Anterior wall right 
Anterior wall left 
Model 2 
Posterior wall right 
Posterior wall left 
Anterior wall right 
Anterior wall left 
GSTMl-7 
OR (95% CI) 
1.13 (0.46; 2.80) 
1.19 (0.48; 2.93) 
1.23 (0.49; 3.09) 
1.03 (0.36; 2.97) 
1.05 (0.40; 2.81) 
1.03 (0.36; 2.98) 
1.06 (0.38; 2.94) 
1.36 (0.40; 4.59) 
GSTM1-0 
OR (95% CI) 
1.97 (0.79; 4.95) 
0.40 (0.17; 0.97) 
1.59 (0.58; 4.35) 
0.48 (0.20; 1.19) 
1.91 (0.69; 5.27) 
0.27 (0.10; 0.74) 
1.70 (0.53; 5.44) 
0.38(0.14;1.04) 
P-valuet 
0.39 
0.09 
0.75 
0.19 
0.33 
0.07 
0.85 
0.08 
*An increased 2-yr CCA-IMT is defined as the upper median levels of change in the 
placebo group, ^ -value for testing differences between genotype groups 
Model 1: adjusted for baseline CCA-IMT and intervention period 
Model 2: model 1 + adjusted for, age and baseline values of plasma LDL-, HDL-cholesterol, 
systolic blood pressure, BMI, presence of CVD, baseline antihypertensive or CVD 
medication and pack years of smoking. 
Discussion 
In this study we showed that the 2-year progression of common carotid intima media 
thickness (CCA-IMT) was clearly more increased for smokers with the GSTM1-0 
genotype, thus lacking the detoxification enzyme glutathione S-transferase u, 
compared to smokers with the GSTMl-7 genotype. Vitamin E supplementation in 
smokers with the GSTM1-0 type was beneficial for specific sites of CCA-IMT shown 
by a 60 to 73% reduced proportion of smokers having increased progression of CCA-
IMT. 
For cancer at various sites studies are available on GSTM1 genotype showing 
increased risk for individuals with the GSTM1-0 type, especially in interaction with 
other factors as e.g. smoking131. It is hypothesized that the detoxification role of 
GSTM1 in smokers is not only important in the development of specific cancers but 
also in the pathogenesis of atherosclerosis. However, studies on GSTM1 genotype and 
atherosclerosis are lacking. Lack of glutathione transferase activity towards trans-
stilbene oxide determined by phenotype was found more frequently among smokers 
with intermittent claudication than among healthy smokers of the same age . 
However, in a study among 159 heavy smokers no higher levels of polycyclic 
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aromatic hydrocarbon-DNA adducts were found in the presence of GSTM1-0 
genotype compared to GSTM1-7 genotype135. 
To give an overall picture we presented the combination of 4 sites of CCA-
IMT as well as the posterior and anterior wall and the individual left and right site 
CCA-IMTs separately. Differences in strength and significance of individual 
associations may reflect real differences or may be related to measurement variability. 
The anterior wall of the common carotid artery may systematically underestimate the 
true IMT as the image does not anatomically reflect the intima media complex 
exactly136. However, it appears to reflect the presence of atherosclerosis elsewhere in 
the arterial system as strongly as the posterior wall132. Furthermore, the general 
association between different sites137 favors a combination of sites in estimating 
progression as this reduces the variability considerably, leading to increased 
precision132. But, differences in IMT values between left and right site associated with 
carotid atherosclerosis have been reported 138 and differences in focal nature of the 
atherosclerotic process would favor presentation of individual sites, thereby increasing 
specificity but reducing precision. 
The use of carotid IMT by B-mode ultrasound in our study as an indicator of 
atherosclerosis is justified by reported associations between carotid IMT and 
generalized atherosclerosis91. At the start of our trial we anticipated a spontaneous 2-
year progression of CCA-IMT of at least 0.10 mm in our high risk smoking 
population77. The smaller than expected progression is not specific to our study as it is 
in line with findings from other studies in smokers76. 
Evidence for a beneficial effect of vitamin E on CVD is limited and results are 
inconsistent. A randomized trial reported no reduction in coronary risk for male 
smokers54 for 50 IU vitamin E. However, in a secondary analysis a reduction in non-
fatal myocardial infarction (MI) but not on fatal coronary heart disease among 
smokers with previous MI was observed55. A secondary prevention trial of 400 and 
800 IU/day showed also a reduction in nonfatal but not in fatal MI56. A recently 
published trial57 among MI survivors showed no reduction after 3.5 year of 300 mg 
vitamin E supplementation on the combined endpoint of death, nonfatal MI, and 
nonfatal stroke. However, a significant reduction in cardiovascular deaths was found. 
As smokers with the GSTM1-0 genotype will have a lower enzymatic defense 
system against reactive metabolites of cigarette smoke this group was hypothesized to 
especially benefit from the antioxidant vitamin E. Our study is the first to report 
beneficial effects of vitamin E on progression of IMT in relation to GSTM1 
polymorphism in smokers. If further studies confirm our data, GSTM1 genotype may 
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importantly improve the predictive value of smoking for CVD. Also the commonly 
present GSTM1 polymorphism could be considered as a useful tool to refine in an 
easy and cheap way the risk group smokers to improve statistical power in future 
epidemiological studies on the etiology of atherosclerosis. 
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Vitamin E supplementation in elderly lowers 
the oxidation rate of linoleic acid in LDL* 
Frouwkje G. de Waart, Ulrich Moser, Frans J. Kok 
Abstract 
Oxidation of LDL-linoleic acid (LDL-LA), major substrate for lipid peroxidation, may be 
counteracted by the antioxidant vitamin E. In a 3-month randomized double-blind placebo-
controlled trial in 83 apparently healthy Dutch elderly, aged 67-85 years, the direct protective 
effect of 100IU vitamin E on the rate of oxidized LDL-LA was studied. The oxidation of LDL-
LA was measured by its disappearance after a 5-h in vitro Cu-oxidation of LDL isolated from 1 
ml plasma. In the vitamin E group, the decrease in oxidized LDL-LA of 10.4% (p<0.05) was 
significantly different (p<0.05) from the smaller 4.6% (p<0.01) decrease in the control group. 
Moreover, within the vitamin E group the decrease was even more marked over tertiles of a-
tocopherol to LDL-LA ratio with a significant difference in decrease (p<0.05) from the lowest 
compared to the highest tertile of, respectively, 18.4% [-24%;-2%] (median and range) and 
2.0% [-16%;34%]. In conclusion, supplementation with 100 IU vitamin E in elderly is 
beneficial in lowering the rate of oxidation of LDL-LA. The protective effect of vitamin E 
might best be monitored by using the ratio of a-tocopherol to LDL-LA as this reflects the 
degree of a-tocopherol available to protect the amount of LDL-LA present. 
Atherosclerosis 1997;133:255-263 
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Introduction 
An inverse association between both intake and status of vitamin E (oc-tocopherol) and 
coronary heart disease (CHD) morbidity and mortality is supported by an increasing 
number of epidemiological studies49"52'56'139'143, although not conclusively54'144'146. A 
randomized controlled trial56 showed a reduced risk of non-fatal myocardial infarction 
in patients with coronary atherosclerosis upon 400 IU or 800 IU cc-tocopherol daily, 
while another54 showed no effect on cardiovascular mortality upon 50 mg a-tocopherol 
daily. A follow-up study among 11,178 elderly showed significant reduced risks on 
total and CHD mortality for those elderly using vitamin E supplements51. The protective 
effect of the antioxidant vitamin E on CHD is thought to originate from its capacity to 
prevent lipid peroxidation in low density lipoproteins (LDL)28'43. Human intervention 
trials44'45'124'147'148, are in line with this hypothesis, although the dose required to 
decrease the susceptibility of LDL to oxidation is still not agreed upon44'45. In addition 
to vitamin E, interindividual differences in linoleic acid, the major substrate for lipid 
peroxidation149, may contribute to the interindividual variation in LDL peroxidation150. 
The rate of LDL oxidation depends on the poly unsaturated fatty acid (PUFA) 
concentration of LDL151. 
We extend on previous trials by investigating whether 3 months of 
supplementation with 100 IU vitamin E has a direct protective effect on the rate of 
LDL-linoleic acid (LDL-LA) oxidation, and on the absolute amount of oxidized LDL-
LA and formation of conjugated dienes. Furthermore, as the amount of a-tocopherol 
required to prevent oxidation might be directly related to the amount of LDL-LA we 
also studied the role of the ratio of a-tocopherol to LA in the LDL particle. We 
conducted our study in elderly (> 65 years) as few data on oxidation of LDL are 
available for this age group152'153. Moreover, oxidized LDL seems not only to play a role 
in the formation of fatty streaks but also in more advanced lesions6'154. 
Methods 
Population and design. The study was designed as a 3-month randomized double-
blind placebo-controlled trial and conducted in 1994. In two consecutive steps, a total of 
83 apparently healthy elderly, aged 67-85 years, were selected from a database of 1012 
elderly from the city of Arnhem, the Netherlands155. The first selection step included the 
following criteria; still living in Arnhem, not institutionalized, no use of prescribed 
drugs for cardiovascular disease, high blood pressure or diabetes mellitus; no reported 
cancer or chronic diseases of the bowel or stomach, kidney, or liver. In the second step, 
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the 355 remaining persons were invited by mail and received a questionnaire on health 
status, smoking habits, and use of supplements and medication. Seventy-five subjects 
did not respond, 129 refused and 151 were willing to participate. From this group 68 
were not eligible because of the following criteria; use of vitamin supplements (A, A/D, 
C, E or multivitamin) (n=25), stopped smoking less than 5 years before (n=5), current 
treatment for CHD, heart attack or stroke (n=31), use of medication for hypertension or 
high cholesterol (n=6), diabetes (n=2). The 83 eligible subjects were randomly assigned 
to intervention (n=42) and placebo group (n=41). To ensure group comparability, 
stratification was conducted before randomization on the following variables: smoking 
habits (current versus non-smokers), five-year age groups and gender. The subjects 
received either 100 IU vitamin E (twice daily 50 IU) as dl-a-tocopheryl acetate or 
placebo (lactose) capsules. 
Data collection. In the beginning and at the end of the 3-month intervention period 
subjects were picked up at home and brought to the examination room in the 
department. Fasting EDTA and heparinized blood samples were taken for determination 
of plasma cholesterol and antioxidant vitamin levels and measurements of LDL 
oxidation. Body weight, height and blood pressure were determined at both occasions as 
well. At baseline the subjects filled in a questionnaire on socio-demographic 
characteristics, physical activity and perceived health score. They were asked to monitor 
during the intervention period occurring illness and/or medicine use in a diary. To 
improve and monitor compliance the subjects were visited at home once during the trial. 
At the end of the study compliance was assessed by pill counts. 
For the first 34 subjects who entered the study no heparinized tubes, necessary for 
the measurements of oxidation, fatty acid- and antioxidant profile of LDL, were 
available. Thus, the data on the oxidation rate of linoleic acid are restricted to a 
subsample of n=49 subjects. The study was approved by the Medical Ethical Committee 
of the Agricultural University and all subjects gave a written informed consent. 
Laboratory measurements. 
Plasma vitamins. Plasma was prepared within 3 h after collection under nitrogen and 
stored at -80°C until analysis, to minimize analytical variation. Laboratory baseline and 
post-intervention measurements on an individual were performed in the same run. 
Following extraction, the concentrations of a-tocopherol, B + y tocopherol, 6-carotene, 
a-carotene and lutein were measured in plasma, by reverse-phase high-performance 
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liquid chromatography (HPLC) (adapted from Hess et al.112). The column was a 
prepackaged 25 cm x 4.6 mm Vydac 201TP54, Ci8 300 A (Hesperia, CA, USA). 
Detection after separation was carried out using two UV detectors, one for 
determination of retinol and carotenoids (UV2000) (set at 0-10 min: 325 nm; 10-32 
min: 450 nm; 32-40 min: 470 nm) and one detector (UV1000) for determination of the 
tocopherols (set at 0-9 min: 325 nm; 9-40 min:292 nm). Total cholesterol and 
triglycerides (Ames, Bayer Diagnostics, Belgium) and HDL cholesterol were analyzed 
in duplo enzymatically (CHOD-PAP method, Boehringer Mannheim GmbH, 
Germany). LDL cholesterol was calculated using the Friedewald equation115. 
LDL oxidation. LDL oxidation was performed as described by Esterbauer et al.28 by 
incubation of LDL isolated from 1 ml plasma with a freshly prepared 2.5 mmol/L CuCl2 
solution in phosphate buffer saline (PBS), pH 7.4 at 20° for 5 h, with a major 
modification in the isolation step156. 
In short, heparinized plasma (EDTA interferes with the Cu-oxidation) was 
adjusted to a density of 1.21 g/ml by addition of solid KBr and overlaid with 150 
mMol/L NaCl. The samples were centrifuged in a TL-100 ultracentrifuge (Beckman) 
for 25 min. at 10° C and 440,000 x g. The LDL was removed by slicing the 
polycarbonate tube, adjusted to a density of 1.21 and centrifuged a second time for 90 
min. at 10° C and 440,000 x g in order to remove attached proteins. The LDL was again 
removed by slicing the polycarbonate tube and used directly for the LDL oxidation 
experiments since any dialysis steps would remove also antioxidants and carotenoids. 
ApoB was determined by RID (Immuno AG, Vienna). Formation of conjugated dienes 
was measured every 15 min for 5 h by continuously monitoring the increase of the 234 
nm absorbance following the above described Cu-oxidation of LDL. The length of the 
lag phase (min) was determined as the intercept of the tangents drawn to the segments 
of the absorbance curves corresponding to the lag and propagation phases of conjugated 
dienes formation as described by Frei and Gaziano157. 
LDL vitamins and fatty acids, a-tocopherol and 6-carotene concentrations in the LDL 
fractions were analyzed simultaneously by reversed phase HPLC. The lipids of the LDL 
were extracted by the method of Bligh and Dyer158. The fatty acids were transesterified 
and the methyl esters analyzed by gas chromatography on a capillary OV-1 column159. 
The data were normalized by comparing the areas of the fatty acid peaks with the area 
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of the internal standard peak (heptadecanoic acid) after correction for the various 
response factors. 
Rate of linoleic acid oxidized was calculated as the disappearance of linoleic acid 
upon LDL oxidation divided by the LDL-LA concentration prior to oxidation times 
100. Rate of arachidonic acid oxidized (LDL-AA) was calculated similarly. The 
absolute amount of LDL-LA oxidized, LDL-AA oxidized, amount of conjugated dienes 
formed, and vitamin concentrations in LDL are expressed per mg apoB. The molar 
extinction coefficient for dienes (29,500 M^cm"1) was used to calculate the maximum 
amount of conjugated dienes formed. The ratio of a-tocopherol to linoleic acid in LDL 
was calculated as (LDL-a-tocopherol/linoleic acid)* 100. 
Data analysis. Baseline results are expressed as mean ± standard deviations (SD) or 
percentage ± SD. Changes in plasma- and LDL vitamins and lipid profiles after 3-
month intervention are expressed as median and range of individual percentage change. 
Changes in oxidation measures (LDL-LA and LDL-AA oxidized, amounts of 
conjugated dienes formed and lag times) are expressed as median and range of absolute 
change. 
One subject in the vitamin E group taking only 15% of the distributed capsules 
was excluded. Therefore, for plasma vitamin and plasma lipid profile analyses 41 
subjects were included in both study groups. For LDL oxidation analyses, this resulted 
in data on 24 in both study group. Mean baseline values ± SD and mean individual 
changes during intervention were compared between the study groups by using the 
Mann-Whitney U test. Mean individual changes over the intervention period for the 
control- and vitamin E group were tested using the Wilcoxon-signed rank test for paired 
comparisons within groups. Presented correlations are expressed as Spearman 
correlation coefficients. Analysis were performed using the statistical package SAS. 
Results 
Table 5.1 presents the mean baseline characteristics of the placebo- and vitamin E 
supplemented group. Pre-stratification on sex, smoking behavior and 5-year age groups 
was successful, as shown by equal distribution of these variables in both study groups. 
No differences were observed for the other characteristics either. During intervention 
similar changes in both study groups occurred in body mass index (control group -0.9%, 
p<0.05; vitamin E group -1.3%, p<0.001) and diastolic blood pressure (control group 
6.0%, pO.Ol; vitamin E group 3.3%, p=0.2). 
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Table 5.1. Baseline characteristics of the control- and vitamin E study groups 
Age (yr.) 
Male (%) 
Smokers (%) 
Body mass index (kg/m2) 
Blood pressure (mmHg) 
systolic 
diastolic 
Perceived health score* 
Physical active (%)b 
Intervention period (days) 
Capsules taken (%) 
Control group 
(n41) 
74.8±5.3 
61 
24 
25.3±3.5 
153.5±19.6 
77.3±10.3 
8.2±1.3 
62.5 
84±6 
93.9±8.6 
Vitamin E group 
(n41) 
74.2±5.3 
61 
24 
26.2±3.6 
156.8±23.5 
80.4±9.5 
8.3±1.3 
70.0 
84±4 
92.3±8.3 
Values are mean ±SD, or percentages ±SD when indicated. ' rating on a scale ranging from 1 
(worst) to 10 (best). b based on subjective comparison of physical activity to people of the same 
age and health status 
Intervention with vitamin E induced a significant 43.0 % (absolute median change 
of 14.0 mmol/L, p=0.0001) increase in plasma a-tocopherol (Table 5.2) and a 40.0% 
(absolute median change of 4.9 mmol/mg apoB, p=0.0001) in LDL-ct -tocopherol 
(Table 5.3). Note however, that there was substantial individual variation in the increase 
in a-tocopherol ranging from -31% to +176% increase in plasma, and -12% to +381% 
increase in LDL. The percentage increase in plasma- and LDL a-tocopherol in the 
vitamin E group was associated with a similar percentage decrease in plasma- and LDL-
B+y tocopherol (both r=-0.5, p<0.01). Baseline characteristics as shown in Table 5.1 and 
plasma vitamin values as shown in Table 5.2 yielded similar figures for the 
subpopulation of 48 with oxidation measurement data. 
The plasma lipid profile did not importantly change during the intervention and 
did not differ between the control and vitamin E group (Table 5.2). The small change in 
plasma HDL cholesterol in the vitamin E group, reached statistical significance 
however. 
About 44% of the fatty acids (FA) in LDL are PUFAs, of which 74 % was linoleic 
acid (CI8:2), the main PUFA in LDL, and 14% arachidonic acid (C20:4), the second 
60 
^Intervention trial: Vitamin E and oxidation ofLDL in elderly 
most important PUFA in LDL and very prone to oxidation. FA profile in LDL as % of 
total FA did not differ between the study groups or change during intervention (data not 
shown). 
Table 5.2. Plasma antioxidant vitamins and lipid profile at baseline and after intervention 
Control group 
baseline 
mean SD 
("41) 
change 
median 
Plasma antioxidant vitamins (ftmol/l) 
a-tocopherol 
p-Hy tocopherol 
P-carotene 
a-carotene 
lutein 
34.3 
4.4 
0.42 
0.05 
0.2 
Plasma lipid profile (mmc 
total cholesterol 
triglycerides 
LDL cholesterol 
HDL cholesterol 
5.5 
1.3 
3.2 
1.7 
6.9 
6.0 
0.2 
0.04 
0.08 
)l/l) 
0.9 
0.5 
0.8 
0.4 
0.6 
-0.1 
0.01 
0.00 
-0.01 
0.1 
0.01 
0.05 
0.03* 
3 months 
Range 
-8-7 
-2-4 
-0.6-0.1 
-0.1-0.1 
-0.1-0.1 
-2-1 
-2-1 
-2-1 
-0.2-0.4 
Vitamin E group (w 41) 
baseline 
mean 
33.5 
5.2 
0.34 
0.05 
0.2 
5.5 
1.4 
3.2 
1.7 
SD 
8.9 
7.6 
0.2 
0.03 
0.09 
1.3 
0.5 
1.1 
0.5 
change 3 months 
median 
14.0**J 
-1.2*$ 
0.04f 
0.00 
0.01 
0.03 
0.01 
0.06 
0.03f 
range 
-7-49 
-30-1 
-0.3-0.3 
-0.1-0.2 
-0.2-0.2 
-1.2-1.8 
-1.4-1.0 
-1.1-1.4 
-1.0-0.5 
Changes significantly different from 0: * p < 0.05, " p< 0.001. Significantly different from control group;T 
p<0.05,Jp<0.001 
Figure 5.1 A shows LDL oxidation over time expressed as the median amount of 
conjugated dienes per mg apoB formed. In Fig. 5. IB the decrease from baseline values 
in conjugated dienes formed during the intervention is illustrated. From the time point 
of 3 h to 4.25 h the observed decrease is significantly higher in the vitamin E group 
(p<0.05). No difference at baseline was observed in lag time (phase preceding the 
propagation phase of lipid peroxidation) between vitamin E (mean lag time (SD); 156 
min (25)) and control group (166 min (22)). The median change in the lag time during 
intervention in the vitamin E group (median lag time [25%-75% range]; 28 min [-2;37] 
was significantly (p< 0.05) higher as compared to the control group (-2 min. [-19;8]). 
The observed similar median decrease in control- and vitamin E group during 
intervention in absolute amount of oxidized LDL-LA (respectively 231.3 and 238.8 
nmol/mg apo B) and amount of conjugated dienes formed (respectively 9.5 and 10.4) 
(Table 4)), can be explained by an observed decrease in LDL-LA concentration during 
intervention in both study groups (respectively 8.7% (156 nmol/mg apoB) and 13.8% 
(223 nmol/mg apoB) (Table 5.3). The correlation in the control group between changes 
in LDL-LA concentration during intervention and changes in oxidized LDL-LA is r=0.9 
(pO.OOl). Therefore, to account for differences in LDL-LA concentrations, the amount 
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Figure 5.1. Time-course curves showing measurement of conjugated diene formation 
(nmol/mg apoB) during copper-mediated low density lipoprotein (LDL) oxidation. LDL was 
isolated from 1 ml plasma and oxidized with 2.5 /umol/L Cu2+ and absorbance at 234 nm was 
measured for 5 hat 15-min intervals. In (A), the oxidation curves are given for the control 
group (D) and vitamin E group (A) at baseline as well as after 3-month intervention; control 
group m andvitamin E group (A). In (B), the decrease from baseline values of formation of 
conjugated dienes during intervention are given for control (U) and vitamin E group (A). 
Median values per time point are given; * denotes a significant difference between control 
and vitamin Egroup (p < 0.05). 
CQ 
o 
D. 
< 
.E 
"5 E 
c 
100 
80 
60 
40 
20 
Ofl-a 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 
•v 
tS 25 cd
60 
3 
O 
O 20 
15 
10 
-5 
B 
Oa-S1 
0 0.5 1 t.5- 2 2.5 3 3.5 4 4.5 5 
Time (hours) 
.Intervention trial: Vitamin E and oxidation ofLDL in elderly 
of oxidized LDL-LA was also expressed as percentage of concentrations of linoleic acid 
in LDL prior to oxidation. In the vitamin E group, the median decrease in percentage of 
oxidized LDL-LA of 10.4% (p<0.05) was significantly different (p<0.05) from the 
smaller 4.6% (pO.Ol) decrease in the control group (Table 5.4). Similar results were 
seen for the oxidation of arachidonic acid (LDL-AA) although the twofold decrease in 
the percentage LDL-AA oxidized seen in the vitamin E group as compared to the 
decrease in the control group did not reach statistical significance. 
To account for changes in LDL-LA concentrations as well as changes in LDL-a -
tocopherol upon supplementation, the a-tocopherol/LA ratio in LDL was studied. 
Changes in the a-tocopherol/LDL-LA ratio in the vitamin E group during the 
intervention were inversely correlated with changes in the absolute amount of LDL-LA 
oxidized (r=-0.5; p< 0.05), the percentage LDL-LA oxidized (r=-0.6; pO.Ol), the 
amount of conjugated dienes formed (r=-0.3; p=0.1) and the percentage of LDL-AA 
oxidized (r=-0.6; pO.Ol). Subjects with the largest increase in the a-tocopherol/LDL-
LA had the lowest baseline values for the ratio (r=-0.6 (p<0.001). From tertiles of 
baseline a-tocopherol/LDL-LA ratios (Table 5.5) it can be seen that subjects in the 
lowest tertile (I) benefited most from the supplementation in terms of absolute and 
relative amount of oxidized LDL-LA with median changes in values of -382 nmol/mg 
apoB LDL-LA and -18.4% LDL-LA respectively, in tertile I as compared to -123 
nmol/mg apoB LDL-LA and -2.0% in tertile III. 
For the oxidation measurements the vitamin E- and control group both contained 
four smokers. Excluding them from the analysis did not reveal different results. 
Discussion 
In this double-blind placebo controlled intervention study in an elderly population, 
supplementation with 100 IU vitamin E resulted in a significant two-fold decrease in 
percentage of oxidized LDL-LA between intervention- and control group. Moreover, 
within the vitamin E group this protective effect was even more marked with increase in 
a-tocopherol to linoleic acid ratio in LDL. 
Our study population was selected as "healthy" using a questionnaire on disease 
and medicine use, and can therefore not be compared with the elderly population in 
general. Underlying subclinical diseases may well have been present but are not 
expected to have influenced the comparison between both study groups because of 
randomization. Schmuck et al.152 showed no differences in indices of oxidation of LDL 
between healthy elderly as compared to a younger age group. Stulnig et al.153 recently 
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showed marginally increased amounts of oxidized LDL, estimated by antibodies against 
LDL modified by 4-hydroxynonenal, in serum from healthy elderly as compared to a 
young control group. But in contrast they153 observed an increased lag time and 
decreased maximal rate of LDL-oxidation in vitro for their elderly study group. 
Plasma cholesterol levels in our study of 5.5 mmol/L, which are relatively low for 
an elderly population, have also been found in healthy elderly by Schmuck and 
colleagues152. 
The relative high baseline plasma ct-tocopherol values of 33 mmol/L we found are 
not unusual for a Dutch elderly population as seen in the SENECA study (a study on 
nutrition and the elderly in 11 different countries in Europe)160, and comparable with the 
values found in healthy elderly by Stulnig et al.153. This does not mean, however, that 
healthy elderly might not benefit from vitamin E supplementation. Also healthy elderly 
will have more accelerated atherosclerosis than younger individuals and it is 
hypothesized that oxidized LDL may not only play a role in the formation of fatty 
streaks but also in more complicated lesions through its cytotoxicity and formation of 
new foam cells at the leading edges of more advanced atherosclerotic lesions6'154'161. 
Although not consistently significant Verlangieri et al.162 found in non-human primates 
that cc-tocopherol does not prevent atherosclerosis but appears to lessen the severity and 
reduce the rate of the disease. Hodis et al.142 demonstrated less coronary artery lesion 
progression in subjects with previous coronary artery graft surgery with supplementary 
vitamin E intake of at least 100 IU per day. Vitamin E studies on CHD end-points in 
elderly populations are scarce51, but worth to consider since studies in middle-aged 
subjects suggest beneficial effects49'50'52'56'141'142. It is hypothesized that vitamin E favors 
a protective effect on atherosclerosis by protecting LDL against oxidation43'54. However, 
an animal experiment163 in hyperlipidemic Watanabe rabbits showed that protecting of 
LDL against oxidation by vitamin E does not necessarily lead to less aortic 
atherosclerosis. In future research attention should be paid to find out if a protective 
effect of vitamin E on atherosclerosis can be partly explained by oxidation susceptibility 
of LDL. 
Instead of looking at oxidation products formed we investigated the disappearance 
of LDL-LA as main substrate for LDL lipidperoxidation upon vitamin E 
supplementation. It showed that pre-oxidative LDL-LA concentrations are not 
necessarily stable across the intervention period as seen in a small but significant 
decrease in both study groups in our study. This was due to an overall decrease in fatty 
acids (FA) in LDL over the intervention period, therefore, the contribution of the 
individual FA to total fatty acids remained constant. The decrease in FA might be due to 
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a seasonal effect in dietary habits where fat intake being higher in winter (start study in 
February) than in summer (end of study in June), as supported by a study in young 
Dutch women164. The pre-oxidation LDL-LA concentrations largely determine the 
absolute amount of LDL-LA oxidized (r=0.9, p<0.001 in our study). Changes in the 
concentration of LDL-LA are therefore influencing the amount of LDL-LA oxidized 
(our study r=0.8, p=0.0001) and may mask the protective effect of vitamin E. Therefore, 
to account for pre-oxidative LDL-LA concentrations the ratio of oxidized LDL-LA to 
pre-oxidative LDL-LA values has to be used. The interindividual variation in elevation 
of plasma and LDL a-tocopherol in the vitamin E group in response to the same doses 
of vitamin E has been observed by others45. Dimitrov et al.165 observed that fat-intake 
affected plasma elevation of a-tocopherol in their supplemented group and suggested 
this as one of the contributing factors to intra- and interindividual variation. To relate 
the degree of protection afforded by a-tocopherol to amount of LA present in LDL we 
investigated the ratio of a-tocopherol to LA in LDL. Our results suggest that this ratio 
may contribute to the individual variation in increase in LDL-a -tocopherol upon 
supplementation as subjects with the lowest (most unfavorable) ratio benefited more 
from the vitamin E supplementation. Although regression towards the mean may be part 
of the explanation, this could not account for the observed decreasing effects on 
oxidation of LDL with improvement of the a-tocopherol to LA ratio in LDL. The 
importance of this ratio is also illustrated by a finding of Croft et al.166 who found a 
positive correlation between LDL-a -tocopherol and extent of FA oxidation and 
concluded a possible pro-oxidant effect of vitamin E while a-tocopherol expressed per 
mg LA showed no correlations with indices of LDL oxidation. When LA is not taken 
into account a positive correlation of a-tocopherol with lipid peroxidation products (in 
our study measured as absolute amount of oxidized LDL-LA) might lead to a possibly 
false suggestion that a-tocopherol has a pro-oxidative effect. 
Lowering the amount of LDL-LA through the diet is not necessarily beneficial in 
decreasing oxidation susceptibility of LDL. After all, food products high in LA are 
usually also high in vitamin E and lower total plasma and LDL-cholesterol thereby 
decreasing the total amount of LDL particles present for possible oxidation. 
Intervention trials have shown that mono unsaturated fatty acids (MUFAs) as oleic acid 
are less susceptible to oxidation than linoleic acid150'167'168 and just as effective in 
lowering total plasma, and LDL-cholesterol levels. In a group of Watanabe 
hyperlipidemic rabbits163, diets high in oleic acid and vitamin E increased the lag time 
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(onset to LDL oxidation) with 140%, LA and vitamin E increased lag time by 59% 
while LA alone decreased lag times for LDL-oxidation with 30%. 
The dose of 100 IU vitamin E in our study is relatively low to obtain an effect 
according to a dose-response study by Jialal and colleagues45 suggesting that doses of 
400 IU per day are required to show a protective effect against LDL oxidation. The 
results observed in our study are more in line with another dose-response study by 
Princen et al.44 who found already oxidative protection after ingestion of only 25 IU 
vitamin E for two weeks. Increases of 40.0% (median) in LDL-a -tocopherol and 
43.0% (median) plasma a-tocopherol in our study are in the same order of magnitude 
compared to the aforementioned studies44'45. High baseline plasma vitamin E levels as 
found in our study have been postulated by others145 to be no longer beneficial in 
reducing CHD risk. Recently, however Stephens et al.56 found in a double-blind placebo 
controlled study a relative risk of 0.23 of non-fatal MI upon 400 or 800 IU vitamin E 
daily in patients with angiographically proven atherosclerosis who had baseline plasma 
a-tocopherol values of 32.4 mmol/L. This shows that subjects with high baseline values 
comparable with those in our study might still benefit from vitamin E supplementation. 
In conclusion this study in elderly shows that supplementation with 100 IU 
vitamin E in elderly is beneficial in increasing LDL- and plasma a-tocopherol 
concentrations and lowering the oxidation rate of LDL-LA. The protective effect of 
vitamin E supplementation is monitored more accurately by taking the ratio of LDL-a -
tocopherol to LDL-LA since it reflects the degree in which the LA present in LDL is 
protected by a-tocopherol against oxidation. 
68 
6 
Effect of 3 months vitamin E supplementation 
on indices of the cellular and humoral immune 
response in elderly subjects* 
Frouwkje G. de Waart, Liitzen Portengen, Gert Doekes, Corne J. Verwaal, Frans J. Kok 
Abstract 
It has been suggested that decreased immune responsiveness in the elderly may be counteracted 
by the antioxidant vitamin E. In a 3-month double-blind placebo-controlled intervention trial 
among elderly subjects aged 65 years and over we studied the effects of a daily dose of 100 mg 
dl-a-tocopheryl acetate on the cellular immune responsiveness (n 52) measured by the in vitro 
response of peripheral blood mononuclear cells (PBMC) to the mitogens concanavalin A 
(ConA) and phytohemagglutinin (PHA). Also effects on the humoral immune responsiveness (n 
74) were investigated by measuring immunoglobulin (Ig)G, IgG4 and IgA antibody 
concentrations against various common antigens. In the vitamin E group plasma ot-tocopherol 
increased by 51% (/>=0.0001) during intervention whereas no significant changes were 
observed in the control group. Initial proliferative PBMC responses differed between the vitamin 
E group and the control group whereas all other baseline characteristics were comparable. No 
significant changes were observed in cellular immune responsiveness when adjusted for initial 
values in either the control group or the vitamin E group and, after the trial period, responses in 
the two groups were not significantly different. Similarly, in the vitamin E group no significant 
changes were found in levels of IgG and IgA raised against Penicillium or IgG4 raised against 
egg, milk, or wheat proteins. In the control group small but significant increases in IgG anti-
Penicillium (P <0.05) and decreases in IgG4 against milk proteins (P <0.05) were observed. 
Thus, the results of this study performed with the relatively low dose of 100 mg dl-a-tocopheryl 
acetate do not support the claims of a beneficial effect of vitamin E intake on the overall 
immune responsiveness of elderly subjects. 
British Journal of Nutrition 1997:78:761-774 
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Introduction 
A decreased functioning of specific immune defense mechanisms with aging11"13,169'170 is 
presumed to contribute to increased morbidity and mortality in the elderly170"174. In 
addition to chronic diseases that accompany aging that may lead to a decrease of 
immune responsiveness in the elderly, the aging process itself is thought to play a major 
role too175 highlighting the potential relevance of improving the immune response in 
'healthy' elderly people. Increased lipid peroxidation and production of eicosanoids such 
as prostaglandin E2 (PGE2) may be important determinants in age-associated 
dysregulation of immune responsiveness. Vitamin E may improve immune 
responsiveness by counteracting these effects61"63'176"179. 
Effects of vitamin E supplementation on the cellular and humoral immune response 
in experimental animals have been reported extensively178'180"186. Observational studies in 
healthy elderly human subjects found no positive associations between vitamin E intake 
or status and indicators of cell-mediated immune response65"67. However, these 
observational studies were cross-sectional and not designed to provide information on 
the effect of (long term) specific vitamin supplementation. In an intervention study 
among free-living healthy human elderly subjects with a daily dose of 800 mg dl-a-
tocopheryl acetate for 30 d, Meydani and colleagues61 observed an overall improvement 
in cell-mediated immune response as shown by increased frequency and size of positive 
delayed type hypersensitivity skintest responses, interleukin-2 production and in vitro 
proliferative response of peripheral blood mononuclear cells (PBMC) to the mitogen 
concanavalin A (ConA). Also a reduced PGE2 synthesis by PBMC was seen, which 
argues in favor of reduction of PGE2 production as a possible working mechanism. In 
the same study no significant differences were found in humoral immune response 
measured as total serum concentrations of immunoglobulin (Ig)M, IgG and IgA, nor in 
the T-cell independent proliferative response of B cells to the mitogen Staphylococcus 
aureus Cowan. In another intervention study among institutionalized healthy elderly 
women, supplementation with 200 mg vitamin E for 1 year had no effect on total IgM, 
IgG and IgA antibody concentrations187. 
The optimal dose for potential beneficial effects of supplemental vitamin E on 
immune variables in the elderly has not yet been determined. Studies investigating low 
or relatively (compared with other trials) low doses of supplemental vitamin E can 
contribute to the debate on whether it is warranted to advise elderly people to increase 
their intake of vitamin E-rich foods, or to explore the possibilities of enrichment of 
eligible food products or to advise vitamin E supplement use. But, at this point there is 
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only limited evidence that the positive effects of vitamin E on immune responses, as 
found in animal experiments, generalize to human elderly subjects. Therefore, we have 
investigated the effects of a 3 month period of 100 a-tocopheryl acetate supplementation 
on cell-mediated immune responsiveness, expressed as in vitro response of PBMC to the 
mitogens ConA and phytohemagglutinin (PHA), and on humoral immune 
responsiveness, assessed by measuring IgG, IgG4 and IgA antibody concentrations 
against various common antigens. To avoid inter-assay variation, inherent to the mitogen 
proliferation assays, isolated PBMC were stored in liquid N2 and mitogen proliferative 
response of pre-and post-intervention PBMC of each individual were measured 
simultaneously in the same run. 
Methods 
Population and design. The study was designed as a 3-month randomized double-blind 
placebo-controlled trial to investigate the association between vitamin E and health 
characteristics in elderly subjects, such as immune response, lung function and as the 
main question the effect on oxidation of LDL- cholesterol, and was conducted in 1994. 
In two consecutive steps a total of eighty-three apparently healthy elderly subjects, aged 
67-85 years, were selected from a database of a population of 1012 elderly in the city of 
Arnhem, the Netherlands155. The first selection step included the following criteria: still 
living in Arnhem, not institutionalized, no use of prescribed drugs for cardiovascular 
disease (CVD), high blood pressure or diabetes mellitus; no reported cancer or chronic 
diseases of the bowel or stomach, kidney, or liver. In the second step, the 355 remaining 
persons were invited by mail and received a questionnaire on health status, smoking 
habits, and use of supplements and medication. Seventy-five subjects did not respond, 
129 refused and 151 were willing to participate. From this latter group sixty-eight were 
not eligible because of the following criteria: use of vitamin supplements (A, A+D, C, E 
or multivitamin; (n 25), stopped smoking less than 5 years before (n 5), current treatment 
for CVD, heart attack or stroke (n 31), use of medication for hypertension or high 
cholesterol (« 6), or diabetes {n 2). The eighty-three eligible subjects were randomly 
assigned to intervention (« 42) and placebo groups (n 41). To ensure group 
comparability, subjects were prestratified before randomization on the following 
variables: smoking habits (current v. non-smokers), 5-year age groups and sex. The 
subjects received either vitamin E (100 mg dl-a-tocopheryl acetate; Hoffmann-La 
Roche, Mijdrecht, The Netherlands; 50 mg twice daily) or placebo (lactose) capsules. Of 
the eighty-three subjects entering the study one subject in the vitamin E group who took 
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only 15% of the distributed capsules was excluded from the data analysis. Eight subjects 
had missing values on baseline or post-intervention humoral immune response 
measurements. A random group of thirty subjects had missing values for baseline and/or 
post-intervention values for the mitogenic proliferation responses due to shortage of 
plasma or isolated blood mononuclear cells to perform all the tests. Data analysis was 
performed on complete data sets. Therefore, baseline- and humoral immune 
characteristics are presented for seventy-four subjects (thirty-six in the placebo group 
and thirty-eight in the vitamin E group). For cell-mediated immune response, data on 
fifty-two subjects (twenty-five placebo and twenty-seven vitamin E group) are presented. 
Data collection. At the beginning and end of the 3-month intervention period subjects 
were picked up at home and brought to the examination room at the University. Fasting 
blood samples were taken into EDTA for determination of antioxidant vitamin levels and 
for measurement of indices of the cellular and humoral immune response. Body weight, 
height and blood pressure were determined at both occasions as well. At baseline the 
subjects filled in a questionnaire on socio-demographic characteristics, physical activity 
and perceived health score. A semi-quantitative food frequency questionnaire was 
administered and used to estimate antioxidant vitamin intake109. Subjects were asked to 
monitor intercurrent illness and/or medicine use in a diary. To improve and monitor 
compliance subjects were visited at home once during the trial. At the end of the study 
compliance was assessed by pill counts. 
The study was approved by the Medical Ethical Committee of the Agricultural 
University and all subjects gave a written informed consent to participate. 
Laboratory measurements. Plasma was prepared under N2 within 3 h after 
venepuncture and stored at -80°Cuntil analysis, to minimize analytical variation. 
Laboratory baseline and post-intervention measurements for each individual were 
performed in the same run. Concentrations of a-tocopherol, 6 + y tocopherol, and B-
carotene were measured in plasma, by reverse-phase HPLC (adapted from Hess et al.m). 
The HPLC analyses were performed using a system from Thermo Seperation Products 
(Freemont, CA, USA). The column was a prepacked 0.25 m x 4.6 mm Vydac 201TP54, 
Cig 300 A (Hesperia, CA, USA). The mobile phase used for the Vydac column was 
methanol-tetrahydrofuran-water in the following proportions: 0 min, 89: 2: 9; 10 min, 
98: 2: 0; 20 min 97: 3: 0; 30 min 90: 10: 0; 40 min, 90: 10: 0 by volume, and the flow 
rate was 1 ml/min. Detection after separation was carried out using two u.v. detectors, 
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one for determination of carotenoids (u.v. 2000) and one (u.v.1000) for determination of 
the tocopherols. 
Humoral immune response: antigen-specific immunoglobulins G and A. The 
following specific antibodies were measured by enzyme immunoassay essentially as 
described previously ' : IgG and IgA against a mixture of extracts of four different 
strains of Penicillium (Allergolisk Laboratorium Kopenhagen, Benelux, Houten, The 
Netherlands; art.no. 25-00) and IgG4 against egg (Laboratorium Diephuis, Groningen, 
The Netherlands; art.no. 58-04), milk (art.no. 58-01) and wheat188 proteins. High-
capacity microtitre plates (Greiner no. 655061; Greiner, Nuertingen, Germany) were 
coated overnight at 4° with the antigen preparations in phosphate-buffered saline (PBS). 
After blocking of free binding sites with gelatin-containing PBS-Tween (PBTG), 
duplicate 0.1 ml portions of sera diluted 1:100 (IgG4) and 1:500 (IgA, IgG) in PBTG 
were incubated in wells coated with the various antigens and in non-coated control wells. 
Binding of IgG, IgG4 or IgA was measured with peroxidase-labelled mouse monoclonal 
anti-human IgG (Central Laboratory of the Red Cross Blood transfusion Service, 
Amsterdam, the Netherlands (CLB) no. M1304), anti-human IgG4 (CLB no. M1331), or 
anti-IgA (CLB, no. M1354) respectively, followed by 30 min incubation with o-
phenylenediamine (OPD). The reaction was read at 405 nm, terminated by addition of 
HC1, and then read at 492 nm. Absorbance values at 492 nm (A492) > 3.0 were obtained 
by extrapolation from the A405 values according to the method of Doekes et al.190. 
Each plate included a positive control (pooled plasma) and no-plasma controls in 
each type of coated and non-coated well. Antibody concentrations were expressed as 
A492* values corrected for values observed in control wells, as follows: 
A492* (Ui) = [A492(i,ai) - A492(0,ai)] - [A492(i,0) - A492(0,0)] 
in which At92(i,ai) is the value obtained with plasma i on antigen ai, A492(0,ai) the value 
obtained with buffer on antigen ab and At92(i,0) and A492(0,0) are the analogous values 
obtained in non-coated wells. 
Pre- and post-intervention plasma samples of each subject were tested in the same 
microtitre plate, to avoid inter-assay variation. 
Cellular immune response: isolation and mitogenic stimulation of peripheral 
blood mononuclear cells. Within 6 h after venepuncture, PBMC were isolated from 
73 
Chapter 6 
EDTA-blood by Ficoll-Hypaque (Pharmacia BiotechAB, Uppsala Sweden) density 
gradient centrifugation (Boyum, 1968). PBMC were harvested and washed twice with 
sterile PBS and resuspended in 1 ml culture medium (RPMI 1640;Sigma-Aldrich Co. 
Ltd., Irvine Strathclyde) with 100 ml/1 dimethylsulfoxide (DMSO) (hybri-max, Sigma-
Aldrich Co. Ltd) in polypropylene vials. The cells were frozen overnight at -80° and 
stored in liquid N2 (-196°) until analysis. 
For mitogenic stimulation, vials containing pre- and post-intervention PBMC were 
removed from the liquid N2 simultaneously and thawed quickly at 37° in a 5% C02-
incubator. DMSO was removed by washing with RPMI 1640. This washing procedure 
was repeated twice to ensure all DMSO had been removed, after which the pellets were 
resuspended in 750 ml RPMI-1640 and the concentration of viable cells was determined 
with the Trypan Blue exclusion method. 
Portions of 0.5 x 106 cells were cultured in twenty-four-well plates (Costar, 
Cambridge, MA, USA) in 0.50 ml RPMI-1640 containing 2 mM L-glutamine (Sigma), 
50 mM 2-mercaptoethanol (Sigma), 30 mg/ml gentamycin (Sigma), and 100 ml/1 normal 
human serum, in the presence of PHA (Sigma) or ConA (Sigma), both at 1 and 5 mg/ml. 
Normal human serum was a pool of sera from five healthy department members; these 
sera had all been tested individually in pilot experiments, and were free of detectable 
mitogenic activity. They were heat inactivated by incubation at 56° for exactly 30 min 
followed by 15 min centrifugation at 1500 rev./min before storage. On each culture-plate 
control wells were included with pre- and post-intervention PBMC of the same subject 
in the same medium without mitogens. 
After incubation for 90 h at 37°, 5% C02 and 95-98% relative humidity, cells were 
washed twice in cold serum-free saline, and resuspended in the original volume (0.5 ml) 
of RPMI-1640, with glutamine, gentamycin and mercaptoethanol, but without human 
serum. In these suspensions metabolic cell activity was assessed by the MTT method191 
with adaptations taken from Denizot & Lang192. Thus, of each 0.5 ml suspension three 
0.12 ml portions were applied to a ninety-six-well flat-bottom plate, mixed with 10 ml 
(10 mg/L) solution of 3,4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT;Sigma) stock solution. After 4 h incubation 120 ml isopropanol was added to each 
well to stop MTT conversion and to dissolve the produced formazan, which was 
quantified spectrophotometrically at 570 nm. 
Mitogenic stimulation was expressed as the difference in A570 between the mean of 
duplicate cells cultured with mitogens and the control cell cultures. 
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Data analysis. Baseline results are expressed as mean and standard deviations (SD) or 
median and 25-75 % range. Mean baseline values and mean individual changes during 
intervention were compared between the study groups by using the unpaired / test in case 
of normal distribution and the Mann-Whitney test. Similarly, mean individual changes 
over the intervention period for the control- and vitamin E groups were tested with the 
paired t test or with the Wilcoxon-signed rank test for paired comparisons within groups. 
Multiple linear regression was used to adjust differences in change in proliferative 
response values between the placebo group and vitamin E group for initial values193. 
Presented correlations are expressed as Spearman correlation coefficients. All analyses 
were performed using the statistical package SAS194. 
Table 6.1.Characteristics of elderly subjects participating in a 3-month intervention 
trial with vitamin E. (Mean values with their standard deviations or frequency (%)) 
Age (years) 
Male (%) 
Smokers (%) 
Intervention period (days) 
Pills taken (%) 
Health score* 
Height 
Body mass index (kg/m2) 
No reported illness or medicine 
Reported illness (days)| % 
use |(%) 
Control Group (n 36) 
Mean 
74.5 
67 
25% 
83.7 
93.9 
8.2 
1.70 
25.1 
44% 
5.5 
SD 
5.2 
6.8 
9.0 
1.3 
0.09 
3.2 
8.7 
Vitamin E Group (« 38) 
Mean 
74.2 
61 
24% 
84.2 
93.0 
8.2 
1.70 
25.9 
55% 
3.5 
SD 
5.2 
4.5 
6.9 
1.3 
0.09 
3.2 
3.4 
* rating on a scale from 1 (worst) to 10 (best), 
f based on self-reported occurrence of illness and use of medicine, recorded in a 
health diary during the 3-month intervention period. 
{ only for the group who reported illness or medicine use in their diary: placebo group, n 20, and 
vitamin E group,« 17. 
Results 
Table 6.1 presents the mean baseline characteristics of the placebo and vitamin E-
supplemented groups. Pre-stratification on sex, smoking behavior and 5-year age groups 
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was successful, as shown by equal distribution of these variables in both study groups. 
Subjects participated for, on average, 3 months in the study (84 d; Table 6.1) with a 
variation from 61 to 94 d. Differences in supplementation period, mainly due to 
measuring during the holiday period (May-June), were not associated with immune 
response nor with particular population characteristics. The number of subjects not 
reporting any intercurrent illness or medicine use during the trial was slightly higher in 
the vitamin E group (n 21) than in the control group (« 16). 
Baseline plasma antioxidant vitamin concentrations and estimated dietary 
antioxidant vitamin intake did not differ significantly between intervention and control 
groups (Table 6.2). In the vitamin E group plasma a-tocopherol increased during 
intervention by 51% (mean 16.7 (SD 12.7) mmol/L, P=0.0001). In the vitamin E group 
the increase in a-tocopherol was correlated with an observed decrease of plasma fi+y 
tocopherol (Spearman correlation r -0.5, P=0.006). At baseline only one subject had a 
plasma a-tocopherol level below the cut-off value of 11.6 mmol/L for risk of vitamin E 
deficiency in human subjects and none below the 2.2 mmol a-tocopherol/mmol 
cholesterol value. Taking the optimal levels to prevent chronic disease as postulated by 
Gey 195, 32% fell below the 30 mmol plasma a-tocopherol/1 limit and 18% below the 5.2 
mmol a-tocopherol/mmol cholesterol value. In this study similar values for the reported 
immune variables were observed between subjects above and below the above 
mentioned optimal a-tocopherol levels mentioned earlier. 
Humoral Immune Response; immunoglobulin G and A antibody concentrations. 
At baseline, median concentrations of IgA and IgG raised against Penicillium and IgG4 
raised against three different food antigens were comparable in vitamin E and placebo 
groups (Table 6.3). In the vitamin E-supplemented group no significant changes in 
antibody concentrations were observed after 3 months. In the control group a small but 
significant increase was seen for the IgG concentration against Penicillium (median 
change A492 0.1; />=0.01) and a small decrease in IgG4 against milk protein (median 
change A492 -0.01; P=0.04). During the intervention period, similar changes were 
observed in the intervention- and placebo groups. Baseline and 3-month antibody 
concentrations were highly correlated (r 0.9 for all antibody concentrations in both 
groups). Baseline concentrations of IgG4 against the three different food antigens 
showed strong mutual correlations (0.6 < r < 0.7; />=0.0001). 
Baseline antibody concentrations for the total study population were not 
significantly correlated with age, BMI, antioxidant plasma concentrations or antioxidant 
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.Intervention trial: Vitamin E and immune response in elderly 
vitamin intake. Higher baseline values of IgG4 against food antigens were seen for 
females than for males (IgG4 against milk-protein: median A492 2.6 (25-75 % interval 
0.3-4.3) for females and 0.5 (interval 0.03 -2.2) for males, P = 0.03). These sex 
differences persisted when comparing non-smoking males (n 30) and females (n 26). No 
sex differences for IgG and IgA raised against Penicillium were observed. The difference 
between smokers and non-smokers was evaluated among men because only one female 
smoker was present. Only for IgG against Penicillium was a significantly (P= 0.0004) 
lower baseline value for smokers (median 2.1 (interval 1.2 - 2.7)) seen as compared with 
non-smokers (median 3.5 (interval 2.7-4.3)). 
Cellular immune response; mitogen stimulation of peripheral blood mononuclear 
cells with phytohemagglutinin and concanavalin A. 
Data for cellular immune responses were available for a subpopulation of fifty-two 
subjects from the total study population. Baseline characteristics of this subpopulation 
were similar to those given for the total study population in Tables 6.1 and 6.2. 
At baseline lymphocyte proliferation to both mitogens ConA and PHA (5 mg/ml) 
was significantly lower (P =0.04) in the control group (Table 6.4). Furthermore, changes 
in PHA proliferative responses during intervention were negatively correlated with 
initial values (r -0.5, P< 0.02 for both study groups). To obtain an unbiased estimate, 
differences in change in proliferative response between the vitamin E group and the 
placebo group were adjusted for initial proliferative response values. As shown in Table 
6.4 the adjusted treatment effect indicates that vitamin E had no effect on mitogenic 
stimulation of PBMC with PHA and ConA. To explore a potential effect of baseline a-
tocopherol plasma values on immune response we analyzed separately the subjects in the 
lower two tertiles of baseline a-tocopherol values. This left thirty-two subjects (« 16 for 
both control and vitamin E groups) for analysis, with mean a-tocopherol baseline values 
of 28.9 (SD 4.9) mmol/L and 27.5 (SD 5.6) mmol/L and increases during intervention of 
0.4 (SD 3.4) and 11.2 (SD 9.6) umol/1 in the control and vitamin E groups respectively. 
The results on mitogenic response for this sub-sample did not differ from those obtained 
from the total sample. 
A57o values for unstimulated PBMC were similar for control and vitamin E group 
showing means of 0.10 (SD 0.05) and 0.11 (SD 0.08) respectively. Correlations between 
baseline and post-intervention measurements for PHA-stimulated PBMC were r 0.5 
(P=0.006) and r 0.8 (P=0.0001) for control and vitamin E groups respectively. For 
ConA, correlations of r 0.6 (^=0.0008) and r 0.7 (P=0.0001) were observed (Fig. 6.1). 
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Figure 6.1. Stimulation of peripheral blood mononuclear cells (PBMC)from elderly subjects 
with the mitogens phytohaemagglutinin (PHA) and concanavalin A (conA) measured at 
baseline v. measurements made after 3 months intervention with vitamin E (9) or a placebo 
(O). For Spearman correlation coefficients, see result section. Proliferation was assessed by 
the MTT method and expressed as the absorbance at 570 nm of the formazan produced. The 
line shown is the plot Y=X. 
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Baseline values for proliferative response were not significantly correlated with 
age, BMI, antioxidant plasma concentrations or antioxidant vitamin intake. No 
differences were found between men and women or between smokers and non-smokers 
in baseline values. 
Similar results were observed for proliferative responses with 1 mg mitogen/1 
(results not shown). 
Discussion 
In this 3-month intervention trial among apparently healthy elderly no effect was 
observed of 100 mg a-tocopheryl acetate on the in vitro proliferative response of PBMC 
to the mitogens PHA and ConA. Also antibody concentrations against various common 
antigens were not affected by vitamin E supplementation. 
Aging itself, and diseases that frequently accompany aging, are thought to be 
factors explaining the decline in immune responsiveness with aging. Goodwin et al.I75 
found no difference in cellular immune responsiveness between healthy and chronically 
ill elderly subjects. This suggests that the major determinant of decreased cellular 
immune function is age per se and not age-associated diseases. Therefore improving 
immune responsiveness in healthy elderly people may be of great public health 
importance. The present study population was selected as 'healthy' using a questionnaire 
on disease and medicine use, and therefore cannot be considered representative of the 
elderly population in general. Underlying subclinical diseases may well have been 
present but are not expected to have influenced the comparison between the two study 
groups because of randomization. Comparison within study groups of those not reporting 
illness during intervention with those reporting illness, did not reveal any differences in 
studied immune variables. 
A great variability inherent to the mitogen proliferation assays has been mentioned 
by Meydani et al.61. To avoid inter-assay variation, isolated PBMC were stored in liquid 
N2 and mitogen proliferative responses of pre-and post-intervention PBMC for each 
individual were measured simultaneously in the same run. The storage period of PBMC 
was not significantly associated with the proliferative responses. 
Intra-individual variation in the mitogenic response measured at different time 
points may lead to regression towards the mean and could have affected our results, as 
we observed unexpected differences in initial values in mitogenic response between 
vitamin E and control groups. Baseline PHA and ConA responses in the control group 
were significantly lower than in the vitamin E group, while post-intervention responses 
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were similar in both groups and at the level of the vitamin E group at baseline. Therefore 
we adjusted the intervention effect (changes in proliferative response between vitamin E 
and control group) for initial values by means of multiple linear regression193. 
Vitamin E is thought to exert its effect on T-cell response and interleukin-2 
production. Therefore an effect on humoral immune response would be primarily 
expected for T-cell dependent antibody responses. Ziemlanski et al.187 and Meydani et 
a/.61 did not show an effect of vitamin E on total antibody (IgG, IgM, IgA, IgD) 
concentrations. Total IgG serum concentrations are, however, a rather crude estimate of 
humoral immune responsiveness. Therefore, we decided to measure specific antibodies 
to various common antigens like Penicillium, milk, wheat, and egg proteins to which 
most individuals are probably constantly exposed, and against which specific IgG and 
IgA antibodies are produced. 
Taking into account the reported steady state of plasma ct-tocopherol after 4-5 d 
following chronic administration of vitamin E165, the lifetime of activated B-cells (4 
weeks) and the half-life of antibodies in circulation (3 weeks), the intervention period of 
3 months seems adequate for detecting important changes in antibody production. 
Improvement of indices of the cellular and humoral immune response by vitamin E 
has been extensively demonstrated in animal experiments. Reviews on the subject (e.g. 
Meydani et a/.63 indicate important implications for the human situation, although this is 
supported by only a few studies in human populations. The first intervention study 
among elderly people on the effect of vitamin E on a large number of cellular and 
humoral immune indices was reported by Meydani et al61. They showed increases in the 
proliferative response of PBMC to Con A but not to PHA after daily supplementation 
with 800 mg a-tocopherol for 30 d. The rise in plasma a-tocopherol in their study was 3-
fold while in our study with 100 mg a-tocopheryl acetate the relative increase was 51%. 
The smaller increase in a-tocopherol in blood and probably also in PBMC (not measured 
in the present study but in the study by Meydani et al61 also 3-fold) might not have been 
enough to improve the in vitro mitogen proliferation of PBMC. This could mean that 
very high vitamin E doses are needed to improve mitogen-stimulated proliferation of 
PBMC. This is supported by another intervention in elderly subjects reported by 
Meydani et al.196, with administration of different vitamin E doses (60, 200 and 800 mg 
vitamin E for 120 d), and in which a significant increase in mitogenic response to ConA 
was observed for the 800 mg dose only. An increased response to delayed-type 
hypersensitivity tests was, however, seen in all supplemented groups. 
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Alternatively, our results may be due partly to the relatively high baseline plasma 
a-tocopherol values in the present study as compared with, for example, the trial of. 
Meydani et al.6X. Chandra197 found, in a 1 year multivitamin supplementation (including 
44 mg vitamin E) trial among healthy elderly subjects, that improvement in 
immunological responses (increase in natural killer cells, lymphocyte proliferation to 
PHA, a higher antibody response to influenza vaccine, and a lower frequency of 
infection-related illness) was greater among subjects who at baseline had low plasma 
nutrient values. Therefore we tested the intervention effect for the subjects in the lower 
two tertiles of the baseline plasma values revealing similar mean plasma a-tocopherol 
values to those in the study of Meydani et a/.61 but still found no effect on mitogenic 
response between the control and the vitamin E group. Therefore, it does not seem likely 
that relatively high baseline vitamin E levels are to be held responsible for not finding an 
effect of vitamin E supplementation on cellular immune response in the present study. 
Our study in the elderly did not show improvements in specific immune indices 
after supplementation with 100 mg a-tocopheryl acetate for 3 months. This does not 
mean that relatively low doses of vitamin E might not affect other immune variables in 
elderly subjects (see Meydani et a/.196. Studies on different doses of vitamin E and 
different immune variables will improve the available information on the overall 
possible positive effects and working mechanism and should provide necessary 
background information on the optimal doses. Better insight in improvement of the 
immune responsiveness in elderly people by vitamin E might warrant studies relating 
vitamin E to morbidity and mortality, especially those factors contributing to infections. 
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Serum carotenoids, a-tocopherol and 
mortality risk in a prospective study among 
Dutch elderly 
Frouwkje G. de Waart, Evert G. Schouten, Anton F.H. Stalenhoef, Frans J. Kok 
Abstract 
Although B-carotene has shown inverse associations with chronic diseases involving free 
radical damage in observational epidemiological studies less attention has been paid to five 
other major carotenoids also showing antioxidant activity in vitro. 
We studied the associations between 7.2 year mortality and serum levels of six carotenoids, 
and a-tocopherol, measured in stored serum, sampled in 1991/1992 during a health survey 
among 638 independently living elderly subjects aged 65-85 years. Proportional hazards 
regression was used to estimate hazard ratios of all-cause mortality for the lowest tertiles of 
serum vitamins with the highest tertiles, adjusting for possible confounding effects. 
During a follow-up period of 7.2 years 171 elderly died. The adjusted hazard ratios for all-
cause mortality for the lowest tertiles of vitamins compared with the highest tertiles were 
between 1.02 and 1.73. The strongest increase in mortality risk was seen for B-cryptoxanthin 
(1.52 with 95% CI: 1.00, 2.32), lutein (1.56 with 95% CI: 1.05, 2.31) and zeaxanthin (1.32, 
95% CI: 0.89, 1.97) and their sum (oxygenated carotenoids: 1.73, 95% CI: 1.12, 2.67). Tests 
for trend were significant (p<0.05) for all-cause mortality risk and serum levels of total 
carotenoids, oxygenated carotenoids and B-cryptoxanthin. 
Our findings suggest that serum levels of individual carotenoids, particularly the 
oxygenated species are inversely associated with all-cause mortality and should be 
considered as candidates for further investigations. 
Provisionally accepted International Journal of Epidemiology 
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Introduction 
Observational studies both on dietary intake of 6-carotene or fi-carotene rich products 
and serum or adipose tissue levels of 8-carotene products show inverse associations 
with cancer and cardiovascular disease198. Observational studies on the five other 
major carotenoids show that cc-carotene intake was a better predictor for lung cancer 
than 6-carotene199 and that lycopene and its main source of tomato products were 
inversely associated with prostate cancer200 and myocardial infarction201. Lower levels 
of serum concentrations of lutein/zeaxanthin and 6-cryptoxanthin were observed in 
cases with asymptomatic atherosclerosis than in controls39. Plasma levels of 6-
cryptoxanthin were also lower in a high than in a low CHD incidence area202 and in 
cases with upper aerodigestive tract cancer than in matched controls203. The outcomes 
of these studies suggest that individual carotenoids, or the products from which they 
are derived, in isolation or in combination, are potentially protective against disease 
processes involving free radical damage204 
In order to add to the limited epidemiological evidence we studied the 
association between 7.2 year all-cause mortality and the individual carotenoid 
components 6-carotene, cc-carotene, lycopene, 6-cryptoxanthin, lutein and zeaxanthin 
among Dutch elderly. Furthermore, a-tocopherol (vitamin E) was included as an 
important antioxidant vitamin and also combined with the individual carotenoids in an 
antioxidant vitamin index. 
Methods 
Population and Design. The present study utilized data derived from a survey 
conducted in 1991/1992 on lifestyle and health among non-institutionalized Dutch 
elderly living in the city of Arnhem, aged 65-85. Mortality follow-up data were 
collected consecutively. The selection of this study population has been described in 
detail elsewhere155. 
Between October 28th 1991 and April 6th 1992 a random sample of elderly, pre-
stratified on sex and age, participated in a health survey, including home interviews 
(n=1012) and a physical examination (n=685), including measurements of height, 
weight, blood pressure , electrocardiographic characteristics and spirometric function. 
In addition, non-fasting blood samples were taken. Of the 685 undergoing physical 
examination 641 donated a blood sample. For three persons the amount of serum 
available for the vitamin analyses was too small. This left 638 subjects for these 
analyses. 
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Written informed consent was obtained from the subjects prior to the physical 
examination. 
Mortality follow-up. Data on death were obtained from the municipal register of 
Arnhem. After the collection of baseline data, information on death and migrations 
was reported to our department every 6 months. Survival status for those who moved 
from Arnhem during follow-up (n=70) was checked starting from February 1998 with 
the municipal authorities of the new residence. Vital status could be determined for all 
but one. Survival time in years began with the date of the blood collection in 
1991/1992 and continued until date of death, date of checking vital status, date of loss 
to follow-up or 23rd of March 1999 whichever came first. 
Total mortality of the 638 subjects after a mean follow-up time of 7.2 yr. was 
27% (n=171; males n=108, females n=63)). 
Serum antioxidant vitamins and cholesterol. Non-fasting serum samples had been 
stored for a mean time of six years at -80°C before vitamin analyses. Following 
extraction205, concentrations of the carotenoids a-carotene, 6-carotene, lycopene, 
lutein, zeaxanthin and 6-cryptoxanthin and of a-tocopherol were measured in serum, 
by reverse-phase HPLC ( adapted from Hess et al.112 and Craft and Wise206). 
Detection after separation was carried out using two UV detectors, one for 
determination of carotenoids (UV. 2000) and one (UV. 1000) for determination of cc-
tocopherol. The coefficient of variation (CV) of pooled serum measured in duplicate 
in every run (n=17) was 12.3% for a-carotene, 10.2% for 6-carotene, 23.9% for 
lycopene, 10.7% for 6-cryptoxanthin, 14.9% for zeaxanthin, 7.2% for lutein, and 5.1% 
for a-tocopherol. 
Total cholesterol was determined by an enzymatic method (CHOD-PAP 
method207). 
Other characteristics. The interview, which was mainly pre-coded, included 
questions on physical activity, drinking and smoking habits, chronic diseases, use of 
health care, medication, supplements and personal characteristics. Physical activity 
was assessed by a validated questionnaire on household activities, sports and other 
physically active leisure time activities, developed for free-living elderly. From the 
responses a total activity score was calculated using an intensity code based on net 
energetic costs of the specific activities208. The presence of diseases was assessed 
87 
Chapter 7 
using a list of chronic diseases and conditions. The use of prescribed medication was 
asked with a reference period of three months prior to the interview. Cardiovascular 
disease (CVD) was considered present in subjects consulting a physician for heart 
disease, stroke or peripheral vascular disease 3 months prior to interview or in subjects 
using drugs for CVD; hypertension in subjects reporting the use of antihypertensive 
medication, or having a systolic blood pressure > 160 mmHg and/or a diastolic blood 
pressure £ 95 mmHg; lung disease in subjects reporting chronic obstructive 
pulmonary disease (COPD) or asthma or the use of drugs for asthma or COPD; 
diabetes mellitus in subjects reporting the use of drugs for diabetes mellitus. 
Alcohol consumption was coded as current drinking yes or no and for the 
drinkers as number of glasses per week. Pack years of cigarette smoking were 
calculated for present and past smokers as the number of cigarettes smoked times the 
number of years divided by 20. Never smokers and cigar and pipe smokers were 
classified as subjects with 0 pack years. 
The physical examination included measurements of height, weight and blood 
pressure. Systolic and diastolic blood pressure were measured twice in supine position 
with a random-zero sphygmomanometer (Hawksley , England). The mean of the two 
measurements was used in the analyses. 
Data analyses. Age-adjusted mean characteristics were compared between survivors 
and deceased by ANCOVA. Age-adjusted differences between the vital status groups 
were tested by using logistic regression with vital status as dependent and prevalence 
characteristics and age as independent variables. Plasma a-tocopherol levels were 
adjusted for plasma cholesterol by calculating their residuals from linear regression 
models with plasma cholesterol as the dependent variable116. For ease of 
interpretation, descriptives are expressed as unadjusted data. 
All serum antioxidant vitamin concentrations are presented as median with their 
90% ranges. Differences in vitamin concentrations between survivors and deceased 
were tested with the Mann-Whitney £/-test. 
Total carotenoids concentration was calculated by summing the absolute 
individual serum carotenoid concentrations. Oxygenated carotenoids were combined 
by summing serum concentrations of 6-cryptoxanthin, lutein and zeaxanthin and the 
hydrocarbon carotenoids were combined by summing 6-carotene, a-carotene and 
lycopene. An index combining both the carotenoids and a-tocopherol concentrations 
was made by summing individual standardized scores (Z-scores) calculated for each 
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log transformed vitamin by subtracting its group mean from the individual values and 
then dividing by the standard deviation. 
Proportional hazards regression methods209 were used to estimate the hazard 
ratios and corresponding 95% confidence intervals for all-cause mortality for tertiles 
of serum antioxidant vitamin concentrations with the highest tertile as reference. Tests 
for trend were performed by fitting the variables in their continuous form in the 
proportional hazards model. 6-Cryptoxanthin, zeaxanthin, lutein and the combination 
of oxygenated carotenoids were log transformed as this gave a better fit of the 
estimated models, as judged by the log likelihood statistic value. 
The proportionality assumption was judged by visual inspection of the log-log 
curves of tertiles of the serum vitamin concentrations. 
Models with interaction terms for gender or smoking status and the individual 
serum antioxidant vitamins revealed no interactions between gender or smoking status 
and antioxidant vitamins, so no interaction terms were included in the multivariable 
210 
models. In a multivariate model adjustments were made for important confounders 
as age, gender, pack years of cigarette smoking, alcohol consumption, serum 
cholesterol, body mass index, physical activity and antioxidant supplement use. 
Furthermore we adjusted for important predictors of total mortality; the presence of 
CVD, hypertension, lung disease or cancer in the multivariate models. 
All analyses were performed with the statistical package SAS194. A p-value 
below 0.05 was considered as statistically significant. 
Results 
Male and female survivors were as expected significantly younger than the deceased 
(Table 7.1). Furthermore, age was significantly associated with most of the other 
characteristics in Table 7.1. Therefore, differences were tested after adjustment for 
age. Some age-adjusted differences in characteristics between survivors and deceased 
were more pronounced in males than females, e.g. significantly lower systolic blood 
pressure, higher activity scores, and a lower prevalence of lung disease and 
hypertension in survivors than in deceased. 
Table 7.2 shows the median serum vitamin concentrations of the female and 
male elderly study subjects according to their survival status. The observed 
differences in serum levels were small but for most of the carotenoids and a-
tocopherol lower in deceased than in survivors. 
Chapter 7 
All serum concentrations except for lycopene, lutein and cholesterol adjusted cc-
tocopherol were lower (p <0.05) in males than in females. Age was inversely 
associated with serum lycopene and (cholesterol adjusted) a-tocopherol in men; 
Spearman correlations of-0.15 and -0.21 respectively (p<0.01). 
Table 7.1 Mean (SD) or prevalence (%) of baseline characteristics for male and female 
deceased and survivors after 7.2 years of follow-up of a Dutch cohort of elderly 
survival time (yr.) 
General characteristics 
age (yr.) 
body mass index (kg/m2) 
systolic blood pressure (mmHg) 
diastolic blood pressure (mmHg) 
serum cholesterol (mmol/L) 
Lifestyle characteristics 
married (%) 
smokers (%) 
ex-smokers (%) 
never smokers (%) 
pack years of cigarette smoking 
alcohol consumers (%) 
antioxidant supplement users (%)a 
sporting regularly (%) 
activity score 
Health characteristics'1 
CVD present (%) 
hypertension (%) 
lung disease present (%) 
cancer present (%) 
diabetes mellitus (%) 
Males 
Censored 
n=227 
7.1 (0.3) 
72.7 (5.2) 
25.5 (3.1) 
146(19) 
80(11) 
5.9(1.1) 
85 
33 
56 
11 
21.3 (26.2) 
84 
19 
37 
11.3(7.7) 
31 
30 
9 
2 
2 
Deceased 
n=108 
4.1 (1.9)*** 
76.0(5.1)*** 
25.3 (3.0) 
152 (21)* 
82(11) 
6.0(1.2) 
81 
34 
59 
6 
25.2 (26.2) 
79 
12 
25 
8.1 (7.0)** 
41 
47* 
20* 
6 
0 
Females 
Censored 
n=240 
7.1 (0.3) 
73.5 (5.6) 
26.4 (4.5) 
151 (21) 
82 (10) 
6.6(1.2) 
40 
18 
24 
58 
5.6(12.3) 
62 
21 
34 
7.0 (4.6) 
26 
46 
9 
3 
4 
Deceased 
n=63 
4.4(1.8)*** 
78.8 (5.0)*** 
26.5 (4.3) 
157(22) 
83 (12) 
6.5(1.4) 
32 
10 
27 
63 
6.1 (17.3) 
59 
14 
30 
5.5 (4.5) 
41 
60 
11 
5 
5 
Antioxidant supplement use comprised vitamin C, vitamin E and multivitamin supplements 
bSee See method section 
*** p < 0.001,** p<0.01 * p <0.05 censored and deceased significantly different after adjustment for 
age 
The individual antioxidant carotenoids were highly correlated (p=0.0001) with 
the sum of these individual carotenoids ranging from Spearman correlations r=0.50 for 
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_Prospective study: Serum carotenoids, vitamin E and total mortality 
lutein to r=0.80 for B-carotene. Serum concentrations of cholesterol adjusted cc-
tocopherol showed a Spearman correlation of r=0.18 (p=0.0001) with total 
carotenoids. Among each other the highest Spearman correlations for the carotenoids 
were seen for 6- and a-carotene and for lutein and zeaxanthin, r=0.78 and r=0.67 
respectively. Lowest correlations were observed for lycopene with the other 
carotenoids ranging from r=0.14 with zeaxanthin to r=0.41 for B-carotene. 
In Figure 7.1 survival curves (Kaplan-Meier) show that the subjects in the lowest 
textile of oxygenated carotenoids and cholesterol adjusted a-tocopherol have a lower 
survival than in the highest tertile. For the hydrocarbon carotenoids this is not 
observed, mainly by a drop in the survival for the highest tertile after 7 years. 
In Table 7.3 the hazard ratios and 95% confidence intervals (CI) for all-cause 
mortality are given of tertiles of the serum antioxidant vitamins. The gender adjusted 
hazard ratios for all-cause mortality are higher for the lowest compared to the highest 
tertiles for all the vitamins except B-carotene and only significantly for the sum of 
oxygenated carotenoids and lycopene with hazard ratios of 1.62 (95% confidence 
interval =1.07, 2.45) and 1.50 (1.03, 2.18), respectively. Also the intermediate tertile 
of cholesterol adjusted a-tocopherol showed an increased risk of 55% on total 
mortality compared to the lowest tertile (hazard ratio of 1.55 (1.06, 2.27). Significant 
(p<0.05) inverse trends are observed between all-cause mortality and serum levels of 
total carotenoids, sum of oxygenated carotenoids, B-cryptoxanthin, lutein and 
borderline for antioxidant index, zeaxanthin and lycopene. For B-carotene and a-
carotene no significantly increased risks are found for the lowest and intermediate 
tertile. While it seems that the intermediate tertile shows the highest risk and also the 
Kaplan-Meier survival curves supported this (data not shown). Therefore, no test for 
trend was performed for those carotenoids. After adjustment for potential confounders 
the hazard ratios were similar in magnitude as for the gender adjusted models. The 
adjusted hazard ratio for the lowest compared to the highest tertile of the sum of 
oxygenated carotenoids remained significantly increased (1.73, 95%CI:1.12-2.67) and 
became significant for B-cryptoxanthin and zeaxanthin with hazard ratios of 1.52 
(1.00,2.32) and 1.56 (1.05,2.31), respectively. The inverse associations between all-
cause mortality and total serum carotenoids, oxygenated carotenoids and B-
cryptoxanthin remained significant after multivariate adjustments and became 
borderline significant (p=0.05) for lutein. 
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Discussion 
In this study we observed that the sum of serum levels of six carotenoids, of 
oxygenated carotenoids and the individual carotenoid B-cryptoxanthin were inversely 
associated with 7.2 year all-cause mortality. For the sum of oxygenated carotenoids, 
B-cryptoxanthin and lutein the subjects in the lowest textile showed a significant 
increase in all-cause mortality with the highest tertile as reference ranging from 56% 
for lutein to 73% for the sum of oxygenated carotenoids. 
Discrepancies between study findings for serum levels of total carotenoids and 
mortality may partly be explained by differences in component carotenoids ' . In 
our study comprising all six major carotenoids an inverse association with all-cause 
mortality was observed. In a prospective nested-case control study21 including only 
lycopene, 6- and a-carotene, no association was found between quartiles of the sum of 
these carotenoids and risk of nonfatal myocardial infarction or death from coronary 
heart disease (CHD) among smoking and non-smoking males. In a study by Sahyoun 
et al.211 it is not clear which carotenoids were included in the total carotenoids 
variable; they211 found in a cohort of 725 elderly aged 60 year and over an inverse 
association between plasma carotenoid levels and 12 year all-cause mortality after 
adjustment for age, gender and serum cholesterol which was no longer significant 
when other potential confounders were controlled for. A nested-case control study 
also combining six individual carotenoids, reported significant inverse associations 
with upper aerodigestive tract cancer203. 
A possible protective effect of serum B-cryptoxanthin and lutein on mortality as 
observed in our study is supported by three other observational studies. Howard et 
al.202 found significantly lower plasma levels of B-cryptoxanthin in a population living 
in an area with a high CHD incidence (Belfast) than in a population from a low CHD 
incidence area (Toulouse). In a cross-sectional study39 significantly lower serum 
concentrations of 6-cryptoxanthin and lutein plus zeaxanthin were observed in cases 
with asymptomatic atherosclerosis (90th percentile of carotid intima media thickness) 
than in controls (below 75th percentile of carotid intima media thickness). For men 
with upper aerodigestive tract cancer lower levels of B-cryptoxanthin were reported 
than for matched controls203. Although a mechanism is not specified yet, the 
suggestion of Howard et al.202 that the oxygenated carotenoids 6-cryptoxanthin, lutein 
and zeaxanthin may be of special interest in preventing CHD is carefully supported by 
the results of the study of Irribarren et al.39 and by our study. We observed an inverse 
trend (p=0.006) between the sum of the oxygenated carotenoids (including B-
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cryptoxanthin, lutein and zeaxanthin) and total mortality, which was higher than for 
the specific carotenoids. If oxygenated carotenoids would be especially important in 
CHD the strong association with total mortality in our study might be due to the large 
contribution of CHD to total mortality in Dutch elderly. 
We studied all-cause mortality to cover the assumed associations of the different 
carotenoids on both CHD and cancer as main causes of total mortality. The possible 
protective effects of the carotenoids on different diseases may be due to common 
mechanisms like their antioxidant activity in vitro213"215, although the effect in vivo is 
debated216. Besides a common protective mechanism of the individual carotenoids on 
a range of diseases, their differences in structure, metabolism, transport and tissue 
distribution217'218 may explain differential effects on different diseases as hypothesized 
for lycopene on prostate cancer200, lutein and zeaxanthin on degenerative macular eye 
disease, B-carotene and a-carotene on specific cancers199,203, and the oxygenated 
carotenoids B-cryptoxanthin, lutein and zeaxanthin on CVD39'202. Unfortunately, we 
were not able to further explore cause-specific disease and mortality as no such data 
were available. 
In our study B-cryptoxanthin (26%), B-carotene (31%) and lutein (25%) were the 
three main contributors to total carotenoids. In a study comparing individual 
carotenoids among elderly from cities in the USA and 10 European countries, it was 
seen that median serum concentrations of B-carotene, lutein and B-cryptoxanthin were 
mostly of similar magnitude as in our study219. Serum lycopene concentrations varied 
considerably among study populations. In our population lycopene concentrations 
were fourfold less than in the elderly populations from the USA, France, Ireland and 
Italy ' . In these populations lycopene was the main contributor to serum total 
carotenoids. This resulted in higher absolute total carotenoid values than in our study. 
As lycopene is mainly derived from the intake of tomato and tomato products, 
differences in diet between these countries are probably responsible. 
For cholesterol adjusted serum vitamin E we found lower concentrations in 
deceased men than in survivors. No significant increased risk or inverse association 
with total mortality was found after adjustment for major confounders. In line with 
other observational studies serum vitamin E in normal physiologic ranges is in general 
not strongly associated with mortality risk. The inverse associations found are usually 
due to intake of high-dosed vitamin supplements50. Our study was not influenced by 
vitamin E supplement use as only six subjects used vitamin E supplements and none 
of the elderly reported the use of specific carotenoids-containing supplements. The 
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antioxidant index results in our study give no support to the suggested interaction 
among carotenoids themselves and a-tocopherol214'220 
The carotenoids we studied are mainly derived from the intake of fruit -and 
vegetables which is consistently inversely associated with CVD and cancer221'222. It 
can, of course, not be ruled out that the observed associations may be linked to other 
protective constituents or factors related to fruit- and vegetable intake223. Associations 
of specific carotenoids with specific diseases would be more suggestive of a possible 
real association with the carotenoids. 
Some of the methodological points in our study to consider will be shortly 
discussed below. Serum concentrations were measured only once in 1991/1992 and 
possible changes over 6 years follow-up were not registered. We assumed in our 
analyses that the serum vitamin concentrations of 1991/1992 were indicative for 
serum concentrations during follow-up time supported by the findings that mean 
plasma concentrations of a-tocopherol, 8-carotene, a-carotene, lycopene, and lutein 
also measured in a subgroup of 77 subjects129 in 1994 were similar with values in 
1991/1992. Moreover, tertile classification of serum vitamins between the two time 
periods was concordant in 54-72% of the cases and for less than 10% of the cases the 
misclassification was more than one tertile. 
Misclassification by a conscious shift in diet, altering serum concentrations, after 
diagnosis of risk factors or chronic diseases prior to baseline measurements may have 
occurred but is not thought to have highly influenced our results as excluding the first 
year of follow-up from analyses did not markedly change the observed associations 
(data not shown). 
Finally, loss of carotenoids or a-tocopherol by storage for 6 years at a 
temperature of-80° is not likely224'225. Furthermore, laboratory personnel was unaware 
of the subjects status and sampling, storage and further handling of the sera was 
carried out identically, so bias in comparing deceased and censored subjects was 
excluded. 
In conclusion, this study provides information on the six major serum 
carotenoids and combinations of them in relation to all-cause mortality risk and 
showed that the inverse association is especially profound for the sum of the 
oxygenated carotenoids (6-cryptoxanthin, lutein and zeaxanthin). Research into the 
possible protective constituents of fruits- and vegetables intake should consider 
individual carotenoids and/or their combinations instead of focusing primarily on 6-
carotene. 
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General discussion 
"The 'antioxidant vitamin-cardiovascular disease' hypothesis is still promising but still 
unproven: need for randomized trials ". 
"Are clinical trials really the answer?226,227" 
The studies reported in this thesis were designed to contribute to the accumulating 
research evidence that supplementation with the antioxidant vitamin E would be 
beneficial for health. The studies specifically focused on the groups of smokers and 
elderly hypothesized to be at risk for high oxidative stress. 
Two intervention trials are the core of this thesis to formally test the causal 
effect of vitamin E on markers of atherosclerosis and immune response (chapters 3 to 
6). In addition, two observational studies among populations abstaining from 
antioxidant supplements are described in chapters 2 and 7. These studies were 
designed to investigate associations between physiological (i.e. unsupplemented) 
levels of vitamin E and total mortality and carotid IMT levels, as a marker of 
atherosclerosis. 
In this concluding chapter, the main findings of our studies (summarized in 
Table 8.1) are discussed in relation to other scientific evidence in this area. 
Methodological aspects that may interfere with the interpretation of these findings are 
discussed. Implications and directions for future research will be presented at the end 
of this chapter. 
Main findings in relation to other scientific literature 
The studies presented in this thesis do not provide unequivocal evidence in support of 
a beneficial effect of vitamin E supplementation on atherosclerosis and general health 
among the populations of smokers and elderly. However, as Table 8.1 reveals, the 
results show a consistent tendency towards benefit in specific cases. The size and 
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strength of this tendency will be discussed relative to other scientific evidence, taking 
into account study design, exposure- and outcome parameters. 
Table 8.1 Main findings of the studies described in this thesis 
Population vitamin E main findings 
Observational studies 
158 CVD-free male smokers 
{Chapter 2) 
low plasma and * no associations with increased IMT 
dietary levels 
638 male and female 
elderly people 
(Chapter 7) 
low serum levels * increased mortality risk (NS) 
Randomized double-blind placebo-controlled intervention trials 
189 male smokers 2 year * tendency of reduced increase in IMT (NS) 
{Chapter 3) 400IU * significant decrease of in vitro susceptibility 
of LDL to oxidation 
Population as in chapter 3: 
by GSTM1-genotype 
(Chapter 4) 
82 elderly people 
(Chapter 5) 
as in chapter 3 
3 months 
100 IU 
null vs. positive GSTM1 genotype: 
* significant increased change in IMT 
* reduced prevalence of increased IMT by 
vitamin E supplementation (NS) 
* significant decrease in oxidation of LDL-
linoleic acid 
* significant increase in lagtime of in vitro 
oxidation of LDL 
Population as in chapter 5 
(Chapter 6) 
as in chapter 5 * no significant effect on immune response 
CVD =cardiovascular disease, IMT =intima media thickness of the common carotid artery, GSTM1-
genotype=glutathione S-transferase genotype, NS =not statistically significant at the p=0.05 level. 
Observational studies 
The cross-sectional analysis among smokers, reported in chapter 2, revealed no 
association between low plasma levels of cholesterol-adjusted a-tocopherol and 
dietary vitamin E intake with intima media thickness (IMT) levels of the common 
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carotid artery. In line with several other studies76'96'101, IMT was strongly associated 
with classical cardiovascular disease (CVD) risk factors such as smoking (more 
specifically depth of inhalation), plasma cholesterol levels, blood pressure, and age. 
Other mainstream cross-sectional comparison studies of physiological (i.e. 
unsupplemented) vitamin E levels on IMT similarly revealed no associations39,103'105. 
Overall, our findings in unsupplemented populations are in line with other 
observational studies that have also failed to find support for the hypothesized 
associations except for those highly specific cases such as for erythrocyte vitamin E 
levels and carotid IMT among elderly102 and for women above 55 years in age in the 
Atherosclerosis Risk in Community (ARIC) study105. 
The prospective study, described in chapter 7, identified lower age- and serum 
cholesterol adjusted serum levels of cc-tocopherol among deceased men compared to 
survivors. After seven years of follow-up, gender adjusted mortality risk was 0.70 
(95% confidence interval CI 0.48-1.04) for the highest compared to the lowest tertile 
of serum a-tocopherol. After adjustment for major CVD risk factors, the mortality 
risk increased to 0.90 (95% CI 0.61-1.35). These findings are in line with all-cause 
mortality risk point estimates for both supplemented and unsupplemented vitamin E 
studies, although studies involving vitamin E supplementation generally report 
stronger effects (see Table 8.2 for details). In the Nurses Health Study49 all-cause 
mortality risk for vitamin E supplement users was 0.87 (95% CI 0.69-1.10), in the 
EPESE study51 relative risk was RR=0.66 (95% CI 0.53-0.83) and RR=0.73 (95% CI 
0.58-0.91) after CVD risk factor adjustment. In the Massachusetts study211, mortality 
risk for high versus low dietary vitamin E intake was RR=0.77 (95% CI 0.51-1.18) 
and RR=0.99 (95% CI 0.58-1.27) for high versus low plasma levels. Despite the fact 
that total mortality risk is clearly a critical marker of general health, in the context of 
this thesis it would have been preferable to assess cause-specific CVD-mortality rates. 
Unfortunately, data were not available for this detailed analysis. 
The intervention trials described in this thesis specifically focus on vitamin E and 
atherosclerosis. As the strength and consistency of prospective studies on vitamin E 
and CVD morbidity and mortality49'52'141'211'228'229 have been sufficiently convincing to 
justify the initiation of formal intervention trials, such as reported in this thesis, these 
prospective studies will be discussed briefly. Overall, these studies (see Table 8.2) 
show a remarkably consistent (albeit not always statistically significant) pattern. Most 
point estimates of relative risks range between 0.60 and 0.80 implying a 20 to 40% 
risk reduction in cardiovascular events and mortality. This effect on cardiovascular 
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General discussion 
risk reduction is clearly more pronounced for long-term users of high dosed vitamin E 
supplements. 
Intervention trials of vitamin E and markers of atherosclerosis 
Among both smokers (chapter 3) and elderly (chapter 5) vitamin E in LDL and plasma 
increased significantly upon supplementation with 400IU for 2 years and 100 IU for 3 
months, respectively. In both studies supplementation reduced the susceptibility of 
low density lipoprotein (LDL) cholesterol to in vitro oxidation. This finding is 
consistent with the vast majority of other vitamin E supplementation trials with doses 
starting from as low as 25 IU44'45'124'147'148,230. Assessment of the clinical relevance of 
these findings is however difficult. Despite the plausibility of a pivotal role for LDL 
oxidation in the onset and progression of atherosclerosis, the validity of the in vitro 
Cu2+-induced oxidation of LDL as a marker of in vivo oxidation and increased CVD 
risk is far from unambiguous (see paragraph on methodological consideration). Yet, 
the in vitro LDL-oxidation measure has considerably progressed the understanding of 
determinants of LDL's susceptibility to oxidation such as several antioxidants, fatty 
acid composition of LDL231 (chapter 5) and density of LDL232'233. This is confirmed 
by our finding (chapter 5) that the oxidation susceptibility of LDL depends on the 
ratio of a-tocopherol to linoleic acid in LDL. 
The progression of carotid IMT is recognized as a good marker for CVD risk 
(see methodological considerations: use of surrogate endpoints for atherosclerosis). 
The trial among smokers described in chapter 3 revealed a non-significant 47% 
reduction in carotid IMT in a randomized trial after 2 years supplementation with 400 
IU vitamin E. This is in line with results from the only comparable study that is 
presently available (presented by J. Salonen at the 1999 Conference of the European 
Society of Cardiology (ESC) in Barcelona). That placebo controlled trial applied a 
two by two factorial design with 200 mg vitamin E and 500 mg slow release vitamin 
C for three years. Smokers receiving only vitamin E showed a non-significant 
reduction in carotid IMT progression very similar to our result of 47%. This finding 
appeared not to generalize to the population of women or to non-smokers. The 
observed significant reduction in carotid IMT progression in the group receiving both 
vitamin E and C led the investigators to the conclusion that slow release vitamin C 
supplementation is additionally required to enable beneficial effects of vitamin E. 
Support for this contention can be found in in-vitro studies that have identified 
regenerating effect of vitamin C on oxidized vitamin E. Assessment of the clinical 
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Chapter 8 
relevance of a non-significant reduction in IMT progression as found for vitamin E 
supplementation in smoking men in our trial (chapter 3) and the trial by Salonen et. al 
(1999 ESC-congress in Barcelona) is complicated by ambivalent findings from large 
intervention trials on vitamin E and clinical hard-endpoints. Detailed information on 
results from these trials can be found in Table 8.3. In short, significant beneficial 
effects on non-fatal but not fatal MI have been reported for 50 IU vitamin E 
supplementation among smokers with previous MI55 and for 400 and 800 IU in CVD 
patients56. MI survivors showed no reduction upon 300 mg vitamin E on the combined 
endpoint of death, non-fatal MI and non-fatal stroke but did show significant 
reductions in cardiovascular deaths especially sudden deaths57. Similarly, results from 
the HOPE trial58 among 9,541 patients at high risk for cardiovascular events 
(presented at 1999 ESC-congress in Barcelona) showed no reduction in incidence of 
MI, strokes, or cardiovascular deaths after 4.5 year supplementation with 400 IU 
vitamin E. However, the vitamin E part of this trial will be continued to assess longer 
term effects of vitamin E on vascular disease58. All together, the ambivalent results 
from these trials do not yet justify a sound conclusion on the effects of vitamin E in 
the prevention of CVD. Overall, they have failed to identify a beneficial effect of 
vitamin E in doses ranging from 50 to 400 IU and follow-up periods up to 8 years. 
To further assess the relevance of the non-significant reduction in progression 
of IMT among smokers as observed in our main study, we hypothesized that possible 
beneficial effects of vitamin E on atherosclerosis may be more pronounced in specific 
sub-populations at multiple risk for oxidative stress. Therefore, the results of the main 
trial described in chapter 3 were further differentiated by genetic predisposition. 
Specifically, smokers with the null- genotype for glutathione S-transferase u 
(GSTM1), thus lacking the detoxifying GSTM1 enzyme were compared to smokers 
with the positive genotype (chapter 4). Indeed, vitamin E supplementation reduced the 
progression of specific IMT sites among those with the GSTMl-null genotype, but not 
for those with the positive genotype. At present there are no comparable studies on 
GSTM1 polymorphism and atherosclerosis and its interaction with vitamin E. If 
further studies confirm our results, GSTM1 genotype may importantly improve the 
predictive value of the relation between smoking and CVD. Furthermore, 
mechanistically it may provide more insight into the potential role of vitamin E on 
CVD risk for populations subject to increased oxidative stress. 
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Intervention trial of vitamin E and immune response 
The results from the intervention described in chapter 6 showed no effect of 100 IU 
vitamin E supplementation on the humoral and cellular immune response among 
elderly. This may partly be due to the relatively low vitamin E dose applied and the 
selection of a healthy elderly population. This is supported by concurrent vitamin E 
intervention trials among healthy elderly61,196 reporting significant positive effects for 
doses of 800 mg vitamin E applied for 30 days61 and doses of 200 mg (but not 60 or 
800 mg) applied for 4.5 months196. Another trial on immunological parameters69 
among healthy elderly applying supplementation of 50 and 100 mg for six months, 
only showed beneficial effects for 100 mg vitamin E among those elderly in a sub-
optimal state of health. New trials investigating the effect of vitamin E on reduction of 
intensity and incidence of infection are currently ongoing and should hopefully 
provide insight into the clinical relevance of vitamin E induced improvements on 
immune response. These results have to be awaited before recommendations on 
increased intake of vitamin E among healthy elderly people would be justified. 
Methodological considerations 
Epidemiological studies are susceptible to several forms of bias. Precision and validity 
of the studies presented in this thesis will be discussed to the extent that they might 
have influenced the interpretation of the results. Specific attention will be paid to the 
use of surrogate endpoints or markers for atherosclerosis and CVD risk, study power, 
selection bias, confounding and information bias. 
Use of surrogate endpoints for atherosclerosis 
The use of surrogates of clinical manifestations of CVD such as oxidation of LDL 
(chapter 3 and 5) and progression of carotid IMT (chapters 2, 3 and 4) provides 
valuable information on mechanisms and/or biological efficacy of preventive 
interventions among humans without the need for very large-scale studies or long-
term follow-up. Such more efficient study designs would in turn allow for more 
flexibility in the testing of different doses and duration. That information would 
provide extremely useful input into the design of large-scale trials on vitamin E and 
CVD endpoints. 
The disadvantage of some intermediate endpoints is that they are often applied 
prior to unequivocal confirmation of their predictive value for the clinical endpoint 
purport to measure. At later state, they may then turn out not to be as valid a marker 
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as originally anticipated. The in-vitro susceptibility of LDL to oxidation28 was used in 
the trials among elderly (chapter 5) and smokers (chapter 6). Although some studies 
have revealed increased in-vitro susceptibility of LDL to oxidation among CVD 
patients31,32, just as many studies fail to demonstrate such confirmation36'39"41. Also in 
our vitamin E trial among smokers (described in chapter 3) the 2 year change in 
susceptibility to oxidation of LDL was not associated with the change in carotid IMT. 
Yet, the hypothesized role of oxLDL in the atherosclerotic process still finds strong 
support and a marker that accurately mimics the situation of in vivo LDL oxidation 
would be of great importance. At the moment auto-antibodies against oxLDL are 
being applied as an in vivo marker for oxidation of LDL and associations with 
cardiovascular events have been promising30'33"35, but not conclusive. 
Progression of the intima media thickness (IMT) of the common carotid artery 
as measured by B-mode ultrasound constitutes a good marker for atherosclerosis. It is 
a noninvasive, harmless and highly reproducible89'90 method that can be applied to 
general populations in large-scale epidemiological studies. Reproducibility data of the 
IMT measurements, as applied in chapters 2 to 4, showed between- and within 
variation lower than 5% for the combined left and right CCA far and near wall90. The 
mean difference (SD) between observers was 0.006 mm (0.03) and 0.006 (0.02) mm 
within observers. Measurement error of IMT tended to increase with increasing levels 
of IMT90, which is in line with reports by others128. The reproducibility study90 among 
subjects with an increased IMT (> 1.1 mm) also revealed that the between-observer 
variation was clearly larger than the within-observer variation. For that reason, in our 
IMT trial (described in chapters 3 and 4) an effort was made to have the same 
ultrasonographer scanning the subjects before and after the two year intervention. The 
use of a combination of sites at the common carotid artery such as near wall and far 
wall at the right and left site was used in estimating progression of IMT in the studies 
described in chapter 2, 3 and 4. Such combination of sites (assuming similar precision 
and validity in measurement for individual sites) will reduce the variability 
considerably, leading to increased precision132. 
The validity of using IMT as a predictive marker for CVD is supported by an 
increasing number of studies showing positive associations between absolute levels 
of IMT with generalized atherosclerosis91, and with peripheral-92, cerebro- and 
cardiovascular disease93"95. Moreover, the clinical relevance of progression of IMT as 
a marker for CVD has been reported117. This allows for direct comparison to other 
studies in the (qualitative) assessment of the clinical relevance of our intervention 
effect of 0.014 mm reduction in progression of CCA-IMT (chapter 2) and 0.022 mm 
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reduction among smokers with the GSTM1-0 genotype (chapter 4). The 8.8 years 
follow-up of the cholesterol lowering atherosclerosis study117 reported a relative risk 
of 3.1 (95% CI [2.1-4.5]) on any coronary event for every 0.03 mm/year progression 
in IMT Also, in a cross sectional study Bots et al.95 reported a relative risk of 1.34 for 
stroke and 1.25 for MI for every additional difference of 0.16 mm in CCA-IMT after 
adjustment for major cardiovascular risk factors. 
Together, these findings support our use of measurement of progression carotid 
IMT as a valid and reproducible marker for progression of atherosclerosis. Moreover, 
the extent of reduction in progression of carotid IMT may indicate substantial clinical 
relevance. 
Study power 
Despite the fact that our intervention trial on vitamin E showed approximately the 
anticipated relevant 50% reduction in progression of IMT among general smokers 
(chapter 2) and even stronger in smokers with GSTM-1 null genotype (chapter 3), this 
result did not reach statistical significance. Study power problems warrant cautious 
interpretation of the lack of a significant effect. It turned out that the spontaneous 2-
year progression of 0.030 mm in the placebo group and the absolute difference in 
progression between vitamin E and placebo group was smaller than was anticipated on 
the basis of the limited information available at the start of the trial77,126. Also, the fact 
that high IMT baseline values, such as in our high risk groups of lifelong male 
smokers, have higher levels of measurement error associated with them128 has further 
contributed to the lower than expected power of our study. 
Selection bias 
"Selection bias are distortions that result from procedures used to select subjects and 
from factors that influence study participation"234. The common element of such 
biases is that the relation between exposure and disease is different for those who 
participate and those who should be theoretically eligible for study, including those 
who do not participate. 
Such selection bias is not thought to be a problem in the observational studies 
described in chapters 2 and 7. It is not conceivable that the selection (and self-
selection) was related to the association between plasma levels of vitamins and IMT 
levels or total mortality during seven year follow-up. Selective dropout was not a 
problem in the double-blind randomized vitamin E intervention trials described in 
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chapters 3 to 6 as such drop out proved equally distributed across vitamin E and 
placebo groups. 
On the other hand, it is quite likely that the elderly and smokers participating in 
the described studies constitute a selective population, which may have consequences 
for the generalizability or external validity of the findings. In general, people 
participating in health surveys or intervention trials may be more health conscious 
than the eligible non-responders. The effect of a selective and possibly more healthy 
population of smokers (chapter 2 to 4) may have reduced the strength of reported 
effects, particularly if the hypothesized effects are stronger among higher risk sub-
populations. The results of a non-response study comparing 534 non-responders with 
73 responders revealed no significant differences in age, history or presence of CVD, 
physical activity, demographic characteristics and subjective health score (chapter 2). 
However, non-responders in this study differed from responders mainly in their 
smoking behavior. Another selection problem among lifelong smokers may be due to 
natural selection. Such natural selection may have influenced the generalizability of 
our findings to the total population of smokers. On the other hand, especially 
peripheral vascular disease is hypothesized to be an especially relevant disease among 
healthier smokers as those with other risk factors such as hypercholesterolaemia or 
hypertension are likely to have diseased at an earlier age235. 
In conclusion, for the intervention trials described in this thesis the influence of 
bias on internal validity is unlikely because of an appropriate double-blind 
randomized placebo-controlled study design. However, our study population of 
elderly and smokers may constitute a healthy sub-populations of the respective source 
populations, affecting generelazibility (external validity). If this has affected the 
results of our intervention trials it is conceivable to have possibly attenuated the 
findings. 
Information bias 
Observational studies as described in chapters 2 and 7 are sensitive to information bias 
causing misclassification of subjects according to exposure or outcome. In our studies 
potential problems regarding differential misclassification, when the proportion of 
subjects misclassified on exposure depends on disease status or vice versa, were dealt 
with either prior to (chapter 2) or within the data analysis (chapter 7). Specifically, in 
the study on increased IMT (chapter 2), differential misclassification of subjects on 
smoking characteristics and vitamin E levels was prevented by studying only healthy 
CVD-free smokers thus excluding those smokers that might have altered their 
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smoking or dietary habits as a consequence of CVD or CVD medication use. In the 
prospective study on antioxidants and total mortality (chapter 7) differential 
misclassification cannot be fully ruled out as prior to baseline measurements subjects 
may have consciously changed their diet, altering their serum concentrations of 
antioxidants, in response to a diagnosis of risk factors or chronic disease However, as 
excluding the first years of follow-up did not markedly change the observed 
associations, this is unlikely to have markedly influenced the results of our study. 
In the prospective study on total mortality (chapter 7) serum levels of vitamin E 
were classified in tertiles. Serum vitamin levels were measured only once at baseline 
and nondifferential misclassification of the tertiles of serum vitamin E may have 
occurred. Bias from independent nondifferential misclassification is usually in the 
direction of the null value, which is diluting the possible effect234. However, when 
more categories are involved the bias may actually be away from the null value. We 
checked the seriousness of this effect by measuring the serum vitamin E levels in a 
sub-sample of our population of elderly halfway through the follow-up and classifying 
them into tertiles again. Tertile classification between baseline and halfway through 
was concordant in 72% of the cases and for only 5% of the cases the misclassification 
was more than one tertile. Hence, such misclassification will not have seriously 
influenced our results. 
In conclusion, information bias was appropriately addressed in the studies 
described in this thesis and is unlikely to have played a substantial role in the 
interpretation of the reported findings. 
Confounding 
The effect of an exposure on outcome may be biased by a confounding factor when 
this factor is a risk factor for the outcome and is associated with the exposure under 
study in the source population and is not in itself an intermediate step in the causal 
path between the exposure and the outcome234. In the observational and intervention 
studies described in this thesis potential confounding was appropriately addressed 
during the data analysis phase by adjusting for potential confounders in multivariate 
analyses. 
Lipid profile is a potential confounder in the observational studies (chapters 2 
and 7) on plasma vitamin E and increased IMT and total mortality, respectively. After 
all, plasma levels of vitamin E are highly correlated with plasma cholesterol levels. To 
account for this potential collinearity problem, in the multivariate analyses plasma 
vitamin E was adjusted for plasma cholesterol by calculating their residuals from 
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linear regression models with plasma cholesterol as the dependent variable. In the 
trials on vitamin E and immune response (chapter 6) and vitamin E and progression of 
IMT (chapters 3 and 4) initial values on the outcome variables of cellular immune 
response and IMT were found to differ between vitamin E and placebo groups. To 
guard against potential confounding on the effect measurements, initial values were 
adjusted for in the multivariate analyses. 
In retrospect, this unexpected issue would preferably have been addressed in 
the design phase rather than the analysis phase, by randomizing within levels of initial 
values (block randomization)234. In the IMT trial (chapter 3) baseline differences 
might have been prevented against at some additional costs arising from extra IMT 
measurements prior to randomization and prolonged recruitment period. In the 
immune response trial (chapter 6) the likelihood of fully successful randomization 
might similarly have been increased by a further increase in the number of subjects234. 
However, in this study the issue of block randomization is slightly more complex due 
to a technical restriction in the analytical phase. To reduce the inter-assay variation 
inherent to proliferative response of immune cells, each subject's pre- and post-
intervention samples need to be analyzed simultaneously in a single run. Hence, block 
randomization on pre-intervention sample values was infeasible, as it would introduce 
considerable inter-assay variation that, in turn, would seriously undermine the 
efficiency of the block randomization. 
Overall, we believe that effects of confounding were adequately accounted for 
in the data-analysis phase of our studies. However, to be fully confident about this, in 
future applications it would be recommendable to anticipate on these unexpected 
effect during the design and resourcing phases (time and money) of these studies, 
whenever feasible. 
Conclusion and implications 
Based on new understanding of the potential mechanistic role of oxidants in 
development and clinical expression of coronary heart disease, in 1991, a group of 
leading experts in the field sat together in a workshop to discuss the role and 
directions for future trials on antioxidants in the prevention of human 
atherosclerosis154. Consensus conclusion of this workshop was that "the available 
evidence justified clinical trials of natural antioxidants (associated with no increase in 
risk) but that clinical trials with antioxidant drugs (which might carry deleterious side 
effects) should be deferred until more knowledge is available". Today, over 8 years 
later, from the accumulating studies including our own, it has to be concluded that 
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there is still limited evidence in favor of beneficial effects of vitamin E 
supplementation on immune response and atherosclerosis in smokers and elderly. 
Our studies did not show an improvement in immune response among elderly 
upon vitamin E supplementation. In other studies61'69,196 such beneficial effects have 
been reported for doses higher than that applied in our study and in populations of less 
healthy elderly. Overall, the results are still mixed and the outcomes of ongoing trials 
on the effect of vitamin E supplementation on incidence and severity of infectious 
diseases will have to be awaited before sound conclusions are justified regarding the 
desirability of a change in recommendation for vitamin E intake in elderly 
populations. 
The other trials described in this thesis are similarly not unequivocally 
supportive for a general beneficial effect of vitamin E supplementation on 
atherosclerosis among smokers and elderly. Modest support for a beneficial effect was 
only found in the very specific case of a hypothesized low antioxidant defense among 
smokers lacking the detoxifying enzyme activity of GSTM-1. The observed beneficial 
effects of vitamin E supplementation on oxidation susceptibility found in both 
smokers and elderly is very difficult to interpret as the relevance of these findings to 
the in vivo situation has yet to be established. 
The evidence that vitamin E may reduce risk of coronary heart disease mainly 
comes from prospective cohort studies and is reasonably strong and consistent. 
However, these results find only limited support from (recent) primary and secondary 
randomized trials. There may be a role in prevention of non-fatal myocardial 
infarction in those with coronary heart disease55'56. Several randomized trials including 
a vitamin E arm are still ongoing and the results will be available in the near future. 
Whether these trials will add to the inconsistency of results or will provide conclusive 
results regarding the potential beneficial effect of vitamin E will have to be awaited. 
Future directions 
Vitamin E and cardiovascular disease 
Except for the specific cases of smokers with the GSTM1-0 polymorphism (this 
thesis, chapter 4) or for nonfatal MI among CVD patients, the hypothesis of a 
beneficial effect of vitamin E on CVD in general is not supported by the studies in this 
thesis nor by currently available results from large primary and secondary prevention 
trials. Several prevention trials on vitamin E and clinical endpoints are ongoing and 
will hopefully shed more light on the inconsistent results found so far. At the moment, 
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prior to the availability of these results initiation of new clinical trials on vitamin E 
and CVD endpoints is not warranted. 
In the meantime, future research may more meaningfully be directed towards 
the concept of biomarkers236 of lipid peroxidation and oxidative damage to the vessel 
walls to establish the significance and optimal intake of vitamin E. Furthermore, 
synergistic effects of other nutrients, such as the hypothesized regenerating effect of 
vitamin C on oxidized vitamin E, can be studied. 
After all, the role of in vivo LDL lipid peroxidation in atherosclerosis is widely 
accepted and the importance of vitamin E as an in vivo antioxidant strongly suggests a 
possible role of vitamin E in the atherosclerotic process. This role is probably more 
subtle and specific than hypothesized at the start of our studies and other large clinical 
trials. A major complication in finding a biomarker for LDL lipid peroxidation in vivo 
is that it occurs within the vessel wall. Considerable resource (time and money) should 
be invested for further improvement of measurement and identification of new and 
better markers. Serious candidates that need further development and validation are 
isoprostanes (general marker for lipid peroxidation) and levels of circulating 
antibodies against oxidized LDL. 
Research should also be directed towards further validation and refinement of 
the measurement of IMT progression and other easy to administer relevant markers 
for preclinical atherosclerosis suitable to administer in large prevention trials. In this 
respect, next to ultrasound measurements recent advances in imaging technology have 
revealed promising methods such as positron emission tomography, magnetic 
resonance imaging and ultrafast computed tomography which are potential methods to 
identify early functional and structural vascular changes237. Such measures can not 
only play a particularly important role in the validation of new biomarkers applied in 
future 'short-term' human experiments but also provide a way to test potential 
preventive agents on a preclinical stages of atherosclerosis in high risk asymptomatic 
subjects. 
All together these directions should provide the platform from which to decide 
the necessity and design of future large-scale clinical trials on optimal vitamin E 
levels, and ideal combinations with synergistic nutrients and in groups that may 
particularly benefit from vitamin E supplementation. 
Vitamin E and immune response 
The study described in this thesis does not provide support for a beneficial effect of 
vitamin E on parameters of the immune response in elderly people. However, studies 
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applying higher doses and in elderly with a sub-optimal health status suggest that such 
effects may be real. This, together with the clinical relevance of age-induced decline 
of immune parameters warrants future trials. Actually, some of such trials on the 
effect of supplementation of vitamin E on incidence and severity of respiratory 
infections in elderly are already ongoing (Graat, Wageningen University The 
Netherlands and Meydani, Tufts University USA). These well-designed and large-
scale studies will provide more definite evidence on the role of vitamin E 
supplementation on infectious diseases. 
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This thesis addresses the hypothesis that the lipid soluble antioxidant vitamin E may 
be beneficial for several health aspects, possibly by counteracting negative effects of 
lipid peroxidation. More specifically the effect of vitamin E is studied in two vitamin 
E intervention trials on atherosclerosis and immune response (chapters 3 to 6) and two 
observational studies on atherosclerosis and total mortality among populations 
abstaining from antioxidant supplements (chapters 2 and 7). The studies focus on 
smokers and elderly hypothesized to be at risk for increased oxidative stress. 
Vitamin E may exert its protective effect on atherosclerosis by protecting the low 
density lipoproteins against lipid peroxidation. Oxidative modification of low density 
lipoprotein cholesterol may render it more atherogenic than native LDL. Lipid 
peroxidation may also negatively influence immune response by structurally changing 
the membranes of cells involved in the immune response. Furthermore, vitamin E may 
exert its immune-enhancing effect by decreasing the production of immuno-
suppressors in elderly, as they contribute to the age-associated dysregulation of 
immune response. 
In chapter 2 a cross-sectional study design was used to study the associations 
between vitamin E intake and plasma levels, smoking characteristics and the common 
carotid intima media thickness (IMT) measured by B-mode ultrasound as a marker of 
atherosclerosis. The 158 male lifelong CVD-free smoking subjects, aged 50 years and 
over, had a mean carotid IMT of 0.93 (SD=0.15) mm. In this group of life-long 
smokers, not using any vitamin supplements, no associations were found between 
carotid IMT and dietary intake of vitamin E or between carotid IMT and serum levels 
of vitamin E. Self-reported depth of inhalation of smoke into the lungs was the only 
smoke characteristic significantly associated with carotid IMT. Age-adjusted carotid 
IMT was significantly 0.053 mm (SD=0.022, p<0.05) thicker (6%) among deep 
inhalers compared to non-or moderate inhalers. This difference decreased to 0.036 
mm (SD=0.021, p=0.08) (4%) when adjusted for other CVD risk factors. Risk factors 
for CVD such as age, blood pressure, LDL- and HDL cholesterol were independent 
predictors of carotid IMT and explained 34% of the variance in carotid IMT. 
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In chapter 3 the effect of a daily dose of 364 mg (400 IU) vitamin E was studied on 
the 2-year change of the carotid IMT. The study was designed as a randomized 
placebo-controlled double-blind intervention trial among 218 male lifelong smokers 
from the general population aged 50 to 75 year with a mean number of 43 (SD=8) 
smoking years. The baseline mean carotid IMT was 0.95 mm (SD=0.16). In the 
placebo group the spontaneous 2-year change ('progression') in carotid IMT was 0.026 
mm (95% confidence interval (CI) 0.005; 0.047, p=0.02) after adjustment for baseline 
IMT. After adjustment for traditional CVD risk factors a non-significant reduced 
progression of carotid IMT of 47% (p=0.34) was observed in the vitamin E group 
compared to the 0.030 mm (95% CI 0.009-0.050, p=0.006) progression in the placebo 
group. Vitamin E supplementation significantly reduced the in vitro susceptibility of 
LDL to Cu2+ oxidation. In the vitamin E group there were no significant associations 
between changes of carotid IMT and changes in lagtime. 
To further assess the relevance of the non-significant reduction in carotid IMT 
progression, as observed in the trial described in chapter 3, these results were 
differentiated by genetic predisposition in chapter 4. Specifically, smokers with the 
null genotype for GSTM1 (GSTM1-0), who thus lack the detoxifying enzyme activity 
of glutathione S-transferase u, were compared to smokers with the positive genotype 
(GSTMl-i). The results were adjusted for baseline IMT and major CVD risk factors. 
In the placebo group smokers with GSTM1-0 showed a significant 2-year carotid IMT 
progression of 0.045 mm (95% CI 0.016-0.074, p=0.002) compared to only 0.012 mm 
(95% CI 0.020-0.043, p=0.47) for those with the GSTM1-/ genotype. Among subjects 
in the placebo group, only for the carotid posterior wall IMT progression was 
significantly (p< 0.05) more increased in the GSTM1-0 group than in the GSTM1-7 
group. Compared to the placebo group, vitamin E supplementation did not reduce the 
carotid IMT progression for those with the GSTM1-7 genotype. However, for those 
with the GSTM1-0 genotype vitamin E supplementation reduced the proportion of 
smokers with increased carotid IMT progression by 62% (95% CI -4%-86%, p=0.06) 
at the left posterior wall and by 73% (95% CI 26%-90%, p=0.01) at the left anterior 
wall. 
In chapter 5 the effect of 100 mg vitamin E on the in vitro susceptibility of LDL to 
oxidation was studied in a three months randomized double-blind placebo controlled 
trial in 83 apparently healthy elderly, aged 67 to 85 years. The susceptibility of LDL 
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to oxidation was measured by the disappearance of linoleic acid from LDL, a major 
substrate for lipid peroxidation, after a 5 h in vitro Cu-oxidation of LDL isolated from 
plasma. Vitamin E supplementation resulted in a significant two-fold decrease in 
percentage of oxidized linoleic acid in LDL of 10.4% compared to a decrease of 4.6% 
in the control group. Moreover, within the vitamin E group this protective effect was 
even more marked in subjects who started with a low baseline level of the a-
tocopherol to linoleic acid ratio. 
In the trial described in chapter 5 also the effects of 100 mg vitamin E on indices of 
the cellular and humoral immune response in elderly subjects (chapter 6) were 
studied. After adjustment for initial values, three months vitamin E supplementation 
had no significant effect on the cellular immune response measured by the in vitro 
mitogenic stimulation of peripheral blood mononuclear cells to the mitogens 
concanavalin A and phytohemagglutinin both at concentrations of 1 and 5 mg/ml. 
Similarly, no significant effect of vitamin E supplementation was found on humoral 
immune response measured by immunoglobulin (Ig)G, IgG4, and IgA antibody 
concentrations raised against various common antigens. 
Finally, in the prospective study described in chapter 7 the association between 7.2 
year all-cause mortality and serum levels of carotenoids and vitamin E were studied 
among 638 independently living elderly aged 65 to 85 years. After adjustments for 
CVD risk factors no significant increased mortality risk was found for the lowest 
compared to the highest tertile of serum a-tocopherol (vitamin E) (hazard ratio 1.11, 
95% CI 0.74; 1.65). 
In chapter 8 these main findings are discussed in relation to other scientific evidence. 
Furthermore, methodological aspects that may have interfered with the interpretation 
of the findings are discussed. Finally implications and directions for future research 
are given. Precision and validity of the studies presented in the thesis were discussed 
to the extent that they may have influenced the interpretation of the results. Specific 
attention was paid to the use of surrogate endpoints or markers of atherosclerosis, 
study power and selection bias, confounding and information bias. In short, the 
interpretation of the beneficial effects of vitamin E found on in vitro measurement of 
susceptibility of LDL to oxidation as a marker of atherosclerosis is difficult as the 
validity of this marker for the in vivo situation is unclear. The validity and 
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reproducibility of progression of carotid IMT as a marker for atherosclerosis is 
supported by an increasing number of studies thus justifying our use of this marker. 
Despite the fact that the vitamin E intervention among smokers approximately showed 
the anticipated 50% reduction in IMT progression and even stronger in smokers with 
the GSTMl-null genotype, this result did not reach statistical significance. The 
spontaneous progression of IMT in the placebo group was less than anticipated 
causing problems with the power of the study. This warrants cautious interpretation of 
the lack of a significant effect. Selection bias, information bias or confounding were 
appropriately addressed in the described studies either in the design phase or in the 
analyses of the described studies and are not believed to have played a substantial role 
in the interpretation of the reported findings. 
In conclusion, except for a modest effect in the highly specific case of smokers with 
GSTM1-0 polymorphism, the studies presented in this thesis do not provide evidence 
in support of a beneficial effect of vitamin E supplementation on atherosclerosis and 
immune response among the populations of smokers and elderly. Large primary and 
secondary prevention trials show modest and inconsistent results for the effect of 
vitamin E on cardiovascular disease. Results from some ongoing trials are awaited. 
Further improvement of measurement and identification of new and better markers of 
lipid peroxidation and oxidative damage to the vessel wall is warranted and this may 
help to establish the significance and optimal intake of vitamin E. A beneficial effect 
of vitamin E on immune response in elderly has been found in other trials with higher 
doses than used in our trial described in chapter 6. Large trials investigating the effect 
of vitamin E on incidence and severity on infectious disease are currently ongoing. 
These studies will provide more definite evidence on the clinical relevance of 
improvement of the age-induced decline of the immune response. 
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In dit proefschrift wordt de hypothese bestudeerd dat het vetoplosbare antioxidant 
vitamine E een gunstig effect heeft op (aspecten van) gezondheid. Hiertoe werden 
twee interventie studies (hoofdstuk 3 tot en met 6) en twee observationele studies 
(hoofdstuk 2 en 7) uitgevoerd. De interventie onderzoeken richten zich op het effect 
van vitamine E op aderverkalking (atherosclerose) en immuun respons. In de 
observationele onderzoeken is de associatie onderzocht tussen vitamine E en 
atherosclerose en totale sterfte in populaties die geen antioxidant 
voedingssupplementen gebruikten. Het onderzoek is uitgevoerd bij rokers en ouderen 
waarvan verwacht wordt dat ze een extra risico hebben op verhoogde oxidatieve 
stress. 
Oxidatieve verandering van de lage dichtheid lipoprote'inen (LDL) die cholesterol 
vervoeren in het bloed, kan ertoe leiden dat deze deeltjes meer atherogeen worden dan 
het gewone LDL. Door de mogelijke bescherming die vitamine E biedt tegen lipide 
peroxidatie kan het een gunstig effect hebben op atherosclerose. Lipide peroxidatie 
kan ook een negatieve invloed hebben op de immuun respons, onder andere door het 
veroorzaken van structurele veranderingen in de membranen van de cellen die 
betrokken zijn bij de immuun respons. Daarnaast zou vitamine E de immuun respons 
in ouderen kunnen verbeteren doordat het de productie vermindert van immuun 
onderdrukkende stoffen die bijdragen aan de leeftijdsgerelateerde vermindering van de 
immuun respons. 
In een dwarsdoorsnede onderzoek beschreven in hoofdstuk 2 is geen associatie 
gevonden tussen vitamine E inneming en plasma niveau enerzijds en de dikte van de 
vaatwand van de halsslagader anderzijds. Deze vaatwanddikte is een marker voor 
atherosclerose die werd gemeten met behulp van B-mode ultrasound. Het onderzoek is 
uitgevoerd onder 158 mannelijke rokers van 50 jaar en ouder, die geen vitamine 
preparaten gebruikten en niet eerder aan hart- en vaatziekten (HVZ) hadden geleden. 
De gemiddelde vaatwanddikte van de halsslagader van deze rokers was 0,93 
(SD=0,15) mm. Bekende risicofactoren voor HVZ, zoals leeftijd, bloeddruk, LDL en 
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HDL-cholesterol bleken onafhankelijke determinanten te zijn en verklaarden samen 
34% van de variantie in vaatwanddikte van de halsslagader verklaarden. 
In hoofdstuk 3 is het effect bestudeerd van een dagelijkse dosis van 364 mg (400 IU) 
vitamine E op de tweejaarlijkse verandering (progressie) in vaatwanddikte van de 
halsslagader. Dit onderzoek is opgezet als een gerandomiseerde placebo 
gecontroleerde dubbelblinde interventie-studie onder 218 mannelijke rokers (50-75 
jaar), die gemiddeld al 43 jaar rookten (SD=8). De gemiddelde vaatwanddikte aan het 
begin van de studie was 0,95 mm (SD=0,16). Vitamine E suppletie verminderde de 
toename van vaatwanddikte met 47% (niet significant, p=0,34) ten opzichte van de 
significante spontane toename in de placebo groep van 0,030 mm (95% BTBHI 0,009-
0,050, p=0,006). Deze resultaten waren gecorrigeerd voor beginwaarden van 
vaatwanddikte en bekende risicofactoren voor HVZ. Twee jaar suppletie met vitamine 
E leidde wel tot een significante reductie in de gevoeligheid van LDL voor in vitro 
koper oxidatie. Deze reductie bleek echter niet samen te hangen met de veranderingen 
in vaatwanddikte van de halsslagader. 
In hoofdstuk 4 zijn de resultaten van hoofdstuk 3 verder uitgesplitst naar genetische 
predispositie. Rokers met verminderde activiteit van het ontgiftende enzym glutathion 
S-transferase u (genotype GSTM1-0) zijn vergeleken met rokers met het positieve 
genotype (GSTM1-7). De resultaten zijn gecorrigeerd voor beginwaarden van 
vaatwanddikte van de halsslagader en de belangrijkste risicofactoren voor HVZ. 
Rokers met het GSTM1-0 genotype die geen extra vitamine E kregen (placebo groep) 
lieten een significante 2 jaarlijkse toename in vaatwanddikte zien van 0,045 mm (95% 
betrouwbaarheidsinterval (btbhi) 0,016-0,074, p=0,002) vergeleken met slechts 0,012 
mm (95% btbhi 0,020-0,043, p=0,47) toename bij niet gesupplementeerde rokers met 
het GSTM1-7 genotype. Dit verschil in progressie van de wanddikte van de 
halsslagader tussen niet gesupplementeerde rokers met het GSTM1-0 en GSTM1-/ 
genotype was alleen significant (p<0,05) voor de achterwand van de halsslagader. Ten 
opzichte van de placebogroep, bleek vitamine E suppletie de toename van de 
vaatwanddikte van de halsslagader niet te verminderen bij rokers met het GSTM1-7 
genotype. Echter, onder rokers met het GSTM1-0 genotype bleek vitamine E suppletie 
de proportie rokers met toegenomen vaatwanddikte significant te verminderen met 
62% (95% btbhi -4%-86%, p=0,06) voor de linker achter wand en met 73% (95% 
btbhi 26%-90%, p=0,01) voor de linker voorwand van de halsslagader. 
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In hoofdstuk 5 is het effect bestudeerd van suppletie met 100 mg vitamine E op de 
gevoeligheid van LDL voor in vitro koper oxidatie. Dit onderzoek is uitgevoerd als 
een drie maanden durende gerandomiseerde dubbelblinde placebo gecontroleerde 
interventie onder 83 ogenschijnlijk gezonde ouderen in de leeftijdsgroep van 67 tot 85 
jaar. De oxidatiegevoeligheid van LDL is gemeten aan de hand van de oxidatie van 
linolzuur, het belangrijkste substraat in LDL voor lipide peroxidatie. Vitamine E 
suppletie resulteerde in een significante vermindering van het percentage geoxideerd 
linolzuur in LDL van 10,4% vergeleken met 4,6% in de placebo groep 
Als onderdeel van de trial onder oudere respondenten, beschreven in hoofdstuk 5, is 
ook het effect bestudeerd van 100 mg vitamine E suppletie op indicatoren voor 
cellulaire en humorale immuun respons (hoofdstuk 6). Na correctie voor 
beginwaarden bleek vitamine E suppletie geen effect te hebben op de cellulaire 
immuun respons. Deze werd gemeten door in vitro stimulatie van bij de immuun 
respons betrokken cellen met de mitogenen concanavaline A en phytohemagglutinine 
in concentraties van 1 en 5 mg/ml. De humorale immuun respons werd bestudeerd aan 
de hand van de concentraties van de immunoglobulines (Ig)G, IgG4, en IgA in reactie 
op verschillende veel voorkomende antigenen. Ook de humorale immuun respons 
werd niet bei'nvloed door vitamine E suppletie. 
Tenslotte is in een prospectieve studie onder 638 zelfstandig wonende ouderen in de 
leeftijdsgroep van 65 tot 85 jaar de associatie bestudeerd tussen sterfte gedurende 7.2 
jaar follow-up en serum concentraties van carotenoiden en vitamine E (hoofdstuk 7). 
Na correctie voor risico factoren voor HVZ is geen verhoogd mortaliteitsrisico 
gevonden voor het laagste vergeleken met het hoogste tertiel van voor cholesterol 
gecorrigeerde serum a-tocopherol (vitamine E) niveaus (hazard ratio 1.11, 95% btbhi 
0,74; 1,65). 
In hoofdstuk 8 worden de belangrijkste resultaten bediscussieerd in relatie tot andere 
wetenschappelijke bevindingen. Bovendien wordt aandacht besteed aan 
methodologische factoren die de interpretatie van onze resultaten zouden kunnen 
bei'nvloeden, zoals het gebruik van surrogaat-eindpunten voor atherosclerose, het 
statistisch onderscheidingsvermogen (power) van onze onderzoeken, selectie bias, 
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informatie bias en confounding. Tenslotte worden implicaties en richtingen voor 
toekomstig onderzoek aangegeven. 
Onze onderzoeken tonen niet aan dat suppletie met vitamine E belangrijke gunstige 
effecten zou hebben op atherosclerose en immuun response bij rokers en ouders. Het 
gunstige effect dat gevonden wordt voor in vitro metingen van oxidatiegevoeligheid 
van LDL is moeilijk te interpreteren omdat de validiteit van deze marker voor de in 
vivo oxidatie niet overtuigend is aangetoond. Een toenemend aantal studies toont aan 
dat de door ons gebruikte vaatwanddikte van de halsslagader een veelbelovende 
(valide en reproduceerbaar) marker is voor atherosclerose. Ondanks het feit dat de 
vitamine E interventie bij rokers leidde tot de vooraf verwachte 50% vermindering in 
toename van de vaatwanddikte was dit resultaat niet statistisch significant. De 
spontane progressie van de vaatwanddikte in de placebo groep was minder dan 
verwacht, wat de statistische power van onze studie aanzienlijk verminderde. Om deze 
reden is terughoudendheid geboden in de interpretatie van het niet-significante effect. 
Andere methodologische factoren zoals selectie bias, informatie bias en confounding 
hebben geen rol van betekenis gespeeld in de interpretatie van de gerapporteerde 
resultaten. 
Concluderend, geven de onderzoeken in dit proefschrift geen ondersteuning voor een 
gunstig effect van vitamine E suppletie op atherosclerose en immuun respons bij 
rokers of bij ouderen. De betekenis van het GSTM1 genotype in dit proces vraagt nog 
om verdere bevestiging in toekomstig onderzoek. Onze resultaten zijn grotendeels in 
lijn met grote primaire en secundaire preventie trials die evenzeer bescheiden en 
inconsistente resultaten laten zien voor het effect van vitamine E op hart- en 
vaatziekten. Resultaten van andere nog lopende trials moeten worden afgewacht. 
Prioriteit dient gegeven worden aan onderzoek naar goede markers voor lipide 
peroxidatie en vaatwandbeschadiging om duidelijker het belang en de optimale 
inneming van vitamine E te kunnen vaststellen. 
Een gunstig effect van vitamine E op de immuun respons bij ouderen is wel gevonden 
in andere trials met een hogere dosis voor vitamine E dan onze dosis in hoofdstuk 6. 
Op dit moment lopen nog grote trials naar het effect van vitamine E op de incidentie 
en ernst van infecties. Deze onderzoeken zullen meer uitsluitsel geven over de 
klinische relevantie van verbetering door vitamine E van de leeftijdsafhankelijke 
vermindering van de immuun respons. 
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Het was tot het eind toe spannend hoe mijn proefschrift er nu werkelijk uit zou gaan 
zien. Het begon met het schrijven van een BRAIO-voorstel waarvoor het onderzoek 
gedeeltelijk in Rusland zou plaatsvinden. De BRAIO plaats werd gehonoreerd, maar in 
Rusland ben ik nog nooit geweest. Voorstellen bedenken, schrijven, en financiering 
zoeken vormden in het begin een groot deel van de werkzaamheden. Steeds 
verschillende projecten met verschillende expertises. Op weg naar het uiteindelijke 
resultaat hebben dan ook heel veel mensen ergens een bijdrage geleverd. 
Hans, ik wil beginnen met jou hier te bedanken. Vanaf het begin heb je meegedacht en 
de handen uit de mouwen gestoken. Meer dan 16.000 pillen hebben we gedraaid, 
duizenden stikkers geplakt, enveloppen gestempeld, buizen geplakt etc. Wat een geluk 
om een persoonlijke begeleider zo dicht bij de hand te hebben. En zeg nou eerlijk, voor 
een marktkundige is het toch altijd handig om ook kennis over vitamine E en de 
oxidatie van LDL paraat te hebben? 
Beste Frans Kok, jij was mijn promoter en begeleider van het eerste uur. Als jij ergens 
enthousiast over bent kun je er donder op zeggen dat het ook wat gaat worden. Ik heb 
veel bewondering voor je inzicht in wat op wetenschappelijk gebied relevant is of beter 
nog, gaat worden. Hier heb ik meerdere malen gebruik van mogen maken. Samen 
hebben we heel wat voorstellen afgewerkt. Alhoewel het binnenhalen van middelen wat 
moeizaam op gang kwam hadden we op een gegeven moment zelfs een project 'over'. 
Af en toe ging het er wel eens hard aan toe maar dit werd altijd direct weer opgelost. 
Frans, bedankt voor je begeleiding, het was een bijzondere tijd. 
Halverwege mijn promotie kwam Nijmegen in zicht. Beste Anton Stalenhoef, jij was 
snel (en ik traag) genoeg om mijn promotor te kunnen worden. Ik heb altijd veel plezier 
beleefd aan onze contacten. Jij bent iemand waar ik altijd op kon bouwen en op kon 
vertrouwen. Ik hoefde maar een kleine kik te geven en het was al geregeld. Jammer dat 
met het einde van dit project ook onze samenwerking ophoudt. Hopelijk kunnen we in 
de toekomst nog eens oude koeien uit de sloot halen! 
Beste Hub Wollersheim, de man met de snor! Bedankt voor je begeleiding en je 
kritische vragen over het "hoe en waarom". Corrigeren voor geslacht bij een groep 
mannelijke rokers vind ik nog steeds moeilijk maar wellicht dat je dit nog eens toelicht. 
Een interventie onderzoek is onmogelijk zonder trouwe deelnemers. Alle ouderen en 
rokers die zo enthousiast mee hebben gedaan wil ik hartelijk bedanken voor hun inzet. 
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Studenten, assistenten, analisten, financiers, prikkers, sjouwers, interviewers, pillen 
draaiers, pillen tellers, commentatoren, begeleiders en gezellige afleiders, jullie waren 
allemaal onmisbaar bij de zeer bewerkelijke interventies. 
Angelika, Henny, Liesbeth, Anouk, Margreet, Peter, Geke, Siegfried, Jaques, en Pieter 
hebben bijgedragen aan het oxLDL onderzoek bij ouderen. Bedankt voor het 
bloedprikken, voedingslijsten afhemen, 's ochtends vroeg ouderen ophalen uit Arnhem, 
labanalyses, stikkers maken, buizen bestellen, ontbijtjes maken, longfunctie-metingen, 
uitleg en andere ongein. Ulrich Moser is gratefully acknowledged for his contribution to 
the fatty acids analyses and oxidation of LDL in Switzerland and useful comments on 
the manscript. 
Corne, Gert, Liltzen, Miranda en Jan B. bedankt voor jullie hulp bij het opzetten van de 
meetmethoden, analyses, en statistische begeleiding bij het immuungedeelte van de 
interventie bij ouderen. 
Anita, Marloes, Herman, Heidi, Magda, Janine, Anneke, Helga, Pierre, Francis, Tineke, 
en Franchette: de Nijmegen-'clan'. Jullie waren betrokken bij het IMT-onderzoek beter 
bekend als 'vitamine onderzoek bij rokers'. Jullie waren onmisbaar door de 
vaatwandmetingen, labanalyses, discussies, lekkere kopjes koffie, gezellige roddels en 
achterklap, bloedprikken en al van dat soort dingen, BEDANKT! Marco en Nicole veel 
dank voor jullie werk aan de voedingsvragenlijsten. Patty van Loenen en Til Terburg 
wil ik hier in het bijzonder noemen. Jullie zorgden er niet alleen voor dat de deelnemers 
enthousiast mee bleven doen (de mannen kwamen tenslotte toch echt voor Til!), maar 
lieten vooral ook zien dat een goede onderzoeksassistent goud waard is en veel meer 
doet dan alleen maar uitvoeren. Met jullie had ik flink wat goud in handen! Juerg 
Haller, bedankt voor je betrokkenheid en dat je hebt laten zien dat GCP en SOPs niet 
alleen maar een administratieve rompslomp betekenen. 
Veel plezier heb ik beleefd aan de collega's van de oude vakgroep HEGL, en de 
excursie naar Scandinavie was een leuke kennismaking met mijn nieuwe collega's van 
Voeding ("wij en zullie"). In het begin, toen de vakgroep nog klein was, hebben we op 
de zolder van John Snow heel wat afgeroddeld en gelachen. Plannen werden gesmeed 
om 'de tent over te nemen' en uit efficientie oogpunt allemaal tegelijk zwanger te 
worden. Dat laatste is redelijk gelukt, al hoewel wat later dan gepland. 
Dirk Joghems, wat jij niet kunt, dat kan ook gewoon niet! 
Met mijn kamergenootjes heb ik lief en leed op werk en prive-gebied gedeeld. Vaak 
denk ik nog aan mijn eerste kamergenootje Karolien die helaas veel te vroeg is 
overleden. Linda, enorme kletsmajoor en feestbeest, onze ijskast op de Dreijenborch 
was altijd goed gevuld! Sorry dat je plantjes toch niet zo van koffie bleken te houden. Ik 
ben bijzonder blij dat mijn laatste twee kamergenoten Esther "lieve meid met een 
stevige bite" en Judith "echt blond is niet dom" mij terzijde willen staan bij de 
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verdediging van dit proefschrift. Ook wil ik mijn nieuwe kamergenootje bij de GGD 
noemen. Alies, wat een bofkont ben ik toch. Deze laatste maanden tijdens de afronding 
van mijn proefschrift stond je altijd klaar om me te helpen en zorgde je ervoor dat ik 
geen afspraak miste. 
Mijn wandel-, senegalees- en vette-bek maatjes van ex-afdeling 1A zorgden voor de 
broodnodige ontspanning. Wie weet ga ik nu ook eens een wandelweekend organiseren. 
Pap, ik vind het jammer dat je niet aanwezig kunt zijn op mijn promotie, die zo 
belangrijk voor je was. Altijd stond je aan mijn kant en de laatste jaren van je leven heb 
je ons ook veel van je persoonlijke kant laten zien. Mam, van jou heb ik mijn felle 
drang naar emancipate in brede zin meegekregen en de moed om door te gaan ook als 
het even niet helemaal gaat zoals ik wil. De rest van de familie; Sytske, en Tineke en 
Dirk op afstand, bedankt voor de 'familie' uitjes waar de De Waart humor de aanhang 
wel eens tot wanhoop dreef. Zonder de oppassers voor Jaap was er geen tijd geweest dit 
proefschrift af te ronden; Sytske, Yvonne, Oma Anneke, Oma van Trijp, Ruud en Petra, 
Hub, Mariet, Marieke en mw. van Vliet bedankt. 
Speciaal wil ik hier Hub, Mariet, Frances en Marieke bedanken. Bijna 12 jaar geleden 
moesten wij afscheid nemen van Jan. De onuitgesproken herinnering leeft altijd voort. 
Bij dit verlies kreeg ik er een familie bij. Wat jullie tijdens en naast mijn promotie voor 
mij betekenen is niet in een dankwoord te vatten. 
Hans, tenslotte nog een zeer persoonlijk nootje voor jou: 
"Lief, wees niet bang 
't Komt wel goed 
Je kunt me nu niet horen maar vertrouw 
Vertrouw maar op de liefde 
Dieje voelt 
Zoveel alsjij nu voelt hou ik 
Hou ik van jou!!" 
Wat was het zwaar he, afgelopen jaar(en) en wat fijn dat dit nu is afgerond. Tijd voor 
ons geluk. Het zit in een klein hoekje en hij eet graag een koekje. 
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